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Abstract 
 
Immune disorders such as allergy and autoimmunity are becoming increasingly common in developed 
countries. Self-reactive T cells exist in both healthy and autoimmune individuals. It is generally 
understood that hyperimmune disorders are caused by insufficient regulation, namely loss of activity of 
regulatory T cells. Whilst regulatory T cells exist naturally it is also possible to induce them both in 
vitro and in vivo. Immunotherapeutic techniques aim to provide noninflammatory exposure of antigen 
to the immune system with the aim of inducing antigen-specific regulatory T cells.  
Interleukin-10 (IL-10) is a cytokine with well known immunosuppressive qualities. It inhibits both the 
migration and the antigen-presenting ability of dendritic cells. It also has direct effects on T cells. 
Indeed, IL-10-secreting TR1 regulatory T cells were identified almost 15 years ago; their in vitro 
generation being dependent on exposure to IL-10. 
Particle-mediated DNA delivery (PMDD) is a promising method of immunisation and is especially 
suited to vaccines intended to have greater control over the response they induce. One of the main 
reasons for this is the possibility of including genes encoding immunomodulatory molecules alongside 
the antigen gene. 
This study utilises a mouse model involving the adoptive transfer of TCR-transgenic CD4+ T cells and 
establishes the response of these cells to PMDD immunisation. The model was then used to examine 
the effect of coadministration of the IL-10 gene. Its inclusion in the vaccine suppressed the response to 
antigen. This effect was maximal when the IL-10 gene was expressed in the same cell as the antigen 
gene. Using sequential immunisations the model was extended in order to study long-term effects, 
namely tolerance and the induction of regulatory T cells. Finally a mouse model of allergic asthma was 
used to examine any tolerogenic/therapeutic effects of the antigen-IL-10 vaccine. No significant long-
term tolerance to antigen was identified. 
These results demonstrate that whilst the presence of IL-10 clearly inhibits the T cell response to 
antigen it does not necessarily confer tolerogenic properties on these cells. This brings into question 
whether IL-10 in the periphery, supplied, for example, by TR1 cells, generates fresh regulatory T cells 
or merely inhibits the response to a particular antigenic challenge. 
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1. Introduction 
1.1. General introduction to interleukin-10  
1.1.1. Discovery 
IL-10, originally Cytokine Synthesis Inhibitory Factor (CSIF), was initially described as a TH2 
cytokine insomuch as it inhibited TH1 cytokines(Fiorentino et al., 1989) and TH1 cells(Macatonia et al., 1993) and 
promoted the humoral response(Defrance et al., 1992; Rousset et al., 1992; Briere et al., 1994). This TH2-like quality 
continues to be confirmed(Biswas et al., 2007) but IL-10 was soon understood to be a more general inhibitor 
of cytokine expression(de Waal Malefyt et al., 1991a; de Waal Malefyt et al., 1991b; Fiorentino et al., 1991a). Indeed, it has been 
shown to be produced by both TH1 and TH2 cells(Del Prete et al., 1993; O'Garra and Vieira, 2007) and, under certain 
conditions, can actually be selectively inhibitory towards TH2 responses(Cottrez et al., 2000; Moore et al., 2004).  
Confirmation of the important immunoinhibitory role of IL-10 comes from studies of IL-10-/- mice. 
These mice naturally develop, or are more susceptible to induction of, a range of immune disorders 
such as microbe-induced colitis and other inflammations(Kuhn et al., 1993; Gazzinelli et al., 1996; Sellon et al., 1998), 
autoimmune encephalitis(Bettelli et al., 1998) and asthma(Tournoy et al., 2000). IL-10-/- mice suffer from 
exaggerated responses to inflammatory mediators(Berg et al., 1995a; Berg et al., 1995b). In contrast, mice 
overexpressing IL-10 are protected from such responses(Lang et al., 2002b) as are mice that receive the 
cytokine parenterally(Howard et al., 1993). 
Further proof of the importance of IL-10 in immunosuppression is the evolution of multiple viral 
homologues of the cytokine, collectively known as viral IL-10 (vIL-10). Epstein-Barr virus (EBV)(Hsu et 
al., 1990; Moore et al., 1990)
 and cytomegalovirus (CMV)(Kotenko et al., 2000) are both viruses of significance to 
human health and encode very different vIL-10 molecules; the former being much more homologous 
to human IL-10. By inhibiting the immune response these vIL-10 confer an advantage on the virus(Salek-
Ardakani et al., 2002; Chang et al., 2004b; Raftery et al., 2004; Jenkins et al., 2008; Nachtwey and Spencer, 2008)
. The stability of the EBV 
vIL-10 gene across isolates further supports the argument that the importance of IL-10 has driven the 
evolution of viral homologues(Kanai et al., 2007). 
1.1.2. IL-10-producing cells 
As described in  1.1.1, IL-10 is commonly known to be produced by TH2 CD4+ T helper cells. 
However, IL-10 can be produced by TH1 cells(Jankovic et al., 2007; Trinchieri, 2007; Rutz et al., 2008) as well as both 
CD4+CD25+(Maloy et al., 2003) and TR1 regulatory T cells (reviewed in (Roncarolo et al., 2001)). CD8+ T cells(Tanchot 
et al., 1998)
 and B cells(O'Garra et al., 1990; Fillatreau et al., 2002; Mauri et al., 2003) are also known to express IL-10. As well 
as lymphocytes, myeloid cells, including macrophages(Boonstra et al., 2006), dendritic cells(Boonstra et al., 2006), 
eosinophils(Nakajima et al., 1996; Kayaba et al., 2001) and, more recently discovered, mast cells, also produce IL-
10(Grimbaldeston et al., 2007). 
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1.1.3. The IL-10 receptor 
IL-10 naturally occurs as a homodimer(Zdanov et al., 1995). The IL-10 receptor, found mainly on 
haematopoietic cells, is comprised of two subunits, and dimerises into a 4-unit complex upon binding 
the IL-10 dimer(Donnelly et al., 1999). Formation of the complex allows the kinases JAK1, associated with 
the IL-10R1 chain, and Tyk2, associated with the IL-10R2 chain, to trans-phosphorylate(Finbloom and 
Winestock, 1995; Ho et al., 1995; Kotenko et al., 1997; Riley et al., 1999)
. The now activated kinases transmit the signal 
downstream via cell-specific pathways (see  1.2.4 and  1.3.4). 
1.2. T cells and their activation 
Figure  1-1 outlines many of the points made in this section. 
1.2.1. T cell-Antigen Presenting Cell interactions 
In addition to MHC-molecule-antigen recognition by the T cell receptor (TCR), effective T cell 
priming requires costimulation, provided by cognate interaction with molecules on the surface of the 
antigen-presenting cell (APC). The two key costimulatory molecules are CD80/86 and B7RP-1 which 
bind to CD28 and Inducible Costimulatory molecule (ICOS), respectively, on the surface of the T 
cell(Linsley et al., 1990; Dong et al., 2001). 
CD28 is expressed relatively constantly on T cells, allowing it to receive an early costimulatory signal 
from CD80/86 on the surface of APC (reviewed in (Lenschow et al., 1996)). Binding of CD28 induces tyrosine 
phosphorylation of the YxxM motif in the cytoplasmic tail by pre-associated kinases(Raab et al., 1995; Holdorf 
et al., 1999)
. The phosphorylated motif is a consensus for src-homology-2 (SH2) domains, allowing the 
subsequent binding of, and signal transduction through, SH2-containing molecules such as 
phosphatidylinositol 3-kinase (PI3-K)(Pages et al., 1994; Prasad et al., 1994; Truitt et al., 1994; Ghiotto-Ragueneau et al., 1996) and 
growth factor receptor bound protein-2 (Grb-2)(Kim et al., 1998).  
Costimulation through CD28 is essential for IL-2 production in response to antigen which, in turn, 
ensures T cell activation as opposed to anergy(Jenkins et al., 1991; Linsley et al., 1991; Harding et al., 1992; Shahinian et al., 1993). 
Indeed, blockage of CD28 may be sufficient to induce anergy(Tan et al., 1993).  
ICOS, as its name suggests, exhibits more variable expression: ICOS expression is upregulated 
following TCR stimulation(Hutloff et al., 1999; Yoshinaga et al., 1999; McAdam et al., 2000) and is maintained on 
experienced T cells(Coyle et al., 2000; Vieira et al., 2004b). ICOS expression can be further enhanced by T cell 
costimulation via the CD28 pathway described above(van Berkel et al., 2005). Lack of ICOS signalling inhibits 
T cell activation. This has been demonstrated both by blockade(Coyle et al., 2000; McAdam et al., 2000; Tesciuba et al., 
2001)
 and by gene knockout(Dong et al., 2001; Tafuri et al., 2001). Interestingly, both techniques suggested ICOS 
signalling to be more important for TH2, rather than TH1, responses. However there is also evidence 
that ICOS is important for TH1 responses(Guo et al., 2001; Ozkaynak et al., 2001; Sporici et al., 2001). ICOS-deficient mice 
also exhibited limited antibody class-switching; in particular an almost complete lack of IgE(McAdam et al., 
2001)
. The fact that stimulation of CD40 restored class-switching in these mice suggests that ICOS plays 
a role in T-B cell interactions.  
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The ligand for ICOS, ICOSL, is expressed on APC and was originally named B7-related protein 
(B7RP)-1 or B7h because of its homology to the B7 molecules CD80 and CD86 (Yoshinaga et al., 1999; McAdam 
et al., 2000; Wang et al., 2000)
. Its expression is more limited than that of CD80 and CD86. One of the cell types 
on which it is expressed is B cells(Yoshinaga et al., 1999). This adds weight to the theory that ICOS is 
involved in T-B cell interactions. 
In common with CD28, the ICOS cytoplasmic tail has a YxxM motif and is able to recruit, and 
therefore signal through, PI3-K(Coyle et al., 2000). In contrast to CD28, however, it does not associate with 
Grb-2(Coyle et al., 2000). This difference may explain why it does not appear to be required for IL-2 
production(Hutloff et al., 1999; Coyle et al., 2000; Harada et al., 2003). ICOS does, however, appear to be key in the 
antibody class-switch to IgE(McAdam et al., 2001). This is relevant for potential treatments for allergic and 
atopic disorders. 
1.2.2. DC:T cell clusters and cis-regulation 
The key site for T cell–T cell interaction is the DC:T cell cluster. Upon recognising antigen being 
presented by a lymph node dendritic cell a T cell will interact with the DC for an extended period as it 
receives stimulatory signals. During that time, other T cells may interact with the same DC due to its 
presentation of the same or a different antigen. This co-association and the physical proximity of the 
two (or more) T cells allows molecules expressed by one (presumably the experienced, due to its faster 
response time) T cell to influence the activation of others. For example if two antigens are presented by 
the same dendritic cell cytokines produced by experienced, TH-polarised cells specific for one antigen 
can bias naïve T cells specific for the other(Creusot et al., 2003a; Schipf et al., 2003). In a similar way, regulatory T 
cells may inhibit the activation of naïve T cells(Onishi et al., 2008). These effects may be mediated either 
directly or via an effect on the dendritic cell.  
A significant consequence of this phenomenon is that an ongoing pathogenic response such as allergy 
or autoimmunity can enhance similarly inappropriate responses to other, juxtaposed antigens - an 
effect known as epitope spreading(Monneaux and Muller, 2002; Klehmet et al., 2004; McMahon et al., 2005) (reviewed in 
(Vanderlugt and Miller, 2002)
 and (Tompkins et al., 2002)).  
1.2.3. The plasticity of effector T cell subsets 
The paradigm of strict T cell subsets has stood for over two decades. Indeed, the term ‘lineage’ has 
been used in this context, indicating the commitment by T cells to their surface phenotype and 
cytokine profile. More recently it has been understood that there is a great deal of plasticity in even 
polarised effector T cells. 
Following many years in which the TH1/TH2 dichotomy was used to describe effector CD4+ T helper 
cells, new subtypes of TH cell have been identified:  TH17, TH9(Dardalhon et al., 2008; Veldhoen et al., 2008), 
TH22(Duhen et al., 2009). The first of these was the TH17 cell, expressing the RORγt transcription factor and 
IL-17(Langrish et al., 2005; Park et al., 2005; Nakae et al., 2007). TH17 cells were originally identified as pathogenic in 
murine EAE and since then have been implicated in several other immune disorders(Chen et al., 2003b; Cua et 
al., 2003; Hellings et al., 2003; Murphy et al., 2003; Nakae et al., 2003; Park et al., 2005)
.  
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TH17 cells have been considered to be related to the TH1 subset, in particular because their archetypal 
cytokines (IL-12 and IL-23, respectively) were shown to share a common subunit(Aarvak et al., 1999; Oppmann 
et al., 2000; Parham et al., 2002)
. Other cytokine studies suggested that they are related to regulatory T cells(Lochner 
et al., 2008; Zhou et al., 2008)
, described in section  1.4. Specifically, TGF-β is associated with the induction of 
both TH17 and Treg cells(Bettelli et al., 2006; Veldhoen et al., 2006). Despite these observations, there is at least some 
degree of distinction between T cell subtypes. Antigen experienced cells of one subype are refractory 
to signals that normally induce another subtype(Yang et al., 2008b; Guo et al., 2009) and cytokines which promote 
one subtype often inhibit the development of another subtype(Langrish et al., 2005; Kryczek et al., 2007a; Kryczek et al., 
2007b)
. 
Nevertheless, the study of TH17 cells has demonstrated that effector T cells exhibit far more plasticity 
than was previously appreciated: TH17 cells are able to switch to a TH1 phenotype(Mathur et al., 2006; Bending et 
al., 2009; Lee et al., 2009)
. Perhaps more surprisingly, the transformation of Foxp3+ regulatory T cells into 
inflammatory TH17 cells, has been demonstrated(Xu et al., 2007; Radhakrishnan et al., 2008; Valmori et al., 2010). In 
humans, IL-17-capable Foxp3+ Treg have been identified, although it is unclear if these cells retain 
suppressive activity or have an entirely altered phenotype(Koenen et al., 2008; Beriou et al., 2009; Voo et al., 2009). 
In addition to these studies involving TH17 cells it has come to light that Foxp3+ Treg, or at least a 
proportion of them, can become effector T cells(Yang et al., 2008a; Duarte et al., 2009; Komatsu et al., 2009; Miyara et al., 2009; 
Zhou et al., 2009)
. The stability of more recently identified TH subtypes is also being investigated(Dardalhon et al., 
2008; Veldhoen et al., 2008)
. 
Although the original TH1/TH2 lineage paradigm clearly stands corrected, it is not yet clear whether all 
subtypes of effector T cells can change to any other or whether there are fixed preferences and 
associations between subtypes. 
1.2.4. The effect of IL-10 on T cell activation 
It was established early on that IL-10 inhibits T cell proliferation and IL-2 production(de Waal Malefyt et al., 
1993; Taga et al., 1993)
. As described in  1.2.1 IL-2 synthesis is directly induced by CD28 stimulation. That 
blockage of this pathway is the mechanism by which IL-10 exerts its effect is confirmed by the 
inability of IL-10 to inhibit stimulation of T cells by anti-CD3 antibodies – a CD28-independent 
mechanism(Del Prete et al., 1993; Akdis et al., 2000). 
It was demonstrated that IL-10 inhibits the phosphorylation of CD28(Joss et al., 2000). In agreement was the 
observation that, in activated T cells at least, IL-10R associates with CD28(Akdis et al., 2000). Following the 
binding of IL-10 to IL-10R, trans-phosphorylation of IL-10R-associated JAK1 and Tyk2 (see  1.1.3) 
allows the association to Tyk2 of SH2-containing protein tyrosine phosphatase 1 (SHP-1)(Yetter et al., 1995). 
Conformational change in(Brockdorff et al., 1999; Stefanova et al., 2003; Yang et al., 2003) and phosphorylation of(Taylor et al., 
2007)
 SHP-1, resulting from this association, activate its phosphatase activity. It had been previously 
demonstrated that SHP-1 can inhibit other PI3 kinase-dependent signalling pathways(Cuevas et al., 1999). 
The cytoplasmic tail of CD28 contains a YxxM motif which, when phosphorylated, is able to recruit 
SH2-containing molecules such as PI3 kinase(Shoelson et al., 1992). Later work confirmed that SHP-1, 
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induced by IL-10, dephosphorylates the cytoplasmic tail of IL-10R-associated CD28, preventing its 
recruitment of, and signalling through, PI3 kinase(Taylor et al., 2007). Also featuring YxxM motifs, it is 
perhaps unsurprising that the IL-10-SHP-1 pathway inhibits costimulation through ICOS and CD2 in a 
similar way(Taylor et al., 2007; Taylor et al., 2008). Thus IL-10 inhibits T cell activation through the suppression of 
costimulatory signal.  
In the context of antigenic signal strength, SHP-1 also plays a role in the suppression of the primary 
TCR signal through ZAP-70(Pani et al., 1996; Plas et al., 1996; Brockdorff et al., 1999; Plas et al., 1999). This is in apparent 
contradiction to the earlier observation that anti-CD3-activation of T cells was not inhibited by IL-
10(Del Prete et al., 1993; Akdis et al., 2000). It is possible that SHP-1, in this case, is recruited by a different pathway 
and not by IL-10. 
In addition to the above mechanism, JAK1 and Tyk2 also phosphorylate tyrosine residues within the 
ITIM domain of the IL-10R cytoplasmic tail(Finbloom and Winestock, 1995; Weber-Nordt et al., 1996). This allows 
recruitment of the immunoinhibitory STAT3 transcription factor via association of its SH2 domain 
with the IL-10R ITIM. This has been shown to induce IL-10 production in T cells(Stumhofer et al., 2007); thus 
the local immunosuppressive environment is maintained. The function of STAT3 in T cells has not 
been studied as extensively as it has in dendritic cells. It will therefore be discussed in more detail in 
the context of DC (see  1.3.4).  
As well as merely limiting the immediate response to antigen, the presence of IL-10 during the 
activation of T cells has been shown to induce their transformation into regulatory T cells (see  1.4.2). 
The mechanism by which this is achieved is currently unclear. 
1.3. Dendritic cells and their maturation 
As well as its direct effect, IL-10 also exerts its inhibitory effect on T cells by limiting the efficacy of 
antigen presenting cells, in particular dendritic cells (DC). Indeed, inhibition via an effect on APC was 
the mechanism originally described(Bogdan et al., 1991; Fiorentino et al., 1991b; Ding and Shevach, 1992). Figure  1-1 outlines 
many of the points made in this section. 
1.3.1. The maturation model of dendritic cells 
Dendritic cells reside in many peripheral tissues where they continuously take up and process antigen. 
From there they are able to migrate to local lymph nodes and become potent antigen presenting cells. 
The model describing the transformation from ‘immature’ antigen-processing cells in the periphery to 
‘mature’ antigen-presenting cells in the lymphoid tissues was formulated over a decade ago(Rescigno et al., 
1997; Banchereau and Steinman, 1998)
 and has since been developed and refined(Banchereau et al., 2000; Guermonprez et al., 2002; 
Iwasaki, 2007)
. Maturation involves, among other things, the upregulation of MHC class II and 
costimulatory molecules and is generally believed to occur following the receipt of an innate immune 
stimulus or ‘danger signal’. This is often provided via recognition by DC Toll-Like Receptors (TLRs) 
of Pathogen Associated Molecular Patterns (PAMPs) such as LPS and bacterial DNA or molecules 
associated with cellular stress or damage such as Heat Shock Proteins (HSPs)(Hagihara et al., 2004; Iwasaki and 
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Medzhitov, 2004; Tsan and Gao, 2004)
. Additionally, other cell types, including epithelial cells, B cells and NK 
cells can mediate DC maturation(Bayry et al., 2005; Munz et al., 2005; Liu et al., 2007). 
Dendritic cells are frequently referred to as ‘decision makers’ or ‘conductors’ of the immune system 
(reviewed in (Banchereau and Steinman, 1998; Banchereau et al., 2000)). These names derive from the concept that they 
direct the immune response appropriately, according to detected danger. The first decision is whether 
or not a response is initiated: As described above, maturation of DC allows them to become potent 
antigen-presenting cells. In contrast, under steady-state conditions, when no danger is detected and DC 
do not mature, they do not induce a response. Much evidence shows that antigen presentation by such 
immature DC can tolerise T cells (discussed in  1.5). This may provide a system for continuous 
presentation of, and tolerisation to, self-antigens(Huang et al., 2000). 
The second decision can be described as one between qualitatively different types of T cell. In this 
decision, the nature of the PAMP or other danger signal is key. Stimulation of certain TLRs, such as 
TLR4 (e.g. by E. coli LPS) and TLR9 (e.g. by CpG sequence-rich DNA; see 1.7.2) will bias towards 
TH1 whereas others, such as TLR2 and TLR6 (e.g. by lipopeptides and yeast zymosan) will cause DC 
to induce a TH2 response(Schnare et al., 2001; Edwards et al., 2002; Dillon et al., 2004) (reviewed in (Zhu et al., 2008b) and (Kaiko et 
al., 2008)). The subject of TLRs in general is reviewed in (Takeda et al., 2003). The stimuli involved in the 
differentiation of more recently defined memory T cell subtypes such as TH17 cells(Harrington et al., 2005; Park 
et al., 2005)
 and TH22 cells(Duhen et al., 2009; Eyerich et al., 2009) is less well defined. However it does appear that 
TLR stimulation remains key in the initiation of the differentiation pathway(Martin et al., 2009). Interestingly, 
recent work on Th17 cells showed TLR expression on T cells and that PAMPs may directly stimulate 
these cells via these receptors(Reynolds et al., 2010). 
1.3.2. IL-10 reduces the quantity of antigen presentation 
The migration of DC from peripheral to lymphoid tissues is an essential part of their ability to present 
antigen and activate T cells (reviewed in (Alvarez et al., 2008; Randolph et al., 2008)). IL-10 decreases migration to, 
and increases emigration from, secondary lymphoid tissues(Wang et al., 1999a; Demangel et al., 2002). This effect 
appears to be mediated by promoting expression of CCR5, inhibiting expression of CCR7 and 
prevention of the CCR6 downregulation associated with DC maturation(Dieu-Nosjean et al., 2001; Takayama et al., 
2001a)
. 
Evidence also exists that IL-10 can reduce the number of DC and other APC by increasing their rate of 
spontaneous apoptosis(Ludewig et al., 1995; Raftery et al., 2004; Bailey et al., 2006; Chang et al., 2007). 
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Figure  1-1 The stimulation of dendritic cells and T cells and the inhibition of both by IL-10 
 
 
 
 
IL
-
10
IL
-
10
R
JA
K1
Ty
k2
ST
AT
3
N
aï
ve
 
T 
c
el
l
CD
28
CD
80
/8
6
TC
R
M
HC
:a
n
tig
e
n
IL
-
2
F
ig
u
r
e
 1
-1
. 
T
h
e
 s
ti
m
u
la
ti
o
n
 o
f 
d
e
n
d
r
it
ic
 c
e
ll
s
 
a
n
d
 
T
 
c
e
ll
s
 
a
n
d
 
th
e
 
in
h
ib
it
io
n
 
o
f 
b
o
th
 
b
y
 I
L
-1
0
.
T
h
e
 
im
m
u
n
o
s
ti
m
u
la
to
ry
 
p
a
th
w
a
y
: 
A
) 
P
A
M
P
s
 
d
e
te
c
te
d
 b
y
 T
L
R
 a
n
d
 o
th
e
r 
m
o
le
c
u
le
s
 o
n
 D
C
 c
e
ll
 
s
u
rf
a
c
e
 
a
n
d
 
in
 
in
tr
a
c
e
ll
u
la
r 
c
o
m
p
a
rt
m
e
n
ts
. 
B
) 
D
e
te
c
ti
o
n
 
o
f 
P
A
M
P
 
in
d
u
c
e
s 
m
a
tu
ra
ti
o
n
 
o
f 
D
C
 
in
cl
u
d
in
g
 u
p
re
g
u
la
ti
o
n
 o
f 
a
n
ti
g
e
n
 p
re
s
e
n
ti
n
g
 M
H
C
 
m
o
le
c
u
le
s
 a
n
d
 c
o
s
ti
m
u
la
to
ry
 C
D
8
0
/8
6
 m
o
le
c
u
le
s
. 
C
) 
R
e
c
o
g
n
it
io
n
 
o
f 
M
H
C
:p
e
p
ti
d
e
 
c
o
m
p
le
x
 
b
y
 
th
e
 
T
C
R
. 
D
) 
C
o
s
ti
m
u
la
ti
o
n
 o
f 
T
 c
e
ll
 v
ia
 i
n
te
ra
c
ti
o
n
 o
f 
C
D
8
0
/8
6
 
a
n
d
 
C
D
2
8
. 
E
) 
C
o
m
b
in
e
d
 
T
C
R
+
C
D
2
8
 
s
ig
n
a
l 
in
d
u
c
e
s 
T
 
c
e
ll
 
a
c
ti
v
a
ti
o
n
 
in
cl
u
d
in
g
, 
c
ri
ti
c
a
ll
y
, 
th
e
 p
ro
d
u
ct
io
n
 o
f 
IL
-2
. 
T
h
e
 i
m
m
u
n
o
s
u
p
p
re
s
s
iv
e
 p
a
th
w
a
y
: 
F
) 
IL
-1
0
 b
in
d
s
 
IL
-1
0
 r
e
c
e
p
to
r,
 r
e
s
u
lt
in
g
 i
n
 t
ra
n
s
-p
h
o
s
p
h
o
ry
la
ti
o
n
 
o
f 
JA
K
1
 
a
n
d
 
T
y
k
2
, 
p
h
o
s
p
h
o
ry
la
ti
o
n
 
o
f 
IT
IM
 
d
o
m
a
in
 
o
f 
IL
-1
0
R
 
a
n
d
 
re
c
ru
it
m
e
n
t 
a
n
d
 
p
h
o
s
p
h
o
ry
la
ti
o
n
 o
f 
S
T
A
T
3
. 
G
) 
S
T
A
T
3
 i
n
h
ib
it
s
 t
h
e
 
u
p
re
g
u
la
ti
o
n
 
o
f 
g
e
n
e
s
 
a
ss
o
c
ia
te
d
 
w
it
h
 
D
C
 
m
a
tu
ra
ti
o
n
 e
it
h
e
r 
d
ir
e
c
tl
y
 o
r 
v
ia
 t
h
e
 r
e
cr
iu
tm
e
n
t 
o
f 
o
th
e
r 
m
o
le
c
u
le
s
. 
H
) 
S
T
A
T
3
 
a
ls
o
 
u
p
re
g
u
la
te
s
 
IL
-1
0
 
e
x
p
re
s
s
io
n
 
b
y
 
D
C
. 
I)
 
IL
-1
0
 
b
in
d
s
 
IL
-1
0
 
re
c
e
p
to
r 
(a
s
 a
b
o
v
e
),
 r
e
s
u
lt
in
g
 i
n
 r
e
c
ru
it
m
e
n
t 
a
n
d
 
p
h
o
s
p
h
o
ry
la
ti
o
n
 
o
f 
S
H
P
-1
. 
J)
 
S
H
P
-1
 
d
e
p
h
o
s
p
h
o
ry
la
te
s
 
C
D
2
8
, 
p
re
v
e
n
ti
n
g
 
it
s
 
tr
a
n
sm
is
si
o
n
 
o
f 
th
e
 
c
o
s
ti
m
u
la
to
ry
 
s
ig
n
a
l.
 
T
h
is
 
d
ir
e
c
tl
y
 
p
re
v
e
n
ts
 
th
e
 
p
ro
d
u
c
ti
o
n
 o
f 
IL
-2
 a
n
d
 t
h
e
 
a
c
ti
v
a
ti
o
n
 o
f 
th
e
 T
 c
e
ll
. 
K
) 
D
C
-d
e
ri
v
e
d
 I
L
-1
0
 a
ls
o
 
a
c
ts
 
in
 
a
n
 
a
u
to
c
ri
n
e
 
m
a
n
n
e
r,
 
p
re
s
e
rv
in
g
 
th
e
 
im
m
u
n
o
s
u
p
p
re
s
s
iv
e
 q
u
a
li
ti
e
s
 o
f 
th
e
 D
C
. 
L
) 
IL
-1
0
-
s
e
c
re
ti
n
g
 
re
g
u
la
to
ry
 
T
 
c
e
ll
s
 
w
h
ic
h
 
re
c
o
g
n
is
e
 
a
n
ti
g
e
n
 
o
n
 
th
e
 
s
a
m
e
 
D
C
 
a
ls
o
 
p
ro
v
id
e
 
IL
-1
0
 
to
 
n
a
iv
e
 T
 c
e
ll
s
.
A
B
F G
J
D
en
dr
itic
 
ce
ll
E
H
C
TL
Rs
PA
M
Ps
Im
m
u
n
o
s
ti
m
u
la
to
ry
 p
a
th
w
a
y
Im
m
u
n
o
s
u
p
p
re
s
si
v
e
 p
a
th
w
a
y
P
o
in
t 
o
f 
in
h
ib
it
io
n
R
eg
u
la
to
ry
 
T 
ce
ll
K
D
L
I
23 
1.3.3.  IL-10 reduces the quality of antigen presentation 
Three stimulatory factors are provided by dendritic cells during antigen presentation to T cells: MHC-
antigen, costimulatory molecules and cyokines. As described above, the ability of DC to provide these 
is acquired during maturation. IL-10 has been shown in many different ways to interfere with DC 
maturation and the ability to efficiently activate T cells. 
IL-10 induces MHC class II molecule downregulation by DC(de Waal Malefyt et al., 1991b; Steinbrink et al., 1997; Faulkner 
et al., 2000; McBride et al., 2002)
. Alone, this effect, if sufficiently acute, may result in antigenic ignorance in 
naïve T cells. However it is more likely that a moderate reduction in the number of cell-surface MHC-
antigen complexes merely reduces the intensity of the overall stimulatory signal(Hugues et al., 2004). 
The classical costimulatory molecules, CD80 and CD86, are also downregulated in response to IL-
10(Ding and Shevach, 1992; Ding et al., 1993; Kawamura and Furue, 1995; Mitra et al., 1995). Pre-treatment of DC with IL-10 has 
shown this effect to inhibit the ability of DC to activate naïve T cells(McBride et al., 2002; Kubsch et al., 2003; Wakkach 
et al., 2003; Woszczek et al., 2008)
. The inhibitory effect of IL-10 on T cells via suppression of signalling through 
CD28 was decribed earlier ( 1.2.4). That CD80/86 are the ligands for CD28 means that IL-10 can 
inhibit the costimulatory signal via downregulation of both the signal transmitter and the signal 
receiver. It would be fair to speculate that if IL-10 were present at the immunological synapse these 
two suppressive mechanisms would likely synergise. 
The key cytokine associated with dendritic cell maturation and the ability of DC to activate lymphcytes 
is IL-12(Macatonia et al., 1995; Dubois et al., 1998; Berberich et al., 2003; Mandrekar et al., 2004). There is evidence that, in this 
way, IL-12 is more important for the induction of TH1 responses(Macatonia et al., 1995; Berberich et al., 2003). 
However, as well as having a direct effect on lymphocytes, autocrine IL-12 is also important for the 
complete maturation of DC(Hilkens et al., 1997; Bianchi et al., 1999). In this way, DC-produced IL-12 is vital to the 
development of T cell responses in general.  
IL-10 has long been known to downregulate IL-12 production by DC(De Smedt et al., 1997). Indeed, the 
presence of IL-10 inhibits IL-12 production (Takayama et al., 1998; Xia and Kao, 2002; Xia and Kao, 2003) and its absence 
allows DC to mature and present antigen more effectively(Demangel et al., 2002). The inverse is also true: 
Neutralisation of IL-12 in vivo can result in the induction of tolerance(Riemann et al., 1996). It has been 
suggested that the mechanism of this reciprocal relationship is at the transcriptional level(Aste-Amezaga et al., 
1998)
. However the blocking of NF-κB also appears to be involved(Wang et al., 1995; Bhattacharyya et al., 2004). 
Interestingly, there is evidence that, whilst it does inhibit IL-12 production, IL-10 still allows transient 
maturation of DC and that this may give rise to tolerogenic DC(Perona-Wright et al., 2007) (see section  1.5).   
Naturally occurring, IL-10-producing DC have been identified(Akbari et al., 2001; Corinti et al., 2001; Monteleone et al., 
2008)
. That autocrine IL-10 might allow these cells to maintain their IL-10+IL-12– phenotype and that 
autocrine IL-12 allows activated DC to reach full maturity promotes the idea that a critical decision is 
made at or around the time of activation, after which time DC are either IL-12-producers or IL-10-
producers(Jiang et al., 2002; Wakkach et al., 2003). However, mutually exclusive production of these two cytokines 
is not necessarily always true; a DC population has been identified that produces both IL-10 and IL-
12(Muthana et al., 2006). Nevertheless, that IL-10 inhibits DC production of IL-12 is clear. 
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1.3.4. The mechanism of the effect of IL-10 on antigen presenting cells 
As described above (see  1.1.3 and  1.2.4), binding of the IL-10 dimer by the IL-10 receptor results in 
trans-phosphorylation and activation of JAK1 and Tyk2 as well as phosphorylation of tyrosine residues 
within the ITIM domain of the IL-10R cytoplasmic tail. This allows recruitment of the 
immunoinhibitory STAT3 transcription factor via association of its SH2 domain with the IL-10R 
ITIM.  
The antiinflammatory effects of IL-10 on APC are mediated entirely through the STAT3 transcription 
factor. In mice, disruption of the  STAT3 gene in macrophages and neutrophils causes constitutive 
activation and nonresponsiveness to IL-10 in these cells and the development of colitis in the 
animal(Takeda et al., 1999). Microarray experiments identify many transcriptional changes induced by IL-10; 
reexamination in STAT3-deficient cells showed all these changes to be dependent on STAT3(Lang et al., 
2002a)
. Transfection of macrophages with a dominant negative STAT3 showed similar effects(Williams et al., 
2004)
. In contrast, constitutively active STAT3 can emulate exposure to IL-10(Williams et al., 2007), as can the 
artificial engineering of other receptors to activate STAT3(El Kasmi et al., 2006). In a similar way to viral 
homologues of IL-10 ( 1.1.1), the importance of STAT3 in the suppression of the inflammatory 
response is demonstrated by a pathogen: Toxoplasma gondii directly, and independently of IL-10, 
activates STAT3, suppressing the potential inflammatory response that would protect the host(Butcher et 
al., 2005; Saeij et al., 2007)
. 
Downstream of STAT3, the IL-10-induced antiinflammatory pathway is still relatively unclear. 
However, it appears to be mainly due to inhibition of transcription of genes normally upregulated by 
detection of PAMPs by TLRs(Lang et al., 2002a; Murray, 2005). Several molecules have been suggested as targets 
for STAT3 including suppressor of cytokine signalling (SOCS)3(Berlato et al., 2002; Lang et al., 2003; Li et al., 2006), 
BCL3(Kuwata et al., 2003; Wessells et al., 2004; Riemann et al., 2005), ETV3 and SBNO2(El Kasmi et al., 2007). 
1.4. Regulatory T cells 
Healthy animals and humans contain potentially self-reactive or otherwise pathogenic T cells that 
escape deletion during their thymic development(Fowell and Mason, 1993; Hafler and Weiner, 1995; Asseman et al., 2003). 
Nevertheless, autoimmunity and allergy do not occur in the majority of individuals. “Suppressor” T 
cells were first proposed as a protective mechanism over 30 years ago(Gershon and Kondo, 1970; Gershon and Kondo, 
1971; McCullagh, 1973)
. However, amongst other things, a lack of tools led to the evolution of increasingly 
complex models and explanations. As technologies advanced, particularly those of genetic sequencing 
and monoclonal antibodies, many highly-regarded theories did not stand up to scrutiny and the field as 
a whole became tainted. Only years later was the subject revisited in a series of experiments that 
culminated in proof that ‘infectious’ tolerance was mediated by CD4+ T cells(Boitard et al., 1989; Qin et al., 1990; 
Qin et al., 1993)
. 
That tolerance is maintained  by one or more subsets of T cells whilst immunity, both protective and 
pathogenic, is mediated by others was suggested  by several different studies. Thymectomy or 
irradiation-induced lymphopoenia can lead to autoimmunity(Penhale et al., 1975) whilst adoptive transfer of 
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normal lymphocytes can prevent this(Penhale et al., 1976). Protective T cells, albeit poorly defined, could be 
isolated from untreated animals at an early stage(Mordes et al., 1987; Boitard et al., 1989). An early distinction 
between pathogenic and protective T cells was provided by the induction of pathogenic immunity by 
transfer of naïve, CD45RBHI T cells into SCID mice and protection from this disease by cotransfer of 
antigen-experienced, CD45RBLO T cells(Powrie et al., 1993). Importantly, it was observed that the same 
subgroups were also responsible for the induction and prevention of protective immunity in a pathogen 
model(Powrie et al., 1994). 
1.4.1. Naturally occurring Treg cells 
To efficiently study regulatory T cells it was necessary to identify a phenotypic marker more unique 
than CD45RB. CD25 was shown to be a suitable marker when depletion of CD25+ cells from 
lymphocyte suspensions adoptively transferred into athymic nude mice resulted in 
autoimmunity(Sakaguchi et al., 1995). In vitro studies confirmed that CD4+CD25+ T cells suppress T cell 
responses to antigen and showed that they require recognition of antigen to function in this way and 
that the mechanism of suppression is cell contact-dependent(Thornton and Shevach, 1998; Stephens et al., 2001). 
Identification of CD4+CD25+ regulatory T cells in human blood provided further confirmation of the 
nature of these cells and of the validity of CD25 as a reliable marker(Dieckmann et al., 2001; Jonuleit et al., 2001). 
CD25 is the IL-2 receptor α chain and thus widely expressed on T cells, especially during their 
activation. Therefore its use as an identifier of Treg has always been limited. Additionally, potential 
blocking of the IL-2 receptor is a caveat in experiments that enrich the CD25+ population using 
antibodies. A more suitable identifier was identified following genetic examination of autoimmune-
prone scurfy mice and humans suffering from immunodysregulation polyendocrinopathy enteropathy 
X-linked syndrome (IPEX); a mutation was discovered in the gene for the forkhead transcription factor 
Foxp3(Bennett et al., 2001; Brunkow et al., 2001; Wildin et al., 2001). High expression of this gene was discovered in 
CD4+CD25+ Treg (Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 2003). Later, its expression was shown to correlate 
with suppressor activity even in the absence of CD25 expression(Fontenot et al., 2005). 
Development of a bicistronic reporter system has allowed the identification of Foxp3+ cells ex vivo(Wan 
and Flavell, 2005)
. Nevertheless, Foxp3 is not merely a conventient marker for immunologists. It is required 
for regulatory activity of naturally-occurring Treg(Gavin et al., 2007) and artificially induced expression of 
Foxp3 can actually invoke regulatory properties in T cells(Fontenot et al., 2003; Hori et al., 2003).  
Not all CD4+CD25+ Treg characteristics are directly controlled by Foxp3(Sugimoto et al., 2006; Gavin et al., 2007). It 
is becoming clear that the decision to become a Treg involves a mechanism upstream of Foxp3(Gavin et al., 
2007; Hill et al., 2007)
. In fact, there is evidence that Treg can develop in the absence of Foxp3(Lin et al., 2007). 
Downstream, Foxp3 appears to prevent expression of key genes involved in T cell activation(Li et al., 2007; 
Marson et al., 2007)
. 
Whilst early literature suggested that regulatory T cells were anergic, traditional T cell stimuli such as 
mature dendritic cells and IL-2 are able to induce proliferation of CD4+CD25+ T cells(Levings et al., 2001; 
Yamazaki et al., 2003; Yamazaki et al., 2006)
. In fact, it appears that IL-2 is actually required for the expansion and 
function of these cells(Furtado et al., 2002; Thornton et al., 2004; Setoguchi et al., 2005).  
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Suppression of T cell responses by CD4+CD25+ Treg is antigen-specific. One possible mechanism is 
competition for cytokines and presented antigen(de la Rosa et al., 2004; Barthlott et al., 2005; Brandenburg et al., 2008; Onishi et 
al., 2008)
. In addition, however, their antigen-specific activation still allows their suppressive effects to be 
mediated upon any neighbouring T cells, likely via downregulation of APC costimulatory 
molecules(Cederbom et al., 2000; Misra et al., 2004; Lewkowich et al., 2005; Oderup et al., 2006; Onishi et al., 2008). Adoptive transfer 
studies with multiple transgenic T cells and their corresponding peptide antigens have shown that this 
mechanism allows CD4+CD25+ Treg to suppress a response to an unrelated, but proximally close, 
antigen(Takahashi et al., 1998; Thornton and Shevach, 1998; Thornton and Shevach, 2000; Tanchot et al., 2004; Sanchez-Fueyo et al., 2006).  
1.4.2. Inducible TR1 cells 
IL-10-secreting regulatory T cells were first proposed following HLA-mismatched stem cell 
transplants that did not result in graft-versus-host disease(Bacchetta et al., 1994). In vitro-generated IL-10-
secreting regulatory T cells were subsequently shown to suppress pathogenic immunity(Groux et al., 1997). It 
is now understood that these cells also protect against pathogenic immune responses to 
autoantigens(Kitani et al., 2000),  commensal bacteria(Duchmann et al., 1995; Cong et al., 2002) and allergens(Akdis et al., 2004). 
It appears that a major role of these TR1 cells is the mediation of tolerance at mucosal and skin sites 
where they prevent pathogenic immunity to foreign, nonpathogenic antigens. Both the discovery of 
TR1 cells and the bulk of later work are focused on these tissues(Powrie et al., 1993; Groux et al., 1997; Cong et al., 2002).  
It is likely that the generation of TR1 cells also occurs at these sites(Duchmann et al., 1995; Meiler et al., 2008). 
The importance of IL-10 for the regulatory activity of TR1 cells is demonstrated by the inability of 
CD45RBLO cells from IL-10-/- mice to protect against colitis induced by CD45RBHI cells (see 
 1.4)(Asseman et al., 1999) and by the ability to artificially generate regulatory T cells that will protect against 
colitis by transfection of T cells with the IL-10 gene(Van Montfrans et al., 2002a; Van Montfrans et al., 2002b). Mice in 
which the IL-10 gene has been disrupted in T cells only suffer from colitis and other syptoms in a 
similar way to mice in which the gene has been disrupted in all cells(Roers et al., 2004). Further restriction of 
this inactivation to Foxp3+ T cells results in much less severe disease, highlighting the distinction 
between the Foxp3+ and TR1 subsets of Treg(Rubtsov et al., 2008). 
Artificial antigenic stimulation of CD4+ T cells in the presence of IL-10 induces the generation of TR1 
cells(Groux et al., 1996; Groux et al., 1997; Cong et al., 2002) as do antigen presentation by IL-10-treated dendritic cells 
(see  1.5.2), antigen presentation by immature DC (see  1.5.1) and specific immunotherapy(Meiler et al., 2008). 
These phenomena are dependent on IL-10 and it is likely that they reflect, to some degree, natural 
antigen presentation under steady-state, noninflammatory conditions. Therefore IL-10 also plays a key 
role in the generation of TR1 cells. 
More recently it was observed that TR1 cells can also be induced by naturally-occurring Foxp3+ 
Treg(Dieckmann et al., 2002; Jonuleit et al., 2002; Kearley et al., 2005; Wakkach et al., 2008). Foxp3+ Treg are certainly not always 
required for TR1 induction(Levings et al., 2004) and even when this is the mechanism responsible for their 
generation direct suppressive activity by the Foxp3+ cell is maintained(Jonuleit et al., 2002). Nevertheless, 
these studies demonstrate the interrelationship between subsets of regulatory T cell.  
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Similarly to Foxp3+ Treg TR1 cells are activated in an antigen-specific manner(Bacchetta et al., 1994; Groux et al., 
1997; Cong et al., 2002; Yu et al., 2005)
. A particularly interesting example of this is the normal tolerance of 
intestinal leukocytes to self gut flora versus their strong proliferation in response to such bacteria from 
the intestine of another individual(Duchmann et al., 1995). Whilst their activation may be antigen-specific, the 
suppressive action of TR1 cells is mediated by a secreted cytokine and therefore precludes a purely 
antigen-specific action on responding T cells. Paracrine effects of IL-10 can inhibit the activation of 
any juxtaposed T cells within a DC cluster. Therefore, whilst suppression may be largely antigen-
specific, regulation of responses to other antigens being simultaneously presented is also likely. 
1.4.3. The distinction between regulatory T cell subsets is becoming blurred 
Whilst there are certainly differences in the origins and functions of the regulatory T cell subsets the 
traditional division between naturally occurring CD25+, Foxp3+ Treg and inducible IL-10-secreting Treg 
has become somewhat less distinct. Perhaps the best example of this is the identification of IL-10-
secreting CD4+CD25+ Treg and the recognition of their importance in protection from disease(Akdis et al., 
1998; Annacker et al., 2001; Francis et al., 2003; McGeachy et al., 2005; Yu et al., 2005; Uhlig et al., 2006; Maynard et al., 2007)
. 
Whilst it was believed that the Foxp3 transcription factor defined a separate lineage of regulatory T 
cell, it has been shown that IL-10-secreting Treg can derive both from Foxp3– and from Foxp3+ 
thymocytes(Maynard et al., 2007). A newly identified marker, TIRC7, is found on both CD25+ and IL-10-
secreting Treg and may distinguish a subset of CD25+ Treg that have the potential to become IL-10-
secreting TR1 cells(Wakkach et al., 2008).  
The origin of CD25+Foxp3+ Treg has also been questioned: Foxp3+ Treg derived from Foxp3– 
thymocytes have been observed(Maynard et al., 2007). Similarly, the characterisation of these cells as 
‘naturally occurring’, as opposed to inducible, is contested by work showing at least some degree of 
inducibility, either by in vitro antigen presentation in the presence of TGF-β(Chen et al., 2003a; Fantini et al., 2004) 
or by tolerogenic antigen administration protocols(Thorstenson and Khoruts, 2001; Zhang et al., 2001; Hauet-Broere et al., 2003; 
Kretschmer et al., 2005)
. Under natural conditions, TGF-β produced by existing Foxp3+ Treg or by DC could 
induce naïve CD4+ T cells to become Treg(Luo et al., 2007; Andersson et al., 2008). 
In other experiments, IL-10-secreting Treg can show similar properties to CD4+CD25+ Treg including 
IL-10-independent suppression(Vieira et al., 2004a). A caveat to this observation is that these IL-10+ Treg were 
induced in vitro with a combination of vitamin D3 and dexamethasone, as opposed to the more 
traditional treatment with IL-10, and have a slightly different cytokine profile(Barrat et al., 2002).  
Despite these observations, the existing division of Treg subtypes is likely to be appropriate to some 
degree. The isolation of viable IL-10-producing T cells based solely on this feature and without a 
unique cell surface marker is difficult. Therefore studies on pure populations have not been carried out. 
Whilst Foxp3+ cell-derived IL-10 appears to play a role it is not the only IL-10-dependent mechanism 
of suppression by these cells; their induction of TR1 cells is probably still more important(Maynard et al., 
2007)). For these reasons it has been suggested that TR1 cells are more strictly defined as those whose 
induction and regulatory activity are dependent on IL-10(Maynard and Weaver, 2008). 
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Finally, the overall function of Treg subtypes may be more relevant than their detailed phenotype and 
origin. In particular, and following on from initial studies, it appears that the key function of IL-10-
secreting TR1 cells is the regulation of immune responses at mucosal interfaces(Uhlig et al., 2006; Rubtsov et al., 
2008)
. It has been suggested that these cells regulate activated T cells which have already reached 
inflamed tissue whilst Foxp3+CD25+ Treg act upstream, inhibiting activation in the secondary lymphoid 
tissues(Samy et al., 2005) (reviewed in (Maynard and Weaver, 2008)). 
1.5. The role of DC in induction of regulatory T cells 
1.5.1. Immature DC as inducers of tolerance 
As mentioned in  1.3.1, DC are key in the decision between immunity and tolerance. Perhaps the most 
widely accepted theory regarding this is that antigen presentation by mature DC (mDC) induces 
immunity whilst that by immature DC (iDC) induces tolerance. An attempt to develop an effective 
immunisation protocol supported this theory when it was discovered that targeting antigen to DC 
which have received no maturation stimulus resulted in tolerance, rather than immunity(Hawiger et al., 2001; 
Bonifaz et al., 2002; Mahnke et al., 2003; Probst et al., 2003)
. 
In vitro, stimulation with allogeneic immature DC induced naïve T cells to become regulatory T cells, 
specifically IL-10-producing TR1 cells(Jonuleit et al., 2000; Levings et al., 2004). The importance of the immaturity 
of the DC is reinforced by studies which target antigen to DC whilst simultaneously providing a DC 
maturation signal(Bonifaz et al., 2002; Bonifaz et al., 2004). In vivo, targeting of antigen to iDC and administration of 
antigen-pulsed iDC both resulted in tolerisation to antigen(Dhodapkar et al., 2001; Bruder et al., 2005).  
The immune system is constantly exposed to innocuous foreign antigens such as those in food and 
pollens. It is generally understood that, due to the normal absence of inflammation (sometimes referred 
to as steady-state conditions), these antigens are presented by immature dendritic cells, thus inducing 
or maintaining tolerance. It is likely that the tolerogenic effect of certain immunotherapeutic antigen 
administration protocols, such as oral and nasal tolerisation and specific immunotherapy, is mediated 
by this same mechanism(Chen et al., 1994; Akdis and Blaser, 1999; Akbari et al., 2001; Hurst et al., 2001; Thorstenson and Khoruts, 2001; 
Hauet-Broere et al., 2003; Unger et al., 2003; Ostroukhova et al., 2004; Van Hove et al., 2007)
. 
1.5.2. IL-10-treated DC and IL-10-producing DC as inducers of tolerance  
The above tolerisation of T cells by immature DC, including the technique of Specific Immunotherapy 
(SIT), appears to be dependent on DC-derived IL-10(Akbari et al., 2001; Levings et al., 2004) and can be enhanced 
by IL-10-inducing adjuvants(Van Overtvelt et al., 2008). In vivo studies show that IL-10-expressing DC 
naturally occur in mucosal tissues such as the lung(Akbari et al., 2001) and gut(Chirdo et al., 2005) as well as 
immune tissues(Wakkach et al., 2003) and that they tolerise T cells to antigen. 
A caveat to the distinction being drawn here is that even if immature DC do induce tolerance, in 
certain situations, DC maturation may not prevent, and might even be a requirement for, 
tolerisation(Lundqvist et al., 2005; Lau et al., 2008). Nevertheless, there is evidence that autocrine IL-10 prevents 
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full maturation of DC; it could be argued that only full maturation leads to immune stimulation(Corinti et 
al., 2001; Demangel et al., 2002; Monteleone et al., 2008)
. 
Autocrine regulation of DC by IL-10 can be studied by artificial exposure of DC to the cytokine. 
Pretreatment of DC with IL-10 has been repeatedly shown to confer tolerogenic properties, including 
the secretion of IL-10 itself(Steinbrink et al., 1997; Steinbrink et al., 1999; Muller et al., 2002; Steinbrink et al., 2002; Kubsch et al., 2003; 
Wakkach et al., 2003; Li et al., 2009)
. Indeed, the STAT3 signalling pathway induced by IL-10 induces 
upregulation of the same cytokine, forming a positive feedback loop(Benkhart et al., 2000; Ziegler-Heitbrock et al., 2003; 
Staples et al., 2007)
. Antigen presentation by these DC to naïve T cells renders the T cell anergic, possibly 
itself becoming a regulatory T cell (McBride et al., 2002; Fu et al., 2008; Yamaura et al., 2008). Interestingly, whilst 
suppressing the adaptive immune response, IL-10-treated DC show an intact, or even enhanced, ability 
to contribute towards the innate, inflammatory response(Nolan et al., 2004). 
Although the tolerogenic properties of immature DC appear to be dependent on their production of IL-
10(Koya et al., 2007), the inverse is not necessarily true: Naturally-occurring, IL-10-secreting, tolerogenic 
DC that are phenotypically mature have been described(Akbari et al., 2001; Akbari et al., 2002). Finer dissection 
may explain these different findings; altered kinetics(Perona-Wright et al., 2007) and reduced IL-12 expression 
(irrespective of surface phenotype; see section  1.3.3) are two existing theories. 
Autocrine IL-10 feedback may be a key to DC-induced tolerance. Indeed, transgenic mice expressing 
IL-10 via the MHC class II promoter are highly resistant to induction of autoimmunity(Cua et al., 1999).  
Studies of IL-10-transfected DC have demonstrated greatly inhibited T cell stimulatory activity(Takayama 
et al., 1998; Takayama et al., 1999)
 and an ability, at least under certain conditions, to induce TR1 regulatory T 
cells(Fu et al., 2008). Both the pre-treatment and the transfection approaches have been extended into 
treatment of immune disorders (discussed in sections  1.6.3 and  1.6.4). 
1.5.3. Specialised subsets of DC? 
As central controllers, DC may select between immunity and tolerance. However, there is evidence 
that specialised tolerising DC may exist (Akbari et al., 2001; Iwasaki and Kelsall, 2001; Chirdo et al., 2005; Yamazaki et al., 2008). 
Most evidence comes from studies on intestine; it is perhaps logical that the mucosal tissue most 
constantly and intensively in contact with foreign antigen be that which most requires a rigorous 
tolerisation mechanism(Coombes et al., 2007; Sun et al., 2007). As discussed in  1.4.3, it appears that TGF-β plays a 
key role in the induction of Foxp3+ Treg by intestinal DC(Coombes et al., 2007; Luo et al., 2007).  
The existence of these tolerising DC may not contradict the paradigm of the DC as a decision-maker. 
That they tend to be located in a specific tissue suggests that their tolerising characteristics such as 
TGF-β expression and even expression of phenotypic markers such as CD103(Coombes et al., 2007; Sun et al., 
2007)
 may be a response to site-specific stimuli in the in gut(Ginhoux et al., 2009) rather than indicating a 
distinct lineage. Indeed, there is evidence that factors secreted by intestinal epithelial cells are able to 
induce these characteristics in monocyte-derived DC(Iliev et al., 2009). Nevertheless it appears that such 
tissue-specific effects may remain even if the DC is removed from its original environment(Akbari et al., 
30 
2001)
. Therefore even if tolerogenic DC are a product of their environment they have the potential to 
remain, to some degree, specialised. 
1.6. IL-10 used against disease 
The ever-strengthening connection between IL-10 and immune suppression/tolerance has led to many 
investigations into the therapeutic use of the cytokine against immune diseases (reviewed in (O'Garra et al., 
2008)). Technological and scientific advances have led to the use of increasingly sophisticated methods 
of cytokine administration, allowing increased accuracy and specificity. It appears clear that no single 
treatment is suitable for all disorders; this in itself provides a better understanding of the variety of 
pathological mechanisms involved. 
1.6.1. Recombinant IL-10  
Experimental Autoimmune Encephalomyelitis (EAE) is a well defined model of human multiple 
sclerosis. The EAE autoantigen is myelin basic protein (MBP), against which transgenic T cells have 
been developed. It was demonstrated early on that rats subcutaneously injected with IL-10 during and 
after immunisation with MBP were resistant to EAE induction(Rott et al., 1994). Intranasal administration of 
IL-10 was also shown to be effective(Xiao et al., 1998). Interestingly, intravenous administration of IL-10 
was unable to inhibit the development of EAE(Cannella et al., 1996). This suggests that the route and timing 
of IL-10 administration  are important for its immunosuppressive properties. That the IL-10 receptor is 
expressed on a wide variety of cells and that its effects can be widespread would agree that, indeed, 
targeting delivery to a specific location or cell type might be desirable. 
Orally delivered, polymer-coated gelatin microparticles containing recombinant IL-10 have been used 
to target the cytokine to the large intestine(Bhavsar and Amiji, 2008). This technique improved the histological 
and clinical outcome in studies on a model of colitis. An IL-10-IL-1 receptor agonist fusion protein 
was developed to target inflamed joint synovia in a model of rheumatoid arthritis (Chang et al., 2004a). 
Recombinant IL-10 has been tested in clinical trials against psoriasis(Asadullah et al., 2001; Reich et al., 2001) and 
Crohn’s disease(Tilg et al., 2002) as well as against febrile responses associated with expermental 
endotoxaemia(Pajkrt et al., 1997). In general, treatments were able to inhibit certain cytokines and symptoms 
but side effects included upregulation of other cytokines and flu-like symptoms. These studies 
demonstrate the broad spectrum of IL-10’s activity as both an immune suppressor and stimulator. It 
also illustrates a significant limitation of the systemic administration of normally locally-produced, 
short-lived cytokines. 
1.6.2. IL-10-expressing bacteria 
That the site of IL-10 administration is important in the inhibition of immune disorders makes diseases 
of specific, accessible organs attractive for treatment. As described in  1.4.2, IL-10-induced, IL-10-
secreting TR1 cells were first defined in the study of colitis. Intestinal immune disorders are therefore 
obvious candidates for IL-10 treatment.  
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Inflammatory bowel disorders are often caused by undesired immune responses to non-pathogenic, 
commensal microorganisms(Singh et al., 2001). As described in  1.1.1, IL-10 has been shown to be important 
in preventing these disorders. A novel approach was developed whereby a gut-commensal lactococcus 
species was genetically engineered to express IL-10(Steidler et al., 2000). Oral administration resulted in a 
significant inhibition of colitis. The bacterium was further engineered to be dependent on thymine and 
thymidine, ensuring it would not be viable in the environment(Steidler et al., 2003). Several technological 
steps were made to increase the efficiency of administration(Huyghebaert et al., 2005a; Huyghebaert et al., 2005b; Termont et 
al., 2006)
. A phase I clinical trial demonstrated that this is a promising method of combating an immune 
disorder with IL-10(Braat et al., 2006).  
The engineered bacterium appears to penetrate into the mucosa(Waeytens et al., 2008). In vitro work suggests 
that at least one mechanism of action is the modulation of DC maturation(Loos et al., 2009).  
1.6.3. IL-10-treated DC 
As described earlier (see  1.5.2) in vitro IL-10 treatment of DC can confer tolerogenic properties. This 
phenomenon was established by studying the interaction of these DC with T cells in vitro. Reduced 
stimulatory ability of these DC has also been shown upon their return to the body(Haase et al., 2002). The 
possibility of using IL-10-treated DC to induce tolerance in disease situations has been explored. In 
mice, such DC were able to inhibit airway hyperresponsiveness in an ovalbumin allergy model(Koya et al., 
2007)
 and to prevent weight loss and histopathology in a SCID model of colitis(Pedersen et al., 2007). The 
facilitation of antigen presentation by the treated DC (by pulsing with OVA or enterobacterial extract, 
respectively) was important in both cases. IL-10-treated DC have also been shown to be effective 
against collagen-induced arthritis (CIA)(Kim et al., 2005) and experimental myasthenia gravis(Xiao et al., 2006). 
The latter study was extended into the clinical setting with some success. 
1.6.4. IL-10-transfected DC 
As described in  1.5, IL-10 expression appears to be more important in determining the immunogenicity 
vs tolerogenicity of a DC than do maturation-specific cell surface phenotypic markers. Several studies 
have examined the forced expression of IL-10 by antigen-presenting DC as a way to induce antigen-
specific tolerance. 
In vitro data shows that transfection of DC with IL-10-encoding retrovirus(Takayama et al., 1998) or 
adenovirus(Whalen et al., 2001; Rea et al., 2004) inhibits their ability to stimulate T cells. The authors suggest that 
these cells could potentially be used to treat immune disease. This possibility is expanded by a 
refinement; the inclusion of the eGFP gene, allowing potentially tolerogenic cells to be purified for use 
in treatment of disease(Takayama et al., 1999).  
Transfer of IL-10-transfected DC to experimental animals has been demonstrated to protect against 
several immune pathogeneses. Lipid, retroviral and adenoviral vectors have been successfully 
employed in this manner against asthma(Henry et al., 2008), allograft rejection(Coates et al., 2001; Moore et al., 2004; Zhang 
et al., 2004; Zhu et al., 2008a)
, colitis(Van Montfrans et al., 2002a), myocarditis(Yang et al., 2006) and hyperimmune responses 
such as DTH(Whalen et al., 2001) and septic shock(Oberholzer et al., 2001). Nevertheless, it is clear that effective 
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suppression by IL-10-transfected DC in vitro does not automatically translate into success in 
vivo(Buonocore et al., 2002). 
Similarly to ex vivo treatment of DC with IL-10, although these attempts to treat disease with IL-10-
transfected DC have shown some success, approaches involving ex vivo treatment of cells followed by 
their return to the body are complex: They must take into account histocompatibility and/or involve 
patient-tailored treatments. Transfection in vivo overcomes these problems. 
The use of retroviral and adenoviral vectors to transfer the IL-10 gene has been extended in vivo. 
Similarly to the above ex vivo work, some inhibition of asthma(Stampfli et al., 1999), DTH(Whalen et al., 2001), 
septic shock(Oberholzer et al., 2001; Oberholzer et al., 2002; Oberholzer et al., 2005), EAE(Cua et al., 2001) and CIA(Apparailly et al., 1998) 
has been documented. Interestingly, whilst an IL-10-encoding viral vector has been shown to protect 
against destruction of synergeic islet transplants due to preexisting immunity to islet antigen(Zhang et al., 
2003)
, it was not able to prevent rejection of islet allotransplants(Zhang et al., 2005). It is important to note that, 
as opposed to viral transfection of DC ex vivo, viral vectors administered in vivo may transduce 
multiple cell types. Nevertheless there is evidence that some such vectors do exhibit a degree of 
specificity to DC(Oberholzer et al., 2002; Oberholzer et al., 2005). 
Sections  1.5.1 and  1.5.2 discuss the immature-tolerogenic / mature-immunogenic model of DC and 
that IL-10 expression by DC may be more important than their maturation state. There is evidence that 
retroviral vectors have inhibitory effects on DC maturation and stimulatory ability, independent of any 
transgene(Chen et al., 2004). In contrast, recombinant adenovirus alone has been shown to mature DC(Morelli et 
al., 2000; Oberholzer et al., 2002)
. That adenovirus vectors have shown a degree of success in IL-10-induced 
immune regulation agrees with the above notion that an immature state is not critical for tolerising: 
perhaps mature (or semi-mature) DC expressing IL-10 might even be more effective(Rea et al., 2004). 
The outcome of administration of IL-10-treated or –transfected DC, or of IL-10-encoding viral vector 
appears to be dependent on the route of administration. IL-10-treated DC successfully inhibited disease 
when administered to the peritoneum but did not when injected subcutaneously(Xiao et al., 2006; Pedersen et al., 
2007)
. IL-10-transfected DC induced allograft tolerance when injected into the portal vein but not the tail 
vein(Zhang et al., 2004). IL-10-expressing adenovirus improved the survival rate in a murine sepsis model 
when injected directly into the thymus(Oberholzer et al., 2001) and prevented the induction of EAE when 
injected directly into the CNS(Cua et al., 2001). In both cases, peripheral administration was ineffective. 
1.7. Genetic immunisation 
The administration of DNA encoding antigen in order to elicit an immune response to the expressed 
protein was first proposed almost 20 years ago(Tang et al., 1992). Quickly several groups produced data 
supporting this suggestion(Robinson et al., 1993; Ulmer et al., 1993; Wang et al., 1993) and protection against infectious 
disease was demonstrated(Lai et al., 1995; Ulmer et al., 1998; Walker et al., 1998; Cornell et al., 1999; Weiss et al., 2000). Genetic 
immunisation has advantages over traditional protein-based vaccines at both the design and the 
administration stages. Firstly, it is possible to rapidly test the genome of a pathogen for immunogeneic 
sequences/epitopes(Haddad et al., 2004). The process does not involve complex protein purification steps and, 
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in the case of naked DNA vaccines, does not carry the risks of using attenuated pathogens. DNA has 
inherent immunostimulatory properties (see  1.7.2) and therefore may not require formulation with 
adjuvant. Secondly, the intrinsic stability of DNA means that, depending on the formulation, DNA 
vaccines can often be stored without refrigeration. One method of administration is particle-mediated 
DNA delivery (PMDD) using the gene gun (see  1.7.3); this method also obviates the use of 
hypodermic needles.  
Broadly speaking there are two types of genetic vaccines: Viral vectors, including adenoviruses and 
retroviruses, and naked DNA, including injected plasmid solutions and the gene gun. The former, 
being least relevant to this study, will be discussed separately and in less detail. 
1.7.1. Viral vaccine vectors 
Recombinant viral vectors are a logical choice as a tool for genetic immunisation because their natural 
transducing abilities can be exploited. Adenoviral vectors were shown early on to produce significant 
cellular and humoral responses against encoded antigens(Xiang et al., 1996; He et al., 2000). Long-lasting cellular 
responses appear to be maintained by the longevity of such vectors within T cells(Tatsis et al., 2007). More 
recently, adenovirus-based vaccines have shown protection against several different pathogens(Fattori et 
al., 2006; Lo et al., 2008; Magalhaes et al., 2008; Raviprakash et al., 2008; Resende et al., 2008; Arevalo et al., 2009)
 as well as tumour 
antigens(Butterfield et al., 2008; Peruzzi et al., 2009).  
A significant disadvantage to viral vector-based vaccines is the presence of viral antigens. Preexisting 
antibodies to these antigens can neutralise the vector, greatly reducing its efficacy(Yang et al., 1995; Fitzgerald et 
al., 2003)
. Similarly, a response generated against an initial administration of vaccine could neutralise 
later, booster, immunisations. Two approaches to avoid this problem show promise: PEGylation, the 
modification of viral particles with polyethylene glycol, appears to shield virions from antibodies, 
allowing them to avoid neutralisation before transfection has occurred(Croyle et al., 2001; Croyle et al., 2002). 
Secondly, boosting an adenovirally primed response with a vector of a different serotype(Pinto et al., 2003), 
or an entirely different virus(Bruna-Romero et al., 2001), may circumvent the problem of neutralisation by 
antibodies generated to the priming vector. However using this route extensively would eventually use 
up all available viral vectors and so would not be suitable as a general method of immunisation.  
Whilst DC remain the most important target for genetic vaccines, adenoviruses do not exhibit a strong 
affinity to these cells. Several studies have shown improvement of DC targeting by alteration or fusion 
of viral envelope proteins(Okada et al., 2001; Korokhov et al., 2005) (Pereboev et al., 2004). As well as shielding them from 
preexisting antibodies, PEGylation also ‘detargets’ adenoviral vectors from their natural targets: CAR-
expressing, non-DC cells(Kreppel et al., 2005; Wortmann et al., 2008). This presumably increases the availability of 
free vector to be taken up by endocytic DC.  
Retroviral vectors have been used to transfect DC ex vivo(Chinnasamy et al., 2000; Schroers et al., 2000) and in 
vivo(VandenDriessche et al., 2002; Esslinger et al., 2003; Palmowski et al., 2004). DC transfected ex vivo by retroviral vectors 
have been shown to be effective at stimulating T cell responses(Granelli-Piperno et al., 2000; Dyall et al., 2001; Metharom 
et al., 2001; Esslinger et al., 2002; He et al., 2005)
. However, as discussed in  1.6.4, ex vivo treatment of cells followed 
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by their return to the body is time- and labour-intensive. Administration of viral vectors in vivo is the 
ideal procedure for this technique and has shown some success(Esslinger et al., 2003; Palmowski et al., 2004; Rowe et al., 
2006; Iglesias et al., 2007; Arce et al., 2009)
. 
Improvements to first generation lentiviral vectors have increased their potential usefulness as 
vaccines. The safety profile of such vaccines has been improved by restricting antigen gene expression 
to DC by placing it under control of the dectin-2 promoter(Lopes et al., 2008) and by inserting mutations 
which prevent integration into the host genome(Karwacz et al., 2009). Safety has also been improved by 
targeting of vector to APC through fusion of single-chain antibodies to an existing envelope 
protein(Gennari et al., 2009). Such targeting also improves the immunostimulatory ability of the retroviral 
vector. Similarly, the encoding of vFLIP, a viral activator of NF-κB, alongside antigen gene induces 
DC maturation and, therefore, enhances the response to antigen(Rowe et al., 2009).  
Despite positive results using viral vectors as vaccines they are inherently complex. Pathogenic 
reactions have arisen in the past(Raper et al., 2002; Raper et al., 2003), and the potential remains for recurrences in 
the future. Naked DNA vaccines involve fewer antigens and the pathways involved are simpler and 
more well understood. A successful naked DNA vaccine is, therefore, likely to be more attractive than 
an equally effective viral vector vaccine.  
1.7.2. DNA as an adjuvant 
As mentioned above, naked DNA vaccines do not require formulation with adjuvants such as 
aluminium hydroxide or IFA. This is primarily due to the presence of unmethylated CpG sequences in 
bacterial DNA which result in the secretion of both TH1 and TH2 cytokines(Yamamoto et al., 1992b; Krieg et al., 
1995; Pisetsky et al., 1995; Halpern et al., 1996; Klinman et al., 1996)
.  The presence of such sequences has been shown to be 
necessary for the induction of an immune response by DNA vaccines(Sato et al., 1996; Klinman et al., 1997). CpG-
rich DNA has, in fact, been used as adjuvant alongside genetic immunisations(Tengvall et al., 2005), protein 
antigen(Brazolot Millan et al., 1998; Davis et al., 2000; Gallichan et al., 2001; Tengvall et al., 2006) or even alone prior to viral 
challenge(Harandi et al., 2003). The importance of the state of methylation of CpG sequences in determining 
their immunogenicity is unclear(Klinman et al., 1997; Feltquate and Robinson, 1999; Cornelie et al., 2004b). 
As described in  1.3.1, dendritic cells detect danger signals by the expression of TLR molecules which 
recognise pathogen-associated molecular patterns. The immunostimulatory effect of CpG sequences is 
mediated by DC(Halpern et al., 1996; Jakob et al., 1998; Sparwasser et al., 1998; Behboudi et al., 2000) and other APC such as B 
cells(Messina et al., 1991; Krieg et al., 1995) following the binding of CpG to TLR-9(Bauer et al., 2001b; Cornelie et al., 2004a; Lin 
et al., 2004b; Coch et al., 2009; Ma et al., 2009)
. Although early data showed that bacterial DNA could trigger both 
TH1 and TH2 cytokine production, more recent studies have shown a clear TH1 bias, most significantly 
the expression of IL-12 by DC(Halpern et al., 1996; Jakob et al., 1998; Behboudi et al., 2000; Kranzer et al., 2000; Weeratna et al., 2000; Liu 
et al., 2005)
.  
Whilst recognition of bacterial DNA by a Toll-like receptor is unquestionably important, recent work 
has also identified other, non-TLR receptors which recognise bacterial DNA(Takaoka et al., 2007; Ishii et al., 2008). 
A caveat to studies of genetic immunisation in murine models is the difference in expression of TLRs 
between mouse and human cells. In particular, studies have shown that human TLR-9 is expressed on 
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plasmacytoid, but not monocyte-derived, DC(Bauer et al., 2001a; Jarrossay et al., 2001; Kadowaki et al., 2001; Krug et al., 2001; 
Hornung et al., 2002)
. However, others argue that the latter do, indeed, express TLR-9(Hoene et al., 2006). 
1.7.3. Naked DNA vaccine vectors 
Intramuscular injection of plasmid DNA results in expression of an encoded gene(Wolff et al., 1990). Soon 
after this observation was made it was shown that encoded antigen can induce an immune response and 
protect against infection(Robinson et al., 1993; Ulmer et al., 1993). The precise mechanism of DNA uptake, gene 
expression and antigen presentation is unclear. Whilst there is evidence of T cell activation by directly 
transfected DC(Casares et al., 1997; Chattergoon et al., 1998), it appears that direct transfection is not an absolute 
requirement and that antigen expressed by other transfected cells is also taken up and presented by 
DC(Doe et al., 1996; Fu et al., 1997; Iwasaki et al., 1997b). It is likely that, in fact, both pathways are involved.  
Immunisation by plasmid injection tends to elicit a TH1-skewed response(Pertmer et al., 1996; Raz et al., 1996; 
Feltquate et al., 1997; Toda et al., 2000)
, making this approach particularly suitable against intracellular 
pathogens(Cornell et al., 1999; Weiss et al., 2000). It has also been suggested that administration of allergen by this 
method could be used to redress the TH1-TH2 balance in allergic disorders(Hsu et al., 1996; Raz et al., 1996; Toda et 
al., 2000; Hochreiter et al., 2003; Scheiblhofer et al., 2007)
. 
Particle-mediated DNA delivery (PMDD) using the gene gun involves the precipitation of vector DNA 
onto microscopic gold particles. It was first demonstrated as an in vitro transformation/transfection 
technique in plant tissue(Klein et al., 1987), algae and yeast(Sanford, 1988), cultured mammalian cells(Zelenin et al., 
1989)
 and, finally, in vivo in mice(Williams et al., 1991). It was soon suggested that the technique be used for 
genetic immunisation(Johnston, 1990) and this was soon realised(Tang et al., 1992). The gene gun was shown to be 
at least as effective as intramuscular injection, to be more reliable and to consume significantly less 
DNA(Fynan et al., 1993; Lai et al., 1995; Weiss et al., 2000; Yoshida et al., 2000).  
The mechanism(s) by which gene gun immunisation results in the activation of T cells has been 
debated. Studies involving immunisation of parent-into-F1 bone marrow chimeras showed that the key 
APC in DNA immunisation are haemopoietic in origin(Corr et al., 1996; Iwasaki et al., 1997b). It has been 
demonstrated by microscopy(Condon et al., 1996; Larregina et al., 2001), flow cytometry(Porgador et al., 1998), luciferase 
expression(Larregina et al., 2001), RT-PCR(Larregina et al., 2001) and antigen-presenting co-culture(Porgador et al., 1998; 
Larregina et al., 2001)
 that PMDD results in directly transfected DC which migrate to the draining lymph 
nodes and express and present antigen. Indeed, removal of the skin immediately after PMDD prevents 
immunisation whilst grafting this skin induces a response in a recipient animal(Torres et al., 1997; Klinman et al., 
1998)
. Finally, transcriptional targeting of DC by placing antigen expression under control of the fascin 
or dectin-2 promoters confirmed that these directly-transfected DC are the key initiators of the immune 
response to PMDD immunisation(Morita et al., 2001; Ross et al., 2003). However, it is clear that other skin cells 
such as keratinocytes are also transfected and that they also play a vital role in the development of a 
full response to antigen(Nickoloff and Turka, 1994; Hon et al., 2005; Lauterbach et al., 2006; Vandermeulen et al., 2009).  
It has been known for some time that stressed or necrotic cells can activate dendritic cells and that 
substances released from these cells can aid in antigen processing(Gallucci et al., 1999; Shi et al., 2000). Among 
these substances are uric acid(Shi et al., 2003) and heat-shock proteins (HSPs)(Basu et al., 2000). The presence of 
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these, normally intracellular, molecules in the extracellular milleu induces dendritic cell activation and 
maturation when detected via the Toll-like receptors TLR2 and TLR4(Vabulas et al., 2002; Flohe et al., 2003; Liu et al., 
2003)
. Evidence suggests that DC activated in this manner are TH1-biased(Flohe et al., 2003; Wan et al., 2003). 
Another HSP receptor, CD91, mediates endocytosis, processing and presentation of HSPs and antigens 
associated with them via the MHC class I pathway(Basu et al., 2001). More recently a C-type lectin, 
CLEC9A, was shown to detect necrotic cells and to enhance cross-presentation of their antigens(Sancho et 
al., 2009)
. Together, DC maturation and increased asntigen presentation efficiency mean that cellular 
damage and death have potent adjuvant activity. 
Successful transfection by gene gun requires plasmid DNA to be delivered into healthy cells which 
remain so and are able to express the introduced gene(s). Nevertheless, many surrounding cells are 
damaged or killed. It is, therefore, likely that cellular damage and death caused during gene gun 
immunisation would be immunostimulatory. Indeed, the doubling of the DC population in the draining 
lymph node caused by gene gun administration occurs in the presence or absence of DNA on the 
beads(Porgador et al., 1998). This, combined with the above described effects of CpG sequences in plasmid 
DNA ( 1.7.2), makes the gene gun an effective method of immunisation that provides its own, intrinsic, 
adjuvant activity.  
Whereas injection of DNA vaccines tends to promote a TH1 response, the gene gun has a more TH2 
bias(Fynan et al., 1993; Pertmer et al., 1996; Feltquate et al., 1997; Kwissa et al., 2000; Toda et al., 2000). The reason for this difference 
is not well understood although there is evidence to suggest that the significantly smaller quantity of 
DNA, and therefore of TH1-inducing CpG sequences, plays a role(Barry and Johnston, 1997).  
The addition of exogenous CpG oligodeoxynucleotides to gene gun beads carrying antigen-encoding 
plasmid is able to shift the response to antigen from TH2 to TH1(Zhou et al., 2003). Other work shows that 
gene gun coadministration of uncoated gold beads alone to the site of an injected DNA-saline vaccine 
was able to TH2-shift the normally TH1 response(Weiss et al., 2002). Therefore the gene gun is, itself, 
intrinsically TH2-inducing.  
Targeting DC by placing transcription of antigen under the control of the fascin promoter results in a 
cellular response comparable to that generated via a ubiquitous (eg CMV) promoter(Ross et al., 2003; Sudowe et 
al., 2003; Vandermeulen et al., 2009)
. However, the antibody response generated is weaker and/or shows a TH1 
bias. This supports the classical model whereby intracellular antigen derived from direct transfection of 
DC is processed and presented via the MHC class I pathway and exogenous antigen derived from other 
transfected cells, and subsequently endocytosed by DC, is processed and presented via the MHC class 
II pathway. Nevertheless, targeting expression to keratinocytes also produces a viable TH1 / cellular 
response(Hon et al., 2005; Sudowe et al., 2009; Vandermeulen et al., 2009). This suggests that, as well as the above 
processes, cross presentation allows exogenous antigen to be internalised by DC and presented on 
MHC class I molecules(Fu et al., 1997; Albert et al., 1998a; Albert et al., 1998b; Cho et al., 2001). 
It is likely that three routes play a part in PMDD immunisation(Sudowe et al., 2009): 1) DC take up antigen 
secreted by other cells and present it via the MHC class II pathway. 2) DC take up antigen and cross-
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present it via the MHC class I pathway. 3) Directly transfected DC present antigen, that they 
themselves synthesise, on both MHC class I and MHC class II molecules. 
1.7.4. Improving genetic immunisations 
As described above, merely administering antigen-encoding plasmid is often sufficient to induce an 
immune response. However, adjustment of, and addition to, genetic vaccines allows this response to be 
augmented or directed. Such improvements have been made at the genetic level and at that of vaccine 
delivery.  
The coadministration of genes encoding immune active molecules has been widely examined. It has 
already been noted that genetic vaccines avoid the difficulty and expense of production and 
purification of recombinant proteins.  This advantage is amplified in such antigen-modulator vaccines 
where an additional, often inherently unstable, protein is required. 
Cytokines and chemokines, natural modulators of the immune system, have been used to improve 
genetic vaccines. Firstly, molecules recognised as being involved in the priming of an immune 
response appear to play similar roles when coadministered alongside antigen genes. For example, IL-
12- or IL-18-encoding plasmid has been demonstrated to improve the CTL response to viral 
antigen(Iwasaki et al., 1997a; Kim et al., 1997a) (Lee et al., 2003). Indeed, inclusion of IL-12 and IFN-γ genes enhances 
the TH1 arm of the response whilst IL-4-encoding plasmid promotes a TH2 bias(Chow et al., 1998). Secondly, 
genes encoding molecules involved in the development and localisation of antigen presenting cells, in 
particular DC, have been coadministered to enhance the response to antigen through increasing the 
number and maturity of these cells(Xiang and Ertl, 1995; Eo et al., 2001; Hu et al., 2004; Nayak et al., 2006; Ma et al., 2007).  
Arguably not a genetic modification, but one involving DNA nonetheless, the coadministration of CpG 
oligonucleotides on gene gun beads has been shown to improve the immunogencity of such 
immunisation(Zhou et al., 2003; Tengvall et al., 2005). 
Rather than actually inducing DC maturation, transfection of DC with the costimulatory molecules 
CD80/86 artificially enhances their immunostimulatory ability. Coadministration of these genes 
alongside antigen has been shown to improve the immunogenicity of genetic vaccines(Corr et al., 1997; Iwasaki 
et al., 1997a; Kim et al., 1997b)
. Similarly, inducing the upregulation of these molecules by immunising with 
coadminisered CD154 gene also enhances the response, particularly the cellular response, to 
antigen(Mendoza et al., 1997; Ihata et al., 1999). 
Genetic immunisation allows the coadministration of genes encoding intracellular signalling 
molecules. In DC, NF-κB-inducing kinase (NIK) activates NF-κB, inducing maturation, migration and 
cytokine production. Coadministration of this gene proved effective in enhancing the response to 
antigen(Andreakos et al., 2006). Another approach improved the response to genetic immunisation by 
including the gene for the antiapoptotic Bcl-xL molecule, prolonging the life of transfected DC and, 
therefore, the duration of antigen presentation(Kim et al., 2003; Kim et al., 2004). 
The fusion of an antigen gene to a cytokine gene can have similar effects to that of the 
coadministration of separate genes: Fusion to IL-12 has enhanced the CTL response to model antigen 
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whilst fusion to IL-18 or IL-4 has shifted the response toward a TH1- or TH2-bias, respectively(Kim et al., 
1997a; Kim et al., 1997c; Maecker et al., 1997; Maecker et al., 2001)
.  
Fusion genes can also be utilised in more elegant ways. Although DC are transfected by genetic 
immunisations many other cell types are also transfected. It has been shown that fusion of antigen gene 
to that of a single chain antibody fragment(Demangel et al., 2005; Nchinda et al., 2008) or that of CTLA4(Boyle et al., 1998; 
Deliyannis et al., 2000; Nayak et al., 2003)
 can target in vivo-synthesised antigen to DC and other APC via DEC-205 
or CD80/86 molecules, respectively. This increases the uptake and, therefore, presentation of antigen 
by APC. On a subcellular level, fusion genes have been used to enhance or modify the processing of 
antigen. Fusion of antigen gene to that of the invariant chain trimerisation domain forces presentation 
via the MHC class II pathway, increasing the antibody response to antigen(Toda et al., 2002; Schneiders et al., 2005; 
Grujic et al., 2009)
. Similarly, fusion to the LAMP-1 gene causes internalisation, processing and presentation 
via the MHC class II pathway(Wu et al., 1995). 
Another modification for enhancing genetic immunisation is the encoding of antigenised antobodies. 
Insertion of epitope sequences into the complementarity-determining region of IgG allows the display 
of antigen and stimulation of an immune response without classical presentation on MHC class II 
molecules(Gerloni et al., 1997; Gerloni et al., 1999; Schuler et al., 2001). This bypasses the problem of haplotype restriction 
which, especially when using monovalent vaccines, restricts efficacy to subpopulations with certain 
genotypes. 
Control over antigen gene expression is another way in which genetic vaccines are superior to protein-
based vaccines. As discussed earlier it is possible to target expression to specific cell types. As 
discussed, targeting transcription to DC causes a bias to cellular immunity; exploiting this phenomenon 
might be useful, especially in cases where the inherent TH2-bias of the gene gun is undesirable. One 
difficulty in using cell-specific promoters is that they often induce lower levels of expression than do 
more promiscuous promoters such as the CMVie promoter. Coadministration of a transactivator to 
upregulate expression of antigen gene under the control of a tissue-specific promoter allows long-
lasting, tissue specific expression but with high expression normally only seen from promoters such as 
CMVie(Li et al., 1999b). 
The second class of improvements made to genetic vaccines is that of delivery. Improved intracellular 
delivery usually concerns plasmid solution injection rather than gene gun immunisation, primarily 
because PMDD is, itself, an intracellular delivery method. The containment of plasmid vector within 
polymer microspheres has been used to improve stability and increase uptake efficiency following 
injection(Wang et al., 2004; Nguyen et al., 2008). The association of plasmid DNA with high molecular weight 
cationic polymers improves its immunogenicity; this is, at least in part, due to increased uptake by 
DC(Chamarthy et al., 2003; Mollenkopf et al., 2004; O'Hagan et al., 2004; Jia et al., 2008). Finally, the permeablisation of cells 
using femtosecond laser pulses has been shown to increase the response following injection of plasmid 
vector solution(Zeira et al., 2007). 
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1.8. Rationale, hypothesis and introduction to the PhD project 
The rationale for the main part of this project is derived from three observations: 1) That regulatory T 
cells, specifically type 1 (TR1) regulatory T cells, can be induced by activation in the presence of IL-
10. 2) That dendritic cells secreting IL-10, either naturally or artificially, can induce the induction of 
regulatory T cells. 3) That a major mechanism of PMDD-mediated immunisation is the direct 
transfection of skin dendritic cells. The hypothesis under invesigation is that coadministration of 
antigen- and IL-10-encoding genes in a PMDD immunisation is able to produce IL-10-secreting 
dendritic cells which present antigen to naïve T cells in the presence of IL-10, thereby tolerising them. 
This part of the project aims to characterise gene gun (PMDD) immunisation in a murine, TCR-
transgenic, adoptive transfer model and to observe the effect of the inclusion of the interleukin-10 gene 
in this immunisation. Similar models have been used previously and provide a system in which 
antigen-specific and –nonspecific T cell responses may be observed and compared, whilst not 
overwhelming lymphoid tissues with an entirely transgenic T cell population(Creusot et al., 2001; Creusot et al., 
2003a; Creusot et al., 2003b)
. The early T cell response in draining lymph nodes will be examined initially. The 
long-term effects of coadministration of the IL-10 gene will then be studied. Specifically, the question 
will be asked whether treatment with the IL-10 gene during a primary immunisation has an impact on 
later antigenic challenge. The magnitude and kinetics of the T cell proliferative and cytokine responses 
will comprise the core data collected. 
The hypothesis of the second part of this project is that the same PMDD immunisation, either via 
induction of TR1 cells or another mechanism, is able to protect mice from the induction of allergic 
airway hyperresponsiveness. 
The study will utilise an existing murine model of antigen-specific allergic airway inflammation. The 
induction of airway inflammation involves priming the animal with antigen prior to an airway 
challenge with the same antigen. The goal is to understand whether earlier immunisation with antigen 
affects the outcome of inflammation induction and whether the coadministration of IL-10 modulates 
this outcome. As well as T cell proliferative and cytokine responses, antibody isotype levels and 
parameters specific to the airway inflammation model, such as cellular infiltration to the lung, will be 
examined.  
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2. Materials and Methods 
2.1. Plasmids 
2.1.1. The p7 vector 
The p7 family of vectors contain a CMV immediate early-based promoter and transfectants are 
selectable due to the presence of the Tn903 kanamycin resistance gene (Figure  2-1). The gene 
encoding chicken egg albumin (OVA), the gene encoding murine interleukin-10 (IL-10) and the gene 
encoding human interferon gamma (hIFN-γ) were independently cloned into the multiple cloning site 
(MCS) of this vector. The resulting plasmids are referred to as p7.OVA, p7.IL10 and p7.hIFNg, 
respectively. 
2.1.2. Synthesis of the OVA gene with ‘sticky ends’ 
The sequence of the chicken egg albumin gene (ova) cDNA (Entrez Nucleotide Accession No 
V00383.1) is shown in Figure  2-4. The pVAC.OVA vector containing this gene was kindly provided 
by Ian Catchpole, GlaxoSmithKline, Stevenage, UK. To obtain the ova fragment the ova.1 and ova.2 
primers (Table  2-1) were used in a standard PCR reaction.  
The PCR mixture (50 µl total) contained 5 µl buffer (final conc 1x; Promega), 5 µl dNTP mixture 
(dATP, dCTP, dGTP, dTTP each at 2 mM final conc; Promega), 2 µl of each primer (final conc 5 µM), 
1 µl Pfu DNA  polymerase (Promega M7741). An aliquot of the product was analysed by agarose gel 
electrophoresis (Figure 2-2a) which showed the amplified fragment to be of the expected size of 1100-
1200 bp. The remaining product was run on an agarose gel, the band cut out and purified using the 
QIAquick gel extraction kit (Qiagen 28704) according to the manufacturer’s guidelines. 
The purified product was digested in the a reaction mixture (total 50 µl) containing 30 µl purified 
product, 3 µl Not1, 3 µl BamH1, 5 µl 10x BamH1 buffer, 1 µl BSA (all from New England Biolabs). 
The mixture was incubated at 37°C for 3 h. The product was purified by agarose gel electrophoresis as 
above. 
2.1.3. Synthesis of the IL-10 gene with ‘sticky ends’ 
The sequence of the murine interleukin-10 gene cDNA (Entrez Nucleotide Accession No M37897.1) is 
shown in Figure  2-5. The Pcmv&muIL10 vector containing this gene was kindly provided by Vincent 
Hart, GlaxoSmithKline, Stevenage, UK. The il10 gene had previously been cloned into this vector 
using Not1 and BamH1 and thus could be obtained by restriction disgest. The digestion mixture (50 µl 
total) contained the same as that above but with 10 µl vector (final conc 200 ng/µl). The total product 
was run on an agarose gel to separate il10 from the backbone vector and the relevant fragment was cut 
out and purified as above. The result was verified by agarose gel electrophoresis (Figure 2-2b). 
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Fig 2.1 – p7 map
Figure 2-1. The p7 expression vector.
The key features of the vector for this study: MCS = Multiple Cloning Site; 
contains several restriction sites delimited by BamH1 and Not1 restriction 
sites. CMVpro = cytomegalovirus immediate early promoter; upstream of the 
MCS; controls expression of inserted gene(s). KanR = Kanamycin resistance 
gene; allows selection of successfully transfected clones.
BamH1
Not1
Ex1
CMVprorGpA
cer
Ori
KanR 
(Tn903)
500
1500
2500
1000
2000
3000
p7
3430 bp
MCS
Figure  2-1 Map of the p7 plasmid vector 
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Table  2-1 Primers used for cloning genes into the p7 vector 
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Figure  2-2 Generation of gene fragments  
Fig 2.2 – Generation of gene fragments
a
600bp
IL
-10
dig
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b c
Figure 2-2. Generation of gene fragments. 
a) ova cDNA was obtained through PCR from 
the pVAC.OVA plasmid. Following restriction 
digest with Not1 and BamH1 the purified cDNA 
with ‘sticky ends’ was purified through agarose 
gel elecrophoresis. b) il10 cDNA was obtained 
through the restriction digest of the 
pcmv&muIL10 vector with Not1 and BamH1. 
The 600 bp gene fragment was then purified 
by agarose gel electrophoresis. c(i)) hIFNg 
cDNA was obtained from I.M.A.G.E. clones. 
Colony PCR was performed on two colonies of 
each of three clones to verify they contained a 
~500 bp sequence. c(ii)) Plasmids were 
purified from overnight cultures of these 
clones. c(iii)) The gene fragment was amplified 
by PCR. Samples of the products were 
analysed by agarose gel electrophoresis. The 
fragment from clone 2410765 was digested 
with Not1 and BamH1 and repurified.
(i)
(ii)
(iii)
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Fig 2.3 – Confirmation of insertion
a
b
c
Figure 2-3. Confirmation of insertion of fragments by colony PCR 
(cPCR) or restriction digest. 
cPCR was performed by inoculating cells from an individual colony into the 
PCR mixture and then into a separate culture. PCR products were run on 
agarose gel to identify successful insertion of p7.OVA (a) or p7.IL10 (b). A 
corresponding culture was subsequently grown up for plasmid preparation. 
cPCR was not successful on p7.hIFNg clones so minipreps were prepared from 
each clone and PCR performed on each preparation. These were then run on 
agarose gel to identify sucessful clones by the presence of the inserted 
fragment (c). A successful clone was subsequently grown up for plasmid 
preparation.
Figure  2-3 Confirmation of insertion of gene fragments 
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Fig 2.4 – ova sequencing
1 gacatacagc tagaaagctg tattgccttt agcactcaag ctcaaaagac aactcagagt
atggg ctccatc
61 tcaccatggg ctccatcggc gcagcaagca tggaattttg ttttgatgta ttcaaggagc
(GGC→GGT = Gly→Gly)
121 tcaaagtcca ccatgccaat gagaacatct tctactgccc cattgccatc atgtcagctc
181 tagccatggt atacctgggt gcaaaagaca gcaccaggac acagataaat aaggttgttc
(CAG→CAA = Gln→Gln)
241 gctttgataa acttccagga ttcggagaca gtattgaagc tcagtgtggc acatctgtaa
301 acgttcactc ttcacttaga gacatcctca accaaatcac caaaccaaat gatgtttatt
361 cgttcagcct tgccagtaga ctttatgctg aagagagata cccaatcctg ccagaatact
421 tgcagtgtgt gaaggaactg tatagaggag gcttggaacc tatcaacttt caaacagctg
481 cagatcaagc cagagagctc atcaattcct gggtagaaag tcagacaaat ggaattatca
541 gaaatgtcct tcagccaagc tccgtggatt ctcaaactgc aatggttctg gttaatgcca
601 ttgtcttcaa aggactgtgg gagaaaacat ttaaggatga agacacacaa gcaatgcctt
(ACA→GCA = Thr→Ala)
661 tcagagtgac tgagcaagaa agcaaacctg tgcagatgat gtaccagatt ggtttattta
721 gagtggcatc aatggcttct gagaaaatga agatcctgga gcttccattt gccagtggga
781 caatgagcat gttggtgctg ttgcctgatg aagtctcagg ccttgagcag cttgagagta
841 taatcaactt tgaaaaactg actgaatgga ccagttctaa tgttatggaa gagaggaaga
901 tcaaagtgta cttacctcgc atgaagatgg aggaaaaata caacctcaca tctgtcttaa
961 tggctatggg cattactgac gtgtttagct cttcagccaa tctgtctggc atctcctcag
1021 cagagagcct gaagatatct caagctgtcc atgcagcaca tgcagaaatc aatgaagcag
1081 gcagagaggt ggtagggtca gcagaggctg gagtggatgc tgcaagcgtc tctgaagaat
1141 ttagggctga ccatccattc ctcttctgta tcaagcacat cgcaaccaac gccgttctct
1201 tctttggcag atgtgtttcc ccttaaaaag aagaaagctg aaaaactctg tcccttccaa
c tacacaaagg ggaatt
1261 caagacccag agcactgtag tatcaggggt aaaatgaaaa gtatgttctc tgctgcatcc
1321 agacttcata aaagctggag cttaatctag aaaaaaaatc agaaagaaat tacactgtga
1381 gaacaggtgc aattcacttt tcctttacac agagtaatac tggtaactca tggatgaagg
1441 cttaagggaa tgaaattgga ctcacagtac tgagtcatca cactgaaaaa tgcaacctga
1501 tacatcagca gaaggtttat gggggaaaaa tgcagccttc caattaagcc agatatctgt
1561 atgaccaagc tgctccagaa ttagtcactc aaaatctctc agattaaatt atcaactgtc
1621 accaaccatt cctatgctga caaggcaatt gcttgttctc tgtgttcctg atactacaag
1681 gctcttcctg acttcctaaa gatgcattat aaaaatctta taattcacat ttctccctaa
1741 actttgactc aatcatggta tgttggcaaa tatggtatat tactattcaa attgttttcc
1801 ttgtacccat atgtaatggg tcttgtgaat gtgctctttt gttcctttaa tcataataaa
1861 aacatgttta agc
ataagaatgcggccgcc
cctagggc
Figure 2-4. Sequence of cloned ovalbumin gene compared to that 
published in the NCBI GenBank. 
The GenBank sequence (V00383.1) is displayed with cloned gene mutant 
codons inserted between lines. Substituted bases are highlighted in red. 
Primers used to clone the gene are displayed in blue. The coding sequence is 
1161 bp.
Figure  2-4 Sequence of cloned ovalbumin gene compared to that published in the NCBI GenBank. 
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1 gggggggggg atttagagac ttgctcttgc actaccaaag ccacaaagca gccttgcaga
atgcc tggctcagca ctgc
61 aaagagagct ccatcatgcc tggctcagca ctgctatgct gcctgctctt actgactggc
121 atgaggatca gcaggggcca gtacagccgg gaagacaata actgcaccca cttcccagtc
181 ggccagagcc acatgctcct agagctgcgg actgccttca gccaggtgaa gactttcttt
241 caaacaaagg accagctgga caacatactg ctaaccgact ccttaatgca ggactttaag
301 ggttacttgg gttgccaagc cttatcggaa atgatccagt tttacctggt agaagtgatg
361 ccccaggcag agaagcatgg cccagaaatc aaggagcatt tgaattccct gggtgagaag
421 ctgaagaccc tcaggatgcg gctgaggcgc tgtcatcgat ttctcccctg tgaaaataag
(TTT→TTC = Phe→Phe)
481 agcaaggcag tggagcaggt gaagagtgat tttaataagc tccaagacca aggtgtctac
541 aaggccatga atgaatttga catcttcatc aactgcatag aagcatacat gatgatcaaa
cgtatgta ctactagttt
601 atgaaaagct aaaacacctg cagtgtgtat tgagtctgct ggactccagg acctagacag
tacttttcga tt
661 agctctctaa atctgatcca gggatcttag ctaacggaaa caactccttg gaaaacctcg
721 tttgtacctc tctccgaaat atttattacc tctgatacct cagttcccat tctatttatt
781 cactgagctt ctctgtgaac tatttagaaa gaagcccaat attataattt tacagtattt
841 attattttta acctgtgttt aagctgtttc cattggggac actttatagt atttaaaggg
901 agattatatt atatgatggg aggggttctt ccttgggaag caattgaagc ttctattcta
961 aggctggcca cacttgagag ctgcagggcc ctttgctatg gtgtcctttc aattgctctc
1021 atccctgagt tcagagctcc taagagagtt gtgaagaaac tcatgggtct tgggaagaga
1081 aaccagggag atcctttgat gatcattcct gcagcagctc agagggttcc cctactgtca
1141 tcccccagcc gcttcatccc tgaaaactgt ggccagtttg ttatttataa ccacctaaaa
1201 ttagttctaa tagaactcat ttttaactag aagtaatgca attcctctgg gaatggtgta
1261 ttgtttgtct gcctttgtag cagcatctaa ttttgaataa atggatctta ttcg
ataagaatgcggccgcc
cctagggc
Figure 2-5. Sequence of cloned IL-10 gene compared to that published 
in the NCBI GenBank. 
The GenBank sequence (M37897.1) is displayed with cloned gene mutant 
codons inserted between lines. Substituted bases are highlighted in red. 
Primers used to clone the gene are displayed in blue. The coding sequence is 
537 bp.
Figure  2-5 Sequence of cloned interleukin-10 gene compared to that published in the NCBI GenBank. 
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1 tgaagatcag ctattagaag agaaagatca gttaagtcct ttggacctga tcagcttgat
at gaaatataca
61 acaagaacta ctgatttcaa cttctttggc ttaattctct cggaaacgat gaaatataca
agttat
121 agttatatct tggcttttca gctctgcatc gttttgggtt ctcttggctg ttactgccag 
181 gacccatatg taaaagaagc agaaaacctt aagaaatatt ttaatgcagg tcattcagat 
241 gtagcggata atggaactct tttcttaggc attttgaaga attggaaaga ggagagtgac 
301 agaaaaataa tgcagagcca aattgtctcc ttttacttca aactttttaa aaactttaaa 
361 gatgaccaga gcatccaaaa gagtgtggag accatcaagg aagacatgaa tgtcaagttt 
421 ttcaatagca acaaaaagaa acgagatgac ttcgaaaagc tgactaatta ttcggtaact 
481 gacttgaatg tccaacgcaa agcaatacat gaactcatcc aagtgatggc tgaactgtcg
541 ccagcagcta aaacagggaa gcgaaaaagg agtcagatgc tgtttcaagg tcgaagagca
(CAA→CGA = Gln→Arg)   cttctcgt
601 tcccagtaat ggttgtcctg cctgcaatat ttgaatttta aatctaaatc tatttattaa 
agggtcatt
661 tatttaacat tatttatatg gggaatatat ttttagactc atcaatcaaa taagtattta 
721 taatagcaac ttttgtgtaa tgaaaatgaa tatctattaa tatatgtatt atttataatt 
781 cctatatcct gtgactgtct cacttaatcc tttgttttct gactaattag gcaaggctat 
841 gtgattacaa ggctttatct caggggccaa ctaggcagcc aacctaagca agatcccatg 
901 ggttgtgtgt ttatttcact tgatgataca atgaacactt ataagtgaag tgatactatc   
961 cagttactgc cggtttgaaa atatgcctgc aatctgagcc agtgctttaa tggcatgtca
1021 gacagaactt gaatgtgtca ggtgaccctg atgaaaacat agcatctcag gagatttcat
1081 gcctggtgct tccaaatatt gttgacaact gtgactgtac ccaaatggaa agtaactcat
1141 ttgttaaaat tatcaatatc taatatatat gaataaagtg taagttcaca act 
ataagaatgcggccgc
cctagggc
Figure 2-6. Sequence of cloned interferon-γ gene compared to that 
published in the NCBI GenBank. 
The GenBank sequence (X13247.1) is displayed with cloned gene mutant 
codons inserted between lines. Substituted bases are highlighted in red. 
Primers used to clone the gene are displayed in blue. The coding sequence is 
501 bp.
Figure  2-6 Sequence of cloned interferon-γ gene compared to that published in the NCBI GenBank.  
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2.1.4. Synthesis of the human IFN-γ gene with ‘sticky ends’ 
The sequence of the human interferon-γ gene cDNA (Entrez Nucleotide Accession No X13247.1) is 
shown in Figure  2-6. The gene sequence was BLAST searched against the expressed sequence tagged 
database and three potential clones were identified in the I.M.A.G.E. database (Table  2-2). They were 
obtained from the HGMP resource centre. 
Each clone was streaked onto Luria Bertani (LB) agar containing 100 µg/ml ampicillin and allowed to 
grow overnight at 37°C. Two colonies of each clone were picked and split into a colony PCR and an 
overnight culture as follows: Each colony PCR mixture (total 10 µl) contained 1 µl 10x buffer 
(Promega), 1 µl dNTP mixture (dATP, dCTP, dGTP, dTTP each at 2 mM final conc; Promega), 1 µl of 
each primer (final conc 5 µM) and 1 µl Pfu DNA  polymerase (Promega M7741). The hIFNg.1 and 
hIFNg.2 primers used are described in Table  2-1. The picked colony was dipped into this mixture and 
vigorously mized, which provided sufficient copies of the clone for the reaction. PCR products 
underwent agarose gel electrophoresis which confirmed the presence of the ~500 bp cDNA (Figure 2-
2c(i)). 
The remainder of the colony was dropped into 4 ml LB medium containing 100 µg/ml ampicillin and 
allowed to grow for 19 h at 37°C with shaking. Plasmids were purified from the cultures using the 
QIAprep spin miniprep kit (Qiagen 27104) and repurified via agarose gel electrophoresis (Figure  
2-2c(ii)).  All three clones contained plasmids. 2403734 and 1589287 which are described by HGMP 
as containing the same plasmid contained plasmids of the same size whereas 2410765 which is 
described as containing a different plasmid contained a larger plasmid. 
On each purified plasmid was performed two separate PCRs using the primers hIFNg.1 and hIFNg.2 
under the conditions described for the ova fragment and an aliquot of each product was analysed by 
agarose gel electrophoresis (Figure 2-2c(iii)). The remainder of the PCR product from clone 2410765 
was purified by gel electrophoresis, digested and repurified as described above for the ova fragment. 
2.1.5. Ligation of fragments into p7 
The p7 vector was kindly supplied by Peter Ertl, GlaxoSmithKline, Stevenage, UK. Each insert had 
been cloned or digested to have Not1 and BamH1 restriction sites as described in  2.1.2,  2.1.3 and 
 0 2.1.4. The ‘open’, ‘empty’ vector with sticky ends was obtained by removal of this insert by 
restriction digest and agarose gel purification as described above. Each gene was independently ligated 
into the empty vector following the setup in Table  2-3, whereby five reactions provide an internally-
controlled ligation. 
Ligation mixtures (total 10 µl) contained 1 µl T4 buffer, 1 µl open p7, 1 µl T4 ligase (Promega 
M180A; except negative control) and 0, 0.5, 1 or 2 µl of gene fragment. Ligation was allowed to 
proceed at 4°C overnight. 
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Table  2-2 IFN-γ clones acquired 
 
 
 
 
 
 
 
 
Entrez Nucleotide Accession No IMAGE clone 
AI862844 2410765 
AI769523 2403734 
AA946992 1589287 
 
 
 
 
Table 2-2. Clones of human IFN-γ gene acquired.  
Clones were matched by searching the BLAST database. Three I.M.A.G.E. 
clones were chosen. Clones were acquired from the HGMP resource centre. 
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Table  2-3 Outline of ligation reactions 
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2.1.6. Transfection into competent host cells and production of plasmids 
30 µl XL1-Blue chemically competent E. coli (Stratagene, 200268) were allowed to thaw on ice for 1 
h. 1 µl ligation product was added to the cells and the mixture was left on ice for another 1 h. The cells 
were heat-shocked by incubating in a waterbath at 42°C for 30 s and immediately returning them to ice 
for 2 mins. They were then allowed to recover in 1 ml Super Optimal Broth with Catabolite Repression 
(SOC) medium at 37°C for 1 h before plating on LB agar plates containing 50 µg/ml kanamycin and 
incubating overnight at 37°C. Ligation/transfection was deemed successful if the number of resulting 
colonies was dependent on the quantity of insert in the ligation reaction. In each case, there were few 
or no colonies from ligation 1 or 2, and increasing numbers of colonies from ligations 3-5. 
To verify further the cloning, several colonies were picked, some cells transferred to a marked spot on 
a LB agar plate containing 50 µg/ml kanamycin and the remainder dropped into a colony PCR (as 
above). p7.OVA colony PCR used the ova.1 and ova.2 primers, p7.IL10 the IL10.1 and IL10.2 primers 
and p7.hIFNg the hIFNg.1 and hIFNg.2 primers (see Table  2-1). Colony PCR of p7.hIFNg clones 
was unsuccessful so PCR was performed on purified DNA, isolated from the clones using using the 
QIAprep spin miniprep kit (Qiagen 27104). 
PCR products were analysed by agarose gel electrophoresis. Colonies that contained the cloned gene 
were distinguishable by a bright band of the correct molecular weight. There were 11/12 p7.OVA 
positives at around 1100 bp, 12/12 p7.IL10 positives at around 500 bp and 4/13 p7.hIFNg positives at 
around 500 bp (Figure  2-3). One insert-positive colony for each plasmid was selected, grown in LB 
medium containing 50 µg/ml kanamycin and plasmid purified for sequencing using the QIAprep spin 
miniprep kit (Qiagen 27104).  
Inserts in each plasmid were sequenced at the internal GSK sequencing facility. Sequences were 
compared with the original BLAST sequences. The ova gene contained two silent mutations and one 
substitution (threonine to alanine) mutation (Figure  2-4). The il10 gene contained a silent mutation 
(Figure  2-5). The hIFNg gene contained one glutamine to arginine substitution (Figure  2-6). The 
sequences were deemed accurate enough to proceed with the study and a functional quantity of 
endotoxin-free plasmid was prepared using the EndoFree plasmid giga kit (Qiagen 12391), following 
the manufacturer’s instructions. 
2.2. Cartridges for PMDD 
2.2.1. Plasmid ratios 
The dose per mouse of p7.OVA and p7.IL10 to be used are established as described in the subsequent 
chapters. To ensure consistent DNA-loading efficiency and to control for any immunotimulatory 
effects of plasmid DNA itself, all cartridges used contained a total of 1 µg DNA on 0.5 mg gold beads. 
Where the total quantity of gene-expressing plasmid required was less than 1 µg per cartridge, the 
difference was made up with empty p7 vector. 
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2.2.2. Cartridge preparation 
Gold particles of mean diameter 2µm (PowderJect) were sonicated in the presence of 0.05M 
spermidine (Sigma S0266) for 30 s. The volume of spermidine used was 100µl if the total volume of 
DNA to be added was less than 100 µl. If the required DNA volume was greater than 100 µl, an equal 
volume of spermidine was used. Plasmids were added in appropriate combinations so that a total DNA 
loading rate (DLR) was always 2 µg DNA per mg gold (Plasmid (µg) = Gold (mg) x DLR). To allow 
multiple plasmids to be loaded onto each bead, the total DLR value (2) is divided appropriately, the 
calculation is performed on the sub-DLR for each plasmid and the amount of each plasmid to be added 
is obtained. This was followed by addition of a volume equal to that of the spermidine of 1M CaCl2 
with immediate thorough vortexing and a 10 min rest, ensuring efficient precipitation of DNA onto the 
gold particles. The DNA-coated gold particles were washed three times in dehydrated absolute ethanol 
and resuspended in 0.05M polyvinylpyrrolidone (PVP, Sigma) in dehydrated absolute ethanol to 8.75 
mg gold/ml. The suspension was injected into and adsorbed onto the inner surface of Tefzel tubing 
(TFX Medical Inc, NH, USA) by centrifugal force using a tube turner device (PowderJect, Chiron 
Corporation, Madison, WI, USA). The tubing was left to dry and cut into 1.27 cm cartridges which 
were stored desiccated at 4°C. 
2.2.3. Cartridge preparation for linkage experiments 
For the linkage experiments that examined the requirement for plasmids to be coated on the same bead, 
a more complex arrangement was required to ensure effective controls. Four, rather than two, 
cartridges were administered per mouse (see  2.7.3). Using the arrangement in Figure  2-7 it was 
possible to immunise with p7.OVA+p7.IL10 on the same bead, on separate beads in the same cartridge 
and in separate cartridges whilst keeping the quantity of both plasmids, as well as total DNA, constant.  
2.2.4. Quality control 
Two cartridges from each batch were tested for loading by eluting DNA in 50µl water/cartridge and 
measuring its concentration by spectrophotometry. Cartridges routinely contained 0.5-0.75 µg DNA. 
2.3. Cell culture 
2.3.1. MC57 murine fibrosarcoma 
MC57, a murine fibrosarcoma cell line, was kindly provided by P. Gilboy, GlaxoSmithKline. It was 
propagated in complete (excluding 2-mercaptoethanol) Dulbecco’s Modified Eagle Medium 
(Invitrogen-Gibco 11960044) with regular passage via trypsinisation (0.025% trypsin solution, 2 min), 
washing and replating. 
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Figure  2-7 Plasmid distribution for properly controlled linkage experiments 
 
 
 
 
 
 
Fig 2.7 – linkage
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2.3.2. Preparation of murine bone-marrow derived dendritic cells 
Day 1: Femurs and tibeas were collected from both legs, sprayed with ethanol and temporarily 
stored in complete Modified Eagles Medium. Distal sections of bones were removed and, using a 
syringe of medium with needle, the lumen of the bone was punctured and the marrow scraped/forced 
out into a clean dish. The mixture was pipetted up and down to break up any clusters of cells and 
transferred to a 50 ml centrifuge tube. The mixture was left for 3 min to allow clumps to fall out of 
suspension before the suspension was transferred to a new tube. Cells were centrifuged and 
resuspended in red blood cell-lysing buffer for 5 min before being washed, counted and resuspended to 
5-7x105 cells/ml in complete Iscove’s medium (Invitrogen) containing 25mM Hepes and 20ng/ml GM-
CSF (PeproTech). 3 ml cell suspension was added to wells of a 6-well plate (Nunc 140675) and 
incubated for 72 h. 
Day 4: Supernatant (containing the non-adherent population such as B cells) was gently swirled 
and carefully removed. 3 ml fresh medium (including fresh GM-CSF) was added to each well. 
Day 7/8: Dendritic cells, having now detatched from the well floor, were obtained by gentle pipetting 
up and down. They were then ready for use after washing and counting. 
2.3.3. In vitro expansion of DO11.10 cells 
One DO11.10 spleen was harvested and a cell suspension prepared by homogenisation using a 70 µm 
cell-strainer (Falcon 2350). This was cultured in complete RPMI plus 250 nM OVA323-339 at 37°C and 
5% CO2. On day 2, cells were split 1:1 into fresh medium and recombinant IL-2 (PeproTech EC 212-
12) was added to give a final concentration of 10 ng/ml. On day 4, cells were split 1:4 and fresh IL-2 
was added to the same concentration. Cells were collected for use on day 7. 
2.4. In vitro transfection 
2.4.1. Transfection of Chinese Hamster Ovary (CHO) cells 
CHO cells were grown in complete Dulbecco’s Modified Eagle Medium GlutaMAX (Invitrogen-
Gibco 10566-016). The day before transfection, cells were seeded at 105 cells per well of a 24-well 
plate. Transfast reagent (Promega E2431) was prepared and cells transfected according to 
manufacturer’s guidelines. Briefly, medium was removed from the cells before addition of a 
thoroughly vortexed mixture of 1 µg DNA, 6 µl Transfast reagent and 200 µl medium per well. 
Transfection was allowed to proceed for 1 h at 37°C before cells were overlaid with 1.5ml medium and 
incubated for a further 48 h. Supernatants were harvested and stored at –20°C. 
2.4.2. In vitro gene gun of the MC57 murine fibrosarcoma cell line 
Before PMDD MC57 cells were reconstituted to 200x106 cells/ml. 20 µl (4x106 cells) was placed in a 
small droplet in a well of a 6 well plate (Falcon 3046) and spread to a diameter of 1 cm. The end of the 
barrel was positioned 1 cm above the droplet. One cartridge was fired at the cells using compressed 
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helium at 275 psi. Cells were allowed to recover for 6 min and were then washed in 1 ml medium. 
Cells were transferred to wells of a 24-well plate (Nunc 143982) in 2 ml medium. 
2.4.3. In vitro gene gun of bone-marrow derived dendritic cells 
Polylysine-coated microscopy coverslips were prepared under sterile conditions: For each transfection, 
a microscopy coverslip was sterilised with ethanol and allowed to dry. Coverslips were coated in 
polylysine by dipping in a 0.1% (w/v) solution of poly-L-lysine hydrobromide (MW >300,000; Sigma, 
P-1524) for several seconds. Excess polylysine was removed by dipping several times in sterile 
distilled water. The corner of the coverslip was dabbed on sterile tissue and the coverslip placed on its 
side against the wall of a well of a 6-well plate. Despite prior sterilisation of the coverslips, the 
polylysine is not sterile and cannot be autoclaved or filter-sterilised. Thus, once dry, the open plate was 
UV-irradiated ensuring that both sides of each coverslip were exposed for at least 15 min. Coverslips 
were used within 24 hours of preparation although they are believed to be stable for over a week. 
For in vitro use, the standard gene gun barrel was modified to diffuse the power of the shot across the 
target site (Figure  2-8). The thread from a 50 ml centrifuge tube was attached to the outside of the end 
of the gene gun barrel liner. The central section of the lid of the centrifuge tube was cut out, leaving a 
screw-on cap which would allow the DNA-loaded gold particles to pass through. Between the barrel 
liner and this cap was sandwiched the diffuser, obtained by cutting out the base of a 70 µm cell strainer 
(Falcon 2350). During the design process, the effectiveness of the modification was established by 
firing the gene gun into a sheet of Nescofilm (Karlan Research Products Corporation, USA) (Figure 
 2-9). Once diffusion had been observed in this way, the apparatus was tested on cells as described 
below: 
Bone marrow-derived dendritic cells were prepared as in  2.3.1. On day 7, DC were washed, counted 
and resuspended to 5x106 cells/ml. Polylysine-coated coverslips were placed flat at the bottom of wells 
of a 6-well plate and 200 µl DC suspension (1x106 cells) was carefully placed at the centre of each 
coverslip. The droplet was normally 1 cm in diameter. The plate was closed and incubated for 2 hours 
in saturated humidity to allow DC to adhere whilst preventing evaporation.  
Just before transfection, the droplet of medium was drained, leaving the DC attached to the polylysine-
coated coverslip exposed. The end of the modified barrel was positioned around the patch of cells, 
touching the bottom of the well. The diffuser was therefore suspended 2-4 mm above the cells. One 
cartridge was fired at the cells at 500 psi. The diffuser was replaced and the barrel sprayed with 
methylated spirits between shots to prevent contamination. One minute after PMDD the cells were 
gently covered with 2 ml complete Iscove’s medium containing 25mM Hepes and 2ng/ml GM-CSF 
medium and incubated for 24 or 48 h. 
Extensive testing showed the modified gene gun barrel was more effective for in vitro PMDD than 
merely reducing the helium pressure; reducing pressure decreased the diameter of the shot site whereas 
the modified barrel produces an equal sized shot site with more homogenous gold density throughout. 
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Fig 2.8 – In vitro gene gun equipment
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Figure  2-8. Modification of the gene gun barrel for in vitro PMDD.
(a) The original barrel of the gene gun. (b) The lid of a 50ml centrifuge tube. 
(c) A 70µm cell strainer. (d) The threaded top of a 50ml centrifuge tube was 
removed and glued to the end of a gene gun barrel. (e) The central section of 
the centrifuge tube lid was removed. (f) The base of a 70µm cell strainer was 
removed to produce a blast diffuser. (g) The diffuser was placed on the end of 
the gene gun barrel and (h) sealed in place by screwing on the modified lid. (i) 
The modified gene gun barrel was installed onto the loaded gene gun and 
used to transfect 4x106 MC57 cells in a droplet of 20 µl medium.
Figure  2-8 Modification of the gene gun barrel for in vitro PMDD 
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Figure  2-9 Testing of the gene gun barrel modified for in vitro PMDD 
 
 
 
 
 
 
Fig 2.9 – testing of IV 
gene gun equipment
Figure 2-9. Testing of the gene gun barrel modified for in vitro PMDD.
The gene gun barrel and its modified equivalent (top). The ballistics of the 
modified and unmodified barrel were examined by firing a cartridge into a 
sheet of Nescofilm (middle). Microscopic examination of transfected cells after 
recovery showed the extent of cell damage caused by each apparatus 
(bottom).
Normal barrel                 Modified barrel
70µm
5mm 5mm
70µm
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2.5. Confocal fluorescence microscopy 
2.5.1. Confocal fluorescence microscopy of bone marrow-derived DC 
24 h following in vitro PMDD, the coverslip onto which the DC had adhered during incubation was 
removed from its tissue culture well and washed by dipping in PBS. DC were simultaneously nucleus-
stained and mounted by simply placing the coverslip cell-side-down onto a droplet of mounting 
medium on a microscope slide. Mounting medium was Vectashield containing 1.5 µg/ml 4',6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories | H-1200). Cells were visualised by confocal 
microscopy on a Leica SP2 AOBS (acoustica optical beam splitter) system. 
2.6. Western Blot 
Samples were run, alongside Rainbow molecular weight markers (Amersham Life Science RPN-800) 
on a 12% polyacrylamide gel and transferred onto a nitrocellulose membrane (Amersham Biosciences 
RPN2020D). The membrane was blocked in 5% milk powder in PBST. It was then incubated with a 
1:500 dilution of polyclonal rabbit anti-OVA (generated by Prof B. Chain) in PBST/2% milk for one 
hour at room temperature with shaking. The membrane was washed thoroughly with PBST and 
incubated with a 1:3000 dilution of swine anti-rabbit horseradish peroxidase conjugated polyclonal 
antibody (DAKO P0399) in PBST/2% milk for one hour at room temperature with shaking. Further 
washes were performed before the blot was visualised by rinsing with ECL reagent (Amersham 
Biosciences RPN2109) and exposing to photographic film (Amersham Biosciences RPN3103K). Gels 
were stained with Coomassie Brilliant Blue to confirm sample loading consistency.  
2.7. In vivo work 
2.7.1. Mice 
DO11.10 mice (Balb/c background, H-2d haplotype), donors of the ovalbumin (OVA323-339) epitope-
specific transgenic T cells(Murphy et al., 1990), were originally obtained from Prof K. Murphy (Washington 
University School of Medicine, St Louis, MO, USA) and a colony was maintained at The Frythe, 
GlaxoSmithKline, Welwyn, UK. Balb/c mice were obtained from Charles River UK or Harlan UK. All 
experiments were carried out under UK ethical guidelines. Unless stated otherwise, mice were 
sacrificed by cervical dislocation. 
2.7.2. Adoptive transfer of DO11.10 cells 
For every three Balb/c recipients, one DO11.10 spleen was harvested and a single-cell suspension 
prepared by homogenisation using a 70µm cell-strainer (Falcon 2350). Cells were washed once in 
HBSS (Invitrogen-Gibco 14175-053) and resuspended in 1 ml red blood cell lysis buffer (Sigma 
R7757) per spleen. Gentle agitation was applied for 2 min at which time a large volume of HBSS was 
added to arrest lysis. The cells were pelleted, resuspended in 40ml HBSS and counted using trypan 
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blue (Sigma T8154) and a haemocytometer. 5x105 cells were stained with anti-mouse CD4-TC and the 
clonotypic antibody KJ1.26-PE. These cells were analysed on a flow cytometer (FACScan™, Becton 
Dickenson) and the percentage of splenocytes that were CD4+KJ1+ was determined. The remaining 
splenocytes were then spun and resuspended in a volume of HBSS to a concentration of 5x106 
CD4+KJ1+ cells/ml. 200 µl (1x106) cells were injected into the tail vein of each recipient Balb/c mouse. 
2.7.3. PMDD immunisation 
The abdomen of mice to be immunised was shaved and one cartridge shot (or two, if specified) was 
administered to each side of the abdomen (Figure 2.10). Helium at a pressure of 500 psi was used to 
propel the microparticles at high velocity using the Helios gene gun (Bio-Rad), kindly provided by 
Prof Jeremy Brockes (Dept of Biochemistry, UCL, London, UK). When repeat doses were 
administered, it was ensured that immunisation sites were non-overlapping. 
2.7.4. Induction of asthma 
In the original model mice were sensitised with 10 µg OVA adsorbed to 2 mg alum in 0.2 ml sterile 
saline, administered intraperitoneally twice, 14 days apart. In this study the first sensitisation was 
replaced by the gene gun immunisation schedule described in chapter 7. On days 10, 11 and 12 post-
sensitisation asthma was induced by intranasal administration of 50 µg OVA in 50 µl saline (”naive”, 
“primed” and “treated” groups). The “control” group instead received intranasal saline. 3 days post-
induction (15 days post-sensitisation), mice were sacrificed and bronchoalveolar lavage (BAL) fluid, 
lymph nodes and blood were obtained. 
2.8. Harvesting of cells 
2.8.1. Preparation of lymph node cells 
On day 3 and/or 5 post-immunisation, inguinal lymph nodes were harvested and homogenised between 
two sterilised ground-glass microscope slides and cells were suspended in HBSS, counted and 
resuspended in a volume of complete RMPI (RPMI-1640, Invitrogen-Gibco), to give a cell 
concentration appropriate to the analysis method(s) used, normally 8x106 cells/ml. 
2.8.2. Asthma model: Blood, BAL fluid and lymph nodes 
Mice were sacrificed by intraperitoneal administration of 200 µl sodium pentobarbital to prevent 
damage to the aorta and trachea. The skin and tissue under the chin was cut away and the resulting 
pool of blood, assisted by heart massage, was harvested by pipette.  
A hyperdermic needle was used to pierce the trachea. A syringe was used to flush the lungs 5 times 
with 1 ml aliquots of PBS containing 0.1% BSA and 0.37% EDTA. 
The rib cage was then opened and mediastinal lymph nodes harvested. 
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Fig 2.10 – PMDD 
immunisation
Figure 2-10. PMDD immunisation. 
The characteristic markings on the skin after the administration of one 
(left) or two (right) immunisation doses to each side of the abdomen.
Figure  2-10 PMDD immunisation  
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2.9. Flow cytometry 
2.9.1. Extracellular antibody staining 
After blocking in 10% rabbit serum, lymph node cells or splenocytes were stained with combinations 
of the following: TriColor-anti-CD4 antibody (Clone CT-CD4, Caltag RM2506), Phycoerythrin-anti-
DO11.10 TCR antibody (Clone KJ1.26, Caltag MM7504-3), Phycoerythrin-anti-TNP (isotype control) 
antibody (Mouse IgG2a, Caltag MG2a04), FITC-anti-CD62L antibody (Caltag RM4301); all at 280 ng 
per million cells. Cells were then washed in PBS containing 0.5% Bovine Serum Albumin Cells were 
collected using a Becton Dickinson FACScan™ and analysis was performed using CELLQuest™ 
(Becton Dickinson) or WinMDI (Joseph Trotter, Scripps Research Institute) software. 
2.9.2. Intracellular antibody staining 
4x106 lymph node cells were restimulated for 6 h in complete RPMI medium containing 1 µM OVA323-
339 (ISQAVHAAHAEINEAGR, provided by GlaxoSmithKline) and 10 µg/ml Brefeldin A. Cells were 
stained extracellularly as above and were fixed and permeablised using the Fix-n-Perm kit (Caltag 
GAS-003) according to the manufacturer’s guidelines. Cells were stained with 5 µl FITC-anti-IL-2 
antibody (Immunotech PNIM3017). 
2.9.3. CFSE labelling 
A stock of CFSE was prepared by dissolving lyophilised CFSE (Molecular Probes / Invitrogen) in 
extra-dry dimethyl sulfoxide (DMSO) to a concentration of 5 mM. The stock was stored airtight at –
80°C. After preparation for adoptive transfer as above, splenocytes were resuspended to 3.77x106 
cells/ml in HBSS and equilibriated to 37°C in a waterbath (around 15 min). Stock CFSE was added to 
a final concentration of 5 µM and the labelling reaction was allowed to proceed at 37°C for another 5 
min. Cells were washed three times in large volumes of HBSS before resuspending to the appropriate 
volume for adoptive transfer (see above). 
2.9.4. Measurement of CFSE-stained T cell proliferation by flow cytometry 
The total number of cell divisions of CFSE-stained DO11.10 cells was calculated as follows: 
Lymphocytes were gated by forward and side-scatter analysis. DO11.10 cells were gated by CD4 and 
KJ1.26 expression. FL1 fluorescence by these cells was displayed on a histogram (see Figure  2-11 for 
example). The peak farthest to the right (i.e. highest fluorescence) was considered to contain cells that 
had not yet divided. Each of the peaks to the left were considered to contain cells that had undergone 
one more division than the peak on their right. For example, the third peak (M3 on the graph) would 
contain cells that had undergone two divisions. The number of cells in each peak was divided by 2X 
where X is the number of divisions for that peak. The figures for each peak were added to give the 
total number of divisions caused by the treatment. A caveat to interpretation of this data is that, for 
simplicity, this method assumes zero cell death.  
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Fig 2.11 – CFSE 
calculation
Figure 2-11. Measurement of CFSE-stained T cell proliferation by 
flow cytometry.  
A characteristic histogram of CFSE fluorescence by adoptively transferred 
DO11.10 cells following immunisation. Rightmost peak represents 
undivided cells; each peak to the left represents cells that have undergone 
one more division than those represented by the peak on its right. For 
example, peak M3 represents cells that have undergone two divisions.
Figure  2-11 Measurement of CFSE-stained T cell proliferation by flow cytometry 
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2.10. Enzyme-linked cytokine assays 
2.10.1. IL-10 ELISA on supernatant of transfected CHO cells 
ELISA plates (Falcon 3915) were coated with 4 µg/ml anti-IL-10 (Pharmingen 554422) in bicarbonate 
buffer overnight at 4°C. They were then washed 3 times with PBST and nonspecific binding sites were 
blocked by incubating for at least 2 hours at room temperature with 200µl per well of PBS/1% BSA. 
Serial dilutions of sample supernatants were added to wells alongside a standard curve of recombinant 
IL-10 (Pharmingen 550010 or PeproTech EC 210-10) and plates were incubated for 2 hours at 37°C. 
After washing 3 times with PBST, 2 µg/ml biotinylated anti-IL-10 in PBS/1%BSA was added to each 
well and incubated for 1 h at room temperature. A further 4 washes was followed by incubation with 
Streptavidin Peroxidase (Pharmingen 554066) 1:1000 in PBS/1%BSA. After a final 5 washes, plates 
were developed using o-phenylenediamine dichloride (Sigma P-6912) and read at 450 nm on a U-1500 
spectrophotometer (Hitachi) using Revelation software (Dynex Technologies). 
2.10.2. IgE ELISAs on blood serum of asthma-induced mice 
The same procedure as above was performed apart from the following differences: For the total IgE 
ELISA the coating (capture) antibody used was anti-IgE (Rat IgG1, Pharmingen 553413) and the 
detecting antibody was biotinylated anti-IgE (Rat IgG1, Pharmingen 553419). The standard curve was 
built using recombinant IgE (Pharmingen 557079). For the OVA-specific IgE ELISA the same 
detecting antibody was used but the coating (capture) substance was ovalbumin (20 µg/ml in PBS) 
rather than antibody. 
2.10.3. ELISPOT 
The day prior to lymph node or spleen harvest, 96-well ELISPOT plates (Millipore, MAIPS45) were 
coated with 50µl per well of sterile anti-cytokine antibody at 10µg/ml (IL-2, IL-4, IL-10) or 15µg/ml 
(IFN-g) in HBSS (anti-IL-2 clone JES6-1A12, eBioscience 14-7022; anti-IFN-γ clone R4-6A2, 
Pharmingen 551216; anti-IL-4 clone 11B11, eBioscience 14-7041; anti-IL-10 clone JES5-16E3, 
eBioscience 14-7101). Plates were incubated at 4°C overnight. On the day of lymph node harvest, 
plates were washed three times with 200µl per well of HBSS and nonspecific binding sites were 
blocked by incubating for at least 2 hours with 200µl per well of complete RMPI. Routinely, 1, 2 and 
4x105 lymph node cells were plated per well (2, 4 and 8x105 for IFN-γ) and data was multiplied so as 
to be presented in spots per million cells. Where coculture ELISPOTs were performed, 5x103 and 
1x104 DO11.10 cells per well were cocultured with 4x105, 2x105 and 1x105 splenocytes per well. 
OVA323-339 was dissolved in complete RPMI to give a final concentration in ELISPOT wells of 1µm. 
Control wells received complete RPMI instead. The total volume in all wells was 200µl. Plates were 
incubated at 37°C and 5% CO2 for 19h. 
Cells were removed from plates by washing in PBS, incubating with 200µl dH20 for 10 mins to lyse 
remaining cells and washing a further three times with PBS. 50µl of the appropriate biotinylated 
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antibody (biotin-anti-IL2 clone JES6-5H4, Pharmingen 554426; biotin-anti-IFN-γ clone XMG1.2, 
Pharmingen 554410; biotin-anti-IL-4 clone BVD6-24G2, Pharmingen 554390; biotin-anti-IL-10 clone 
JES5-2A5) at 1µg/ml in HBSS was added to the relevant wells and incubated at room temperature with 
shaking for 2 hours. Plates were washed three times and 50µl streptavidin-alkaline phosphatase 
conjugate (Caltag SA1008) diluted 1:1000 in HBSS was added per well. After another one hour room 
temperature incubation with shaking, wells were washed five times. 50µl reagent (Bio-Rad 170-6432) 
was added to each well and spots were allowed to develop. The reaction was stopped by washing twice 
with 200µl dH20 per well. Spots were counted a day later using an image analysis system (Autoimmun 
Diagnostika GmbH, Strassberg, Germany). 
For human interferon-γ (h-IFN-γ) ELISpot, used to detect migrating p7.hIFNg-transfected DC, Iscoves 
medium replaced RMPI for all steps. The spots produced by the h-IFN-γ ELISpot were initially of too 
low intensity to be reliably counted. Therefore incubation was extended to 45 h. 
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3. Expression of vector constructs 
3.1. Introduction 
As well as confirming the successful construction of the vectors to be used, this chapter examines and 
validates some of the current knowledge of the mechanism of particle mediated DNA delivery (PMDD 
or gene gun). 
There has been much discussion over the exact mechanism of PMDD immunisation. Most relevant to 
this chapter is the temporal distribution of antigen expression versus dendritic cell (DC) migration 
from the skin to the lymph node. Even under control of a promoter as well studied as CMVie 
variations in the kinetics of expression and antigen presentation are possible. Firstly this novel method 
of introducing the promoter and gene into the cell may bypass the natural processes which would 
normally define expression kinetics. Secondly there is the question of which cell or cells are 
transfected and on which of these is detection of expressed protein dependent. More specifically are 
DC directly transfected prior to their migration or do they take up antigen from adjacent transfected 
skin cells (e.g. keratinocytes)? 
It has been shown that, under the control of the CMVie promoter, expression of transgene occurs <24 h 
post-PMDD(Torres et al., 1997; Porgador et al., 1998; Larregina et al., 2001; Ludwig-Portugall et al., 2004). However it is not obvious 
when expression ceases, not least because the product of each transgene studied will have a different 
half-life, both within the cell and in the extracellular space. In the case of immunisation, also important 
is the duration of antigen presentation by any transfected skin DC – partially dependent on transgene 
expression but also on the stability of antigen-MHC complexes on the cell surface. 
PMDD immunisation directly transfects both skin DC and keratinocytes(Condon et al., 1996; Lu et al., 1996; Porgador 
et al., 1998)
. The number of keratinocytes in skin greatly exceeds that of DC and it is likely that the 
proportion of transfected cells follows this ratio. However the evidence suggests that skin DC 
predominantly present antigen from direct transfection as opposed to antigen from surrounding 
transfected cells(Porgador et al., 1998; Timares et al., 2003). It has been shown that directly transfected DC migrate to 
the lymph node and that they are vital for immunisation(Morita et al., 2001; Ross et al., 2003). Although the precise 
characteristics of migration and transgene expression may be dependent on the specific model, this 
information suggests that, whereas transgene expression in the skin occurs in all cell types, the 
majority of expressed protein in draining lymph nodes will originate from directly transfected, 
migrated skin DC. This has implication for the detection of transgene expression in vivo. 
3.2. Expression of IL-10 in vitro 
3.2.1. Transfection of Chinese Hamster Ovary cells with p7.IL10 
To establish the functionality of the p7.IL10 vector, expression of IL-10 was tested following in vitro 
transfection of Chinese Hamster Ovary (CHO) cells. CHO cells were transfected with 1µg p7.10. 48h 
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later supernatants were harvested and IL-10 expression analysed by ELISA (Figure  3-1). To detect any 
possible interference by p7.OVA on p7.IL10, the same procedure was performed using a mixture of 
1µg of each vector. As a negative control, a third transfection was performed using p7.OVA alone. 
Transfection with p7.IL10 alone produced a detectable quantity of IL-10. This was not quantified in 
these experiments since the objective was only to confirm that the vector was functional. There was no 
background production or cross-reaction with other molecules as evidenced by the cells transfected 
with p7.OVA alone. p7.OVA did not interfere with transfection or expression of p7.IL10; when 
transfected together, the level of IL-10 production was indistinguishable from that of p7.IL10 alone.  
3.3. Expression of OVA in vitro 
3.3.1. In vitro gene gun of MC57 fibrosarcoma cells with p7.OVA  
In order to test the expression of p7.OVA it was necessary to perform an experiment similar to that in 
 3.2.1. In addition, it was important to determine the ability of DNA bound to gold particles in the gene 
gun system to be expressed. Therefore an in vitro gene gun system was developed (see Materials and 
Methods).  
Gene gun cartridges containing low (0.05 µg), medium (0.1 µg) and high (0.5 µg) doses of p7.OVA 
and/or p7.IL10 were prepared. Negative control cartridges containing only empty p7 were also 
prepared. 4x106 MC57 cells were transfected with one of these three cartridges. Recombinant IL-10 
was added to relevant wells to a final concentration of 20 ng/ml. Cells were incubated for 24 h after 
which time wells were lysed with 200 µl H20.  
Cell lysates were analysed by Western blot (Figure  3-2). Ovalbumin, with a molecular weight of 
around 43kDa, was observed to form a double-band roughly midway between the 30kDa and 50kDa 
molecular weight markers. This band was absent in lane 1, containing lysate from empty p7-
transfected cells. Lanes 2, 3 and 4 show an increase in band intensity corresponding to an increase in 
p7.OVA dose. Into the highest dose of p7.OVA (0.5 µg) was titrated a range of p7.IL10 doses. Lanes 5 
and 6 show that low and medium doses of p7.IL10 have no detectable effect on the expression of 
p7.OVA. However the highest dose of p7.IL10 was observed to cause a slight decrease in the 
concentration of OVA in the cell lysate (lane 7). To estimate the relative concentration of OVA as 
compared to cells transfected with p7.OVA alone, the band intensity of lane 7 was compared to that of 
lanes 2-4. From this comparison it is evident that cells transfected with 0.5 µg of both p7.OVA and 
p7.IL10, although expressing p7.OVA to a lesser degree than cells transfected with 0.5 µg p7.OVA 
alone, expressed p7.OVA to a greater degree than cells transfected with 0.1 µg p7.OVA.  
To distinguish between plasmid competition and a specific effect on expression by synthesised IL-10, 
recombinant murine IL-10 (20 ng/ml) was added to cells transfected with low and high doses of 
p7.OVA (lanes 8 and 9, respectively). Band intensity was similar, if not identical, between lanes 2 and 
8 and between lanes 4 and 9. Thus expression of p7.OVA, at least by MC57 cells, was not affected by 
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the presence of IL-10 protein. Any reduction in expression seen in lane 7 must therefore be due to 
competition on the nucleic acid level. 
3.3.2. In vitro gene gun of bone marrow-derived dendritic cells – p7 constructs 
To extend the possibilities of in vitro PMDD and to further validate the expression of the p7.OVA 
vector the standard gene gun barrel was modified (see Materials and Methods). Whereas the standard 
equipment successfully transfected MC57 fibrosarcoma cells ( 3.3.1), it was not efficient at transfecting 
bone marrow-derived dendritic cells (BMDC); it caused extensive cell death, especially in the central 
‘dead’ zone of the blast. The modified barrel diffused the power of the gene gun blast and spread the 
gold particles more evenly over the blast area (see  2.4.3). This made it possible to examine the 
expression of p7.OVA in cultured DC. 
BMDC were transfected with 0.5µg p7.OVA with or without 0.5µg p7.IL10. Controls were either 
transfected with empty p7 or were untransfected. Recombinant murine IL-10 (20 ng/ml) was added to 
the relevant wells. Cells were incubated for 24 h, lysed in 200 µl H20. and lysates analysed by Western 
blot (Figure  3-3). 
Blot A compares various gene gun treatments with untransfected DC. The distinct double-band is seen 
only in lysates of cells that received p7.OVA. Whereas Figure  3-2 indicates a small inhibition of 
p7.OVA by p7.IL10, Figure  3-3 suggests that this may not be the case in DC: No difference was 
observed between cells that received p7.OVA alone and those that received p7.OVA + p7.IL10. 
Similar to expression in MC57 cells, the presence of recombinant murine IL-10 had no effect on the 
expression of p7.OVA. 
The accompanying Coomassie stain (B) of the polyacrylamide gel used shows equal loading in each 
lane. In this case it is particularly important as cells that have been bombarded by PMDD are being 
compared to those which have not. 
To confirm that the double-band seen in the previous Western blots was indeed expressed ovalbumin, 
lysates of transfected DC were run alongside a solution of ovalbumin. Blot C shows that the double-
band present in the lysate of p7.OVA-transfected DC, and absent in untransfected and p7-transfected 
DC, is the same size as ovalbumin. 
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Fig 3-1 Expression of IL-
10 in CHO cells
Figure 3-1. In vitro expression of IL-10.
CHO cells were transfected with 0.5 µg p7.IL10, 0.5 µg p7.OVA or both. After 
48 h incubation supernatants were analysed by IL-10 ELISA. Data are the 
mean of two independent experiments; each dot represents an individual well.
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Figure  3-1 In vitro expression of IL-10 
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Fig 3-2 Expression of 
p7.OVA in MC57
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Figure 3-2. In vitro expression of OVA using PMDD.
A droplet containing 4x106 MC57 cells was transfected with one gene gun 
cartridge using compressed helium at 275 psi. Each cartridge contained a 
combination of high (0.5 µg; +++), medium (0.1 µg; ++), low (0.05 µg; +) or 
no (–) p7.OVA and/or p7.IL10. Cells were incubated for 24 h in the presence 
(+++) or absence (–) of 20 ng/ml recombinant murine IL-10. Cells lysates were 
examined by Western blot.
Figure  3-2 In vitro expression of OVA using PMDD 
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Figure  3-3 In vitro transfection of bone marrow-derived dendritic cells using PMDD 
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Figure 3-3. In vitro transfection of bone marrow-derived DC using 
PMDD.
1x106 bone marrow-derived DC were transfected, using modified gene gun 
equipment, with 0.5 µg p7.OVA with or without 0.5 µg p7.IL10. Controls were 
either transfected with empty p7 vector alone or were untransfected. Cells were 
incubated for 24 h and lysed in 200 µl H20. Lysates were run on a 12% 
polyacrylamide gel, transferred onto nitrocellulose membrane and probed with a 
polyclonal anti-OVA antisera. A) Western blot comparing expression of p7.OVA 
in the presence or absence of p7.IL10 or recombinant murine IL-10. B) 
Coomassie stain of the polyacrylamide gel to examine lane loading. C) Western 
blot to compare the band present in lysates of p7.OVA-transfected cells with a 
standard solution of ovalbumin (3 pg).
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Fig 3-4 Fluorescence microscopic analysis of in vitro PMDD system using a GFP-encoding vector
Figure 3-4. Fluorescence microscopic analysis of in vitro PMDD system 
using a GFP-encoding vector.
1x106 BMDC were left untransfected (top row) or transfected, using modified 
gene gun equipment, with empty p7 (middle row) or with p7.GFP (bottom row) 
Cells were incubated for 24 h and then, bound to coverslips, were washed and 
mounted onto microscope slides using Vectashield mounting medium containing 
1.5 µg/ml DAPI. Cells were studied by confocal microscopy. Blue fluorescence 
delineates DAPI-stained cell nuclei (left column). Green fluorescence identifies
gene gun beads and GFP (middle column). Merged colours produce a clear 
picture of GFP expression/nonexpression in cells (right column).
Figure  3-4 Fluorescence microscopic analysis of in vitro PMDD system using a GFP-encoding vector 
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3.3.3. In vitro gene gun of bone marrow-derived DC – GFP constructs 
To follow expression of genes administered by PMDD at the single-cell level and to potentially enable 
future tracking of in vivo transfected cells, expression of a GFP-encoding vector (pHR-SIN-cPPT-
SE(Demaison et al., 2002), kindly provided by M. Collins) was examined following in vitro PMDD. 
Transfected DC were incubated for 24 h at which time they were stained, mounted and examined by 
confocal microscopy (Figure  3-4). 
The nuclei of all cells were highly visible due to the DAPI stain. In cells which had received PMDD of 
empty p7 vector, the gold beads were visible as punctate green fluorescence that was not present in DC 
that had not received PMDD. These points were also present in cells that had received the GFP-
encoding vector. However in this case green fluorescence was seen throughout the cytoplasm, 
suggesting expression of GFP. Further work would probably be required to prove absolutely that the 
beads were inside the cells and not merely associated with the membrane. 
3.4. Expression of OVA in vivo 
3.4.1. Detection of expression of p7.OVA by Western blot 
Several attempts were made to measure OVA in homogenates of transfected skin tissue and draining 
lymph nodes by Western blot (Figure  3-5). In skin homogenates, occasional blots suggested detectable 
levels of the protein but results were not reproducible. The problem was confounded by cross-
reactivity of the polyclonal anti-OVA antibody with a component of skin. Figure  3-5a demonstrates 
this cross-reactivity: Lanes containing homogenates of untransfected and p7-transfected skin display 
two bands, one of approximately the same molecular weight as OVA and the other of approximately 
30 kDa. Despite increased intensity in the p7.OVA-transfected skin, it was not possible to confidently 
detect OVA. 
Homogenates of lymph nodes from the same mice were also analysed for OVA expression. In a similar 
way to skin samples, occasional blots suggested the presence of detectable amounts of ovalbumin but 
the majority of attempts were unable to detect the protein (Figure  3-5b). Therefore expression of 
p7.OVA in vivo could not be confirmed by Western blot. 
3.4.2. Detection of plasmid expression by antigen presentation ELISpot 
An indirect method to demonstrate the expression of p7.OVA in vivo was devised, the aim being to 
detect the presence of transfected skin DC in the draining lymph node via antigen presentation ( 
Figure  3-6). p7.OVA or empty p7 were administered by PMDD. In this case mice received 4 gene gun 
shots, totalling 1 µg vector, in order to maximise the possibility of detecting transfected DC. 24 h 
following PMDD lymph node cells were cocultured with pre-primed DO11.10 cells on an anti-IL-2-
coated ELISpot plate and incubated for 24 h. 
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The number of spots detected was extremely small: Cells from mice that had received p7.OVA 
produced an average of 15 spots per lymph node while those from mice immunised with empty p7 
produced around 5-10 spots. However the number of spots was similar in the presence or absence of 
added DO11.10 cells, suggesting that they may have been due to background production of IL-2 by the 
lymph node cells. These experiments did not convincingly demonstrate antigen presentation by DC 
from immunised mice. 
3.4.3. Detection of plasmid expression by direct ELISpot 
A more direct method to detect plasmid expression in vivo (or ex vivo) was tested in order to provide 
more accurate enumeration of transfected, migrating cells. To prevent the cross-reactivity of anti-OVA 
detection antibody that was seen in Western blots and to avoid confusion with endogenous production 
of protein, neither p7.OVA nor p7.IL10 were used for this purpose. Instead the human interferon-γ 
(hIFN-γ) cDNA was cloned into the p7 vector and a standard capture-detection antibody pair was used 
in an ELISpot to detect hIFN-γ-expressing cells in the lymph node.  Mice received two shots of either 
a ‘normal’ (0.5 µg) or high (1.0 µg) dose of p7.hIFNg. 6 h and 21 h post-PMDD a 45 h ELISpot was 
performed on cells from draining inguinal lymph nodes. 
At 6 h post-PMDD, an average of <1 spot per lymph node was detected. Because all three groups 
produced a similar number of spots, this was considered background. After 21 h both low and high 
doses of p7.hIFNg showed a increase in the number of hIFN-γ-producing cells with an average of 6.6 
and 7.1 spots per lymph node, respectively. Thus around 6 detectable transfected cells migrated from 
the skin to each lymph node. A doubling of the number of plasmid copies per gold particle had little 
effect on the number of cells detected. 
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Figure 3-5. In vivo PMDD – detection of OVA expression by Western 
blot.
Mice either received PMDD of 0.5 µg p7.OVA or empty p7 or did not receive 
PMDD. After 24 or 48 h skin from the gene gun site (A) or draining lymph 
nodes (B) were harvested, homogenised and analysed by Western blot. Each 
group consisted of three mice.
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Fig 3-5 In vivo PMDD – detection of OVA expression by Western blot
Figure  3-5 In vivo PMDD – detection of OVA expression by Western blot 
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Figure  3-6. Detection of migrating transduced skin cells in the lymph 
node by antigen presentation ELISpot.  
Mice (3 per group) either received PMDD of p7.OVA or empty p7 or did not 
receive PMDD. PMDD consisted of 4 gene gun shots of 0.5 µg vector to maximise 
the number of transduced cells. After 24 h draining lymph nodes were harvested 
and cell suspensions prepared.  
1x106 lymph node cells were cocultured with 5x104 antigen-experienced DO11.10 
T cells in an IL-2 ELISpot. Control wells contained lymph node cells with no 
DO11.10 cells or contained exogenous OVA323-339. 
Figures are adjusted to spots per lymph node. Graphs represent independent 
experiements. Each bar represents a triplicate ELISpot well. 
** p<0.01 by one-way ANOVA 
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Figure  3-7. Detection of migrating transduced skin cells in the lymph 
node by human IFN-γ ELISpot. 
Mice received 2 shots of either empty p7, a ‘normal’ dose of p7.hIFNg (0.5 µg) or 
a ‘high’ dose of p7.hIFNg (1.0 µg). Draining inguinal lymph nodes were harvested 
either 6 h (panel A) or 21 h (panel B) post-PMDD and cultured alone for 45 h in 
an anti-hIFN-γ-coated ELISpot plate. Each point represents an individual mouse. 
Bars represent the mean for each group. 
***p<0.001 
0
2
4
6
8
10
12
Sp
o
ts
 
pe
r 
ly
m
ph
 
n
o
de
0
2
4
6
8
10
12
Sp
o
ts
 
pe
r 
ly
m
ph
 
n
o
de
p7 (empty) 
p7 (empty) 
p7.hIFNg 
(High dose) 
p7.hIFNg 
(High dose) 
p7.hIFNg 
(Normal dose) 
p7.hIFNg 
(Normal dose) 
A 
B *** *** 
77 
3.5. Discussion 
3.5.1. Expression of vectors in vitro 
In vitro transfection of both p7.IL10 and p7.OVA into CHO cells and MC57 fibrosarcoma cells 
resulted in reliable expression of IL-10 and OVA, respectively. No significant inhibition or 
competition was detected between the vectors when transfected together.  
This expression study required the development of a novel technique for the transfection of DC in 
vitro. Whether it is generally more efficient than other techniques remains to be seen but it does 
provide a more appropriate means by which aspects of PMDD immunisation can be studied in vitro. 
Western blot analysis of p7.OVA-transfected bone marrow-derived DC (BMDC) provided evidence of 
successful transfection but the system was not entirely reliable. Although the polyclonal detection 
antibody used was remarkably sensitive (bands contained <3pg OVA), background noise and multiple 
bands were common problems. 
An antibody-free technique was developed to circumvent these problems: BMDC were transfected 
with vector encoding GFP. It came as some surprise that the gold beads used to transfect the DC were 
themselves visible through the green channel. However, initial concerns that the green fluorescence 
observed in the cytoplasm of GFP-transfected cells was merely diffusion of light from the gold beads 
were laid to rest upon observing the p7-transfected cells which contained the beads but whose 
cytoplasm did not fluoresce. Unfortunately one of the reasons for developing the GFP gene-gun system 
was to track transfected cells in vivo, possibly by flow cytometry. Even if green-fluorescing cells were 
detectable, those containing beads and GFP may well be indistinguishable from those containing beads 
alone. Nevertheless, reliable detection of green fluorescent cells in the p7.GFP-transfected group was 
achieved, demonstrating the efficiency of this novel transfection technique.  
3.5.2. Expression of vectors in vivo 
Similar problems to those above were encountered when Western blot analysis of transfected skin and 
its draining lymph nodes was performed. Cross-reactivity with an endogenous component of skin 
prevented the identification of expression of p7.OVA in that tissue. This component was not present in 
draining lymph nodes but reliable detection by Western blot was nevertheless not possible. 
Previous studies have also found that detection of protein in migratory skin DC was problematic. In 
one model expression, under control of the CMVie promoter, occurred 12-24 h post-PMDD whereas 
collection of a useful number of migratory DC required 48 h(Larregina et al., 2001). By this time expression 
was no longer detectable. It is possible, therefore, that the kinetics of expression versus those of 
migration could have contributed to the difficulty of detecting OVA expression in vivo.  
The small number of transfected skin DC that appear in the lymph node make detection by flow 
cytometry very difficult(Akbari et al., 1999). Using β-gal as the transgene, Porgador et al. were able to count, 
histologically, 10-20 transgene-expressing cells per lymph node per gene gun shot(Porgador et al., 1998). A 
more elaborate β-gal reporter system was developed by Garg et al., using flow cytometry to identify 
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100 times more transfected DC in the lymph node than were counted by Porgador et al(Garg et al., 2003). A 
key difference between these studies is that the latter involves permanent tagging of transfected DC 
whilst the former relies on continued expression of transfected gene. Therefore transfected DC can 
continue to be identified at later timepoints. Indeed the number of transfected DC in the lymph node 
continued to increase for 2.5 days; the earlier study only examined migration after 1 day. 
Despite the existence of these techniques, the potential difficulty in distinguishing p7.GFP-transfected 
cells by flow cytometry (described in  3.5.1) led to the decision to use two ELISpot assays to detect 
transgene expression in the draining inguinal lymph nodes. Direct detection of human IFN-γ showed 
the presence of 5-10 p7.hIFNg-transfected cells per lymph node 21 h post-PMDD. Although not 
identical, this number is comparable to that determined by Porgador et al. Unfortunately, the antigen 
presentation ELISpot could not confirm the presence of transfected skin cells in the lymph node. Since 
this study was performed a similar technique, detecting IFN-γ produced by antigen-specific CD8+ T 
cells, was successfully developed(Dzutsev et al., 2008). Therefore it is possible that future refinement of our 
antigen presentation ELISpot might successfully detect antigen-transfected skin cells that have 
migrated to the lymph node.  
Despite this low number of directly transfected DC we know that keratinocytes are transfected during 
PMDD and might have hypothesised that untransfected DC will also obtain OVA from them. The data 
did not provide any evidence for an extensive indirect antigen processing/presentation pathway in this 
model.  
Although the number of directly transfected DC in the lymph node is low, a measurable immune 
response is mounted. This is also seen elsewhere and demonstrates the potent immunostumulatory 
ability of DC(Akbari et al., 1999). 
In conclusion the data confirms that the vectors to be used for PMDD immunisation can drive 
expression of their inserted gene in both conventional lipid-based, and novel PMDD-based, in vitro 
transfection systems. The data also shows that these vectors are not mutually inhibitory. It may also be 
suggested that OVA is expressed in the skin of mice transfected with p7.OVA. 
Based on this data and the many previous reports of gene gun immunisation it was decided to proceed 
with the study of the immune response to p7.OVA and the effect on this response of p7.IL10. 
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4. Characterisation of the Adoptive Transfer Model 
4.1. Introduction 
Although the ultimate aim of immunology is to understand the normal immune system of an animal, 
genetically modified animal models have proved useful in doing so. The DO11.10 transgenic α/β T 
cell receptor (TCR) recognises the OVA323-339 epitope of OVA presented on the I-Ad class II MHC 
molecule and can be identified using the KJ1.26 clonotypic antibody(Murphy et al., 1990). T cells expressing 
this TCR can be distinguished using the same antibody. Adoptive transfer of T cells from DO11.10 
transgenic mice into synergeic Balb/c recipients allows the study of the transgenic subpopulation in the 
context of a wild-type general T cell population(Kearney et al., 1994; Pape et al., 1997). This convenient 
identification of DO11.10 transgenic cells and their inevitable dilution into the host population 
eliminate the need for their purification prior to transfer. This reduces potential artifactual modification 
due to ex vivo manipulation. 
The overall aim of this study is to examine the effect of IL-10 on PMDD immunisation, particularly to 
determine if its inclusion alongside antigen could induce antigen-specific tolerance. In order to 
facilitate this, the adoptive transfer model to be used was characterised. 
4.2. Results 
4.2.1. DO11.10 cells can be identified in DO11.10 spleen by CD4 and KJ1.26 
expression 
Splenocytes from Balb/c or DO11.10 were stained with anti-CD4-TC and anti-KJ1.26-PE. Flow 
cytometric analysis identified a distinct population of CD4+KJ1.26+ cells that were present in DO11.10 
but not Balb/c spleen (Figure  4-1). This population routinely comprised 12%-14% of total DO11.10 
splenocytes. CD4+KJ1.26+ cells from DO11.10 mice or recipient Balb/c mice will routinely be refered 
to as DO11.10 cells. 
4.2.2. After adoptive transfer into a Balb/c host, DO11.10 cells can be recovered 
and identified 
As described in Materials and Methods, spleen cells from DO11.10 mice containing 1x106 DO11.10 
cells were adoptively transferred into naïve Balb/c recipients. 72 h later inguinal lymph nodes were 
harvested and lymph node cells stained with anti-CD4-TC and anti-KJ1.26-PE. Flow cytometric 
analysis identified the DO11.10 cells as a distinct CD4+KJ1.26+ population that was absent in the 
lymph nodes of Balb/c mice that did not receive the transfer (Figure  4-2). This population routinely 
comprised 0.25%-1.0% of lymph node cells.  
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Figure 4-1. DO11.10 cells can be identified by flow cytometry. 
Splenocytes from Balb/c or DO11.10 mice were stained with anti-CD4 and anti-
KJ1.26 (clonotypic TCR). Lymphocytes were gated by forward- (FSC) and side-
(SSC) scatter profile (A). Balb/c (B) and DO11.10 (C) lymphocytes were 
analysed for their CD4 and clonotypic TCR expression. DO11.10 cells were 
identified by their CD4+KJ1.26+ phenotype. Plots are representative of at least 
40 independent experiments.
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Figure  4-1 DO11.10 cells can be identified by flow cytometry 
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Figure 4-2. Following adoptive transfer, DO11.10 cells can be identified 
in lymph nodes.
1x106 DO11.10 cells were (B) or were not (C) adoptively transferred into a 
Balb/c recipient. 96h later, inguinal lymph nodes were harvested and cell 
suspensions stained with anti-CD4-TC and anti-KJ1.26-PE. Lymphocytes were 
gated by forward- (FSC) and side- (SSC) scatter profile (A) and DO11.10 cells 
identified by their CD4+KJ1.26+ phenotype (B and C). Data are representative of 
at least 40 independent experiments.
Figure  4-2 Following adoptive transfer, DO1110 cells can be recovered from lymph nodes 
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4.2.3. PMDD of p7.OVA increases the proportion of transferred DO11.10 in 
draining lymph nodes 
1x106 DO11.10 cells were adoptively transferred into Balb/c recipients. 24 h later the recipient mice 
were immunised by PMDD with 1 µg p7.OVA or 1 µg empty p7 vector. At various timepoints the 
draining inguinal lymph nodes were harvested and lymph node cells stained with anti-CD4-TC and 
anti-KJ1.26-PE. Flow cytometric analysis showed the number of DO11.10 cells in the draining lymph 
nodes increased dramatically following immunisation with p7.OVA (Figure  4-3). This increase could 
first be detected 72 h after immunisation and peaked at 96 h post-immunisation. During this time the 
proportion of CD4+KJ1.26+ cells roughly doubled every 24 h. Although this effect was not seen 
following PMDD of p7, a small, transient increase in CD4+KJ1.26+ cells was observed; seemingly a 
result of antigen-nonspecific effects of the gene gun. In this case the number of CD4+KJ1.26+ cells 
peaked between 72 h and 96 h post-immunisation. 
4.2.4. PMDD-induced increase in DO11.10 cells is at least partially due to 
proliferation, not only migration 
The increased number of T cells in draining lymph nodes following PMDD immunisation, could be 
due to antigen-specific T cell proliferation and/or antigen-nonspecific immigration (see discussion). To 
examine this further a timecourse experiment, similar to that in  0, was performed. In this case, 
however, splenocytes were stained with carboxyfluoroscein succinimidyl ester (CFSE) prior to 
adoptive transfer and an additional control group was introduced which received no immunisation at 
all. 72 h post-immunisation (or 96 h post-adoptive transfer, in the case of the unimmunised group) 
draining inguinal lymph nodes were harvested and stained with anti-CD4-TC and anti-KJ1.26-PE. As 
seen in Figure  4-3, immunisation with p7.OVA caused the proportion of DO11.10 in the draining 
lymph nodes to increase to around 50,000 per million over 72 h and to remain for at least a further 48 h 
(Figure  4-4a). Also previously observed, immunisation with empty p7 resulted in a transient increase 
in the CD4+KJ1.26+ population. The additional control group confirmed that this increase was specific 
to mice that received PMDD: No increase was seen in mice that did not receive PMDD.  
At the 72 h timepoint, flow cytometric analysis was extended to measure the number of cell divisions 
made by each group (Figure  4-4b). Neither the group that received no gene gun nor that which was 
immunised with empty p7 exhibited DO11.10 cell division. Significant cell division was seen, 
however, in the group immunised with p7.OVA. The lack of cell division in either of the first two 
groups confirms that the increase in DO11.10 cell number in the draining lymph node following 
immunisation with empty p7 is due to increased net immigration and not to proliferation.  
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Figure  4-3 The number of lymph node D011.10 cells increases in response to immunisation with 
p7.OVA 
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Figure 4-3. The proportion of DO11.10 cells in the draining lymph
nodes increases in response to immunisation with p7.OVA.
Following adoptive transfer of DO11.10 cells, recipient mice (3 per group)
were immunised with 1µg empty p7 or with 1µg p7.OVA.  At various points
post-immunisation mice were sacrificed and draining lymph nodes harvested.
Lymph node cells were stained with anti-CD4 and anti-KJ1.26. DO11.10
cells, identified as CD4+KJ1+, were enumerated by flow cytometry. Data are
the means of four independent experiments.
*** p<0.001; ** p<0.01 by t-test as compared to p7 control at same
timepoint
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Figure  4-4 The increase of DO11.10 cells is  due to proliferative expansion 
 
 
0
0
20000
40000
60000
48 72 96 120
p7
p7.OVA
no GG *** ***
***
***
Hours post-immunisation
D
O
1
1
.1
0
p
e
r 
m
il
li
o
n
 l
y
m
p
h
o
c
y
te
s
Figure 4-4.  DO11.10 expansion in response to p7.OVA is due to
proliferation.
DO11.10 cells were stained with 5 µM CFSE and 1x106 adoptively
transferred into recipient mice. 24 h post-transfer recipient mice (15 per
group) were immunised with 1µg empty p7 or with 1µg p7.OVA or were left
unimmunised. A) At various timepoints post-immunisation mice (3 per
timepoint except 72 h; see below) were sacrificed and draining lymph
nodes harvested. Lymph node cells were stained with anti-CD4 and
anti-KJ1.26. DO11.10 cells, identified as CD4+KJ1+, were enumerated by
flow cytometry. Data are the means of four independent experiments. B)
At the 72 h timepoint an additional 3 mice per group were sacrificed and
CFSE fluoresence on gated CD4+KJ1+  DO11.10 cells examined.
*** p<0.001 by t-test as compared to p7 control for same timepoint
B
A
no GG p7 p7.OVA
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4.2.5. The increase in number of DO11.10 cells in draining lymph nodes is dose-
dependent 
To understand the relationship between the quantity of antigen-encoding plasmid and the response to 
antigen the experiment was performed with a range of p7.OVA doses. As explained in detail in the 
Materials & Methods chapter, all changes to PMDD immunisations ensured a consistent total DNA 
load per cartridge by buffering with empty p7 vector. 
An initial experiment was carried out to assess the viability of 3H-thymidine incorporation and IL-2 
ELISpot as techniques to measure T cell activity (Figure  4-5). Both techniques showed similar 
p7.OVA dose-dependent increases in T cell activity. This similarity and the already established link 
between IL-2 expression and T cell proliferation suggest IL-2 ELISpot is, in this model, a suitable 
indicator of the proliferative ability of T cells.  3H-thymidine incorporation assays were therefore 
discontinued. 
A series of more extensive dose-response studies were carried out. During this time the loading of the 
gene gun cartridges was adjusted for the purpose of consistency between these and future studies 
which would employ the addition of additional plasmids. The maximal dose of p7.OVA began as 1 
µg/mouse (0.5 µg/cartridge) and ended as 0.5 µg/mouse (0.25 µg/cartridge). This provided data from a 
broad range of doses as is displayed in Figure  4-6. 
Empty p7 alone gave rise to around 10,000 DO11.10 cells per million lymph node cells. Interestingly 
only 5 ng p7.OVA per animal was sufficient to cause this proportion to more than double in size. 
However further dose increases did not result in corresponding population increases until a dose of 0.1 
µg/mouse. At and above this dose, the DO11.10 population in the draining lymph nodes was 
significantly increased to an average of around 50,000 per million lymph node cells. 
4.2.6. Dose-dependent proliferation is associated with a corresponding increase 
in cytokine potential. 
Lymph node cells from the dose-response experiment above were cultured with or without 
restimulation with OVA323-339 in ELISpot assays to detect cytokine production in response to 
restimulation (Figure  4-7). Several cytokines were tested: IL-2 as a general marker of T cell activation 
and, as seen in  0Figure  4-5, an indicator of proliferation; IL-4 and IFN-γ to determine a TH1/TH2 ratio 
and IL-10 because of its association with T-cell tolerance and relevance to later parts of this study. 
Lymph node cells cultured in the absence of antigen were unable to generate any of the cytokines 
measured. Incubation with antigen, however, stimulated the production and secretion of all four. In 
each case the number of cytokine-producing cells was dependent on the immunisation dose of 
p7.OVA. IL-2 production followed the same pattern as the in vivo proliferation seen in  0Figure  4-3; a 
sigmoidal curve with maximal numbers at 0.1 µg/mouse p7.OVA and above. The number of IL-4 
producers also followed this pattern although at roughly half the number of IL-2-producers. IFN-γ- and 
IL-10-producing cells were much less frequent and the increase in their numbers showed a more linear 
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relationship with p7.OVA dose. The ratio of IL-4-producing to IFN-γ-producing responders was 
roughly 5:1. 
ELISpot is a very sensitive technique for detecting cytokine-producing cells; it can readily detect fewer 
than 100 cytokine-producing cells per million. A disadvantage to this technique, however, is that it 
doesn’t easily allow for further phenotyping of cytokine-producing cells. To establish that the 
cytokine-producing cells detected in Figure  4-7 were indeed the adoptively transferred DO11.10 cells, 
the experiment was repeated using mice that either did or did not receive an adoptive transfer (Figure 
 4-8). As seen previously, 1000-2000 per million lymph node cells from immunised mice that received 
an adoptive transfer of DO11.10 cells secreted IL-2 and/or IL-4 whilst cells from unimmunised mice 
did not. In contrast, in mice that did not receive a DO11.10 adoptive transfer, these cytokines were not 
produced irrespective of immunisation. Thus the cytokine-producing cells seen in figure 4-7 were 
produced by adoptively transferred DO11.10 cells. 
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Figure  4-5 p7.OVA dose-dependent increase in  proliferation and IL-2 production following PMDD 
 
 
 
Figure 4-5.  p7.OVA dose-dependent increase in  proliferation and
IL-2 production following PMDD
Following adoptive transfer of DO11.10 cells, recipient mice (3 per group)
were immunised with  0.01, 0.1 or 1.0 µg p7.OVA.  Control mice received
empty p7 vector. At various points post-immunisation mice were sacrificed
and inguinal lymph nodes harvested. Lymph node cells were restimulated with
1µM OVA323-339 peptide in both thymidine-incorporation and IL-2-ELISpot
assays. Each point   (diamonds=thymidine incorporation; circles=ELISpot)
represents an individual mouse.
*** p<0.001;  * p<0.05  by one-way ANOVA as compared to p7 control
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Figure  4-6 The increase in lymph node DO11.10 cells is dependent on the dose of p7.OVA 
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Figure 4-6. The increase in lymph node DO11.10 cells is dependent
on the dose of p7.OVA.
Following adoptive transfer of DO11.10 cells, recipient mice (3 per group)
were immunised with  various doses of p7.OVA.  Control mice received
empty p7 vector. 72 h post-immunisation mice were sacrificed and inguinal
lymph nodes harvested. Lymph node cells were stained with anti-CD4 and
anti-KJ1.26. DO11.10 cells, identified as CD4+KJ1+, were enumerated by
flow cytometry. Each point represents an independent experiment; the line
represents the mean.
*** p<0.001  by one-way ANOVA as compared to p7 control
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Figure  4-7 Cytokine production in response to p7.OVA increases in a dose-dependent manner 
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Figure 4-7.  Cytokine production in response to p7.OVA increases in
a dose-dependent manner.
Following adoptive transfer of DO11.10 cells, recipient mice (3 per group)
were immunised with  various doses of p7.OVA.  Control mice received
empty p7 vector. 72 h post-immunisation mice were sacrificed and inguinal
lymph nodes harvested. Lymph node cells were restimulated with 1 µM
OVA323-339 peptide in cytokine ELISpot assays. Each point represents an
independent experiment; the line represents the mean.
*** p<0.001;  ** p<0.01  by one-way ANOVA as compared to p7 control
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Figure  4-8 Cytokine production requires adoptive transfer of DO11.10 cells 
 
 
  
Figure 4-8.  Cytokine production requires adoptive transfer of
DO11.10 cells.
Balb/c mice (6 per group) either did or did not receive 1x106 adoptively
transferred DO11.10 cells. 1 day later, three mice were immunised with
p7.OVA and three with empty p7 vector. 72 h post-immunisation mice
were sacrificed and inguinal lymph nodes harvested. Lymph node cells were
restimulated with 1µM OVA323-339 peptide in IL-2 and IL-4 ELISpot assays
(A and B, respectively). Data are the mean of triplicate wells of a single
experiment.
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4.2.7.  Phenotypic changes in DO11.10 cells following PMDD  
Following gene gun immunisation, harvested lymph node cells were triple-stained in order to examine 
cell surface phenotypic changes by flow cytometry. Upregulation of two common activation markers 
by CD4+KJ1.26+ cells was detected, accompanying their post-immunisation proliferation. 
CD69 (an early marker of T cell activation) was upregulated on DO11.10 cells within 72 h of PMDD 
(Figure  4-9). This upregulation was not seen in CD4+KJ1– cells. Immunisation with p7.OVA caused 
upregulation of CD69 on almost all DO11.10 cells with almost 70% expressing high levels after 72 h. 
After 96 h this had reduced to 50%. Interestingly, CD69 was also upregulated on CD4+KJ1.26+ cells in 
p7-immunised control mice. However the pattern of expression was different in this case: A distinct 
population of CD69+ DO11.10 cells comprising around 50% of total CD4+KJ1.26+ cells was seen. This 
population remained roughly the same size until at least 96 h post-PMDD. It is interesting that this, 
presumably antigen-nonspecific, effect was specific to CD4+KJ1.26+ cells. This could be explained by 
a low level of pre-activation caused by the adoptive transfer: Although we have seen that division of 
the DO11.10 cells does not occur, a degree of nonspecific activation may be caused by agitation during 
the adoptive transfer process. In this case it would be logical, rather than to compare between 
CD4+KJ1.26+ and CD4+KJ1.26- cells, to take CD4+KJ1.26+ cells from p7-immunised mice as the 
negative control. Comparison between these two groups shows that 60% of previously CD69– 
CD4+KJ1.26+ cells express this molecule at a high level within 72 h of immunisation with p7.OVA. 
Expression returns to control levels within the following 24 h. 
Unlike CD69, control group expression of CD25 was not higher in CD4+KJ1.26+ cells than in 
CD4+KJ1.26– cells: Figure  4-10 shows that 7-9% of all CD4+ cells in empty p7-immunised mice 
express CD25. The same proportion was detected on CD4+KJ1.26– cells in mice immunised with 
p7.OVA. However expression on CD4+KJ1.26+ cells increased to 22% 72 h after immunisation with 
antigen. Within a further 24 h expression had returned to control levels. 
Both CD69 and CD25 are considered early activation markers. A limit to the data here is that it begins 
72 h post-immunisation; before this time the low number of CD4+KJ1.26+ cells in the draining lymph 
node made analysis of cell surface markers on this subgroup impractical. Nevertheless, this data 
contributes to the general understanding of the model. 
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Figure 4-9. Adoptively transferred DO11.10 cells upregulate CD69 
after gene-gun immunisation with p7.OVA. 
1x106 DO11.10 cells were adoptively transferred into Balb/c recipients. 24 
hours later mice were immunised with 1 µg p7 or 1 µg p7.OVA. 72 or 96 h 
post-immunisation inguinal lymph nodes were harvested and lymphocytes
triple-stained with anti-CD4-TC, anti-KJ1.26-PE and anti-CD69-FITC.  
CD4+KJ1+ and CD4+KJ1– lymphocyte populations were gated (A) and CD69 
expression of these two populations examined (B).
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Figure  4-9 Adoptively transferred DO11.10 cells upregulate CD69 after gene-gun immunisation with 
p7.OVA  
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Figure  4-10 Adoptively transferred DO11.10 cells briefly upregulate CD25 after gene-gun 
immunisation with p7.OVA 
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Figure 4-10. Adoptively transferred DO11.10 cells briefly upregulate
CD25 after gene-gun immunisation with p7.OVA. 
1x106 DO11.10 cells were adoptively transferred into Balb/c recipients. 24 
hours later mice were immunised with 1 µg p7 or 1 µg p7.OVA. 72 or 96 h 
post-immunisation inguinal lymph nodes were harvested and lymphocytes
triple-stained with anti-CD4-TC, anti-KJ1.26-PE and anti-CD25-FITC.  
CD4+KJ1+ and CD4+KJ1– lymphocyte populations were gated (A) and CD25 
expression of these two populations examined (B).
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4.3. Discussion 
The adoptive transfer of TCR-transgenic DO11.10 T cells into Balb/c recipients allowed the study of 
the CD4+ T cell response to PMDD-administered antigen. Both the magnitude and kinetics of the 
response have been examined, as well as the cytokine potential of the resulting antigen-experienced T 
cells. Although Creusot et al. have previously used a similar model, both the plasmid vector and the 
mouse strain used are different in this case. In order to facilitate the later study of the effect of IL-10 on 
the responding T cells, it was first necessary to characterise the nature of this specific model which 
employs the p7 vector and the H-2d Balb/c mouse.  
4.3.1. The suitability of the DO11.10 adoptive transfer model for the examination 
of the effect of IL-10 on the CD4+ T cell response to PMDD immunisation 
TCR-transgenic DO11.10 cells can be clearly identified using the KJ1.26 clonotypic monoclonal 
antibody. Their quantification amongst total splenocytes allows the adoptive transfer of a specific fixed 
number simply by adjusting the total number of splenocytes transferred. 1x106 DO11.10 cells allowed 
to equilibriate within the recipient routinely results in a lymph node population of 0.5%-1.0%. This 
number is high enough to allow clear identification and examination of the population. However, 
unlike the population within the original DO11.10 host, the population is not so dominant so as to 
preclude the interpretation of any results as a description of the natural response. 
The in vivo proliferative response to PMDD antigen cen be detected 3 d post-immunisation. Peak 
numbers, however, occur on day 5; two days later than similar experiments that used protein 
antigen(Rogers et al., 1997). This delay could be attributable to the need for in situ synthesis from the cDNA 
template and subsequent accumulation of processed antigen. 
These kinetics prohibit more detailed examination of the DO11.10 population by flow cytometry at 
any time earlier than 72 h post-immunisation as the number of gated events is simply too small for any 
meaningful analysis of surface phenotype or intracellular cytokine staining. ELISpot, as mentioned 
earlier, is more suited to the examination of smaller fractions of cytokine-producing cells. 
4.3.2. Response to restimulation 
Direct ex vivo examination of DO11.10 cells following a single PMDD immunisation can only 
characterise their response to that particular challenge. However later restimulation analyses can 
provide an insight into the lasting effect of the immunisation on their state of activation. The secretion 
of detectable levels of IL-2 (as well as other cytokines) by DO11.10 cells within 19 h of contact with 
OVA323-339 demonstrates previous antigen experience and the effector state of the T cell. This provides 
a useful tool for the study of the effect of IL-10 on PMDD immunisation. 
The cytokine ELISpots in this chapter demonstrate that the immune response to OVA in this model is 
TH2-biased, with five times as many IL-4-producing as IFN-γ-producing responders. Interestingly, the 
number of IL-10-producing responders also increased with the dose of p7.OVA, the population being 
of similar size to that of the IFN-γ-producers.  
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4.3.3. Dose response 
PMDD is different from traditional immunisation regimens because antigen (or at least the gene 
encoding antigen) is directly deposited intracellularly. The data therefore reflect responses to an 
increased number of plasmid copies per bead (and therefore per cell); not to increased numbers of 
transfected cells. Expression and antigen presentation may not be directly proportional to the copy 
number of antigen gene. It is therefore especially important to understand how the dose of antigen gene 
affects the response to antigen. In fact, a dose-dependent relationship was observed. 
The gene gun delivers DNA indiscriminately at the site of administration. Although dendritic cells are 
directly transfected(Larregina et al., 2001; Morita et al., 2001), non-APC-specialised cells such as keratinocytes are, 
purely through their numbers, more frequently transfected(Lu et al., 1996). Although they could process and 
present antigen themselves via the MHC class I pathway, it is more likely that the main role of these 
cells in the generation of the immune response is that of synthesis and secretion of antigen for uptake 
and cross-presentation by professional APC(Dean et al., 2003; Stoitzner et al., 2006).  
One or both of two general mechanisms may be responsible for the dose-dependent increase in 
proliferation and activation of DO11.10 cells. 
1) Antigen remains intracellular: The increased copy number per cell results in increased synthesis of 
antigen. A larger antigen dose can produce a stronger activation signal and thus increased quality of 
presentation to CD4+ T cells(Ruedl et al., 2000; Rothoeft et al., 2006). 
2) Antigen is secreted: The higher concentration of antigen resulting from increased synthesis allows 
its diffusion over a larger area and thus its uptake and presentation by a larger number of APC i.e. 
increased quantity of antigen presentation to CD4+ T cells. 
Whether the synthesised OVA protein was retained intracellularly or secreted was not directly tested. 
However the wild-type 48 amino acid secretory signal was encoded intact in the OVA transgene so a 
working assumption would be that secretion did occur. A cytoplasmic version of the gene lacking this 
sequence can be used to ensure retention(Rowe et al., 2006). This not being the focus of this study, the 
mechanism was not examined further. The relevant point for this and later discussion is that, unless 
specified, when the term “increased dose” is used, it refers to an increased intracellular dose of gene. 
For later studies of the effect of p7.IL10 on the immune response to p7.OVA, it was important to 
ensure any measured differences were not a result of plasmid interference inhibiting expression of the 
antigen-containing vector. Although Figure  3-2 and Figure  3-3 demonstrate that coadministration of 
p7.OVA and p7.IL10 was possible, there remains the possibility that very minor inhibition occurs. 
Therefore, a minimum p7.OVA dose of 0.5 µg/mouse was established. This is five times higher than 
the lowest dose that resulted in peak proliferation and cytokine production and, therefore, any minor 
decrease in expression should not affect their amplitude. The maximum p7.OVA dose was prescribed 
by the capacity of the gene gun cartridges. The maximum reliable loading rate allows 0.5 µg DNA per 
cartridge and thus no more than 1 µg total DNA  could be administered per mouse. However, to allow 
for the inclusion of other plasmids within the same cartridge, a maximum of 0.5 µg/mouse was loaded. 
0.5 µg/mouse was used as the standard dose for p7.OVA in all later studies unless stated otherwise. 
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4.3.4. Gene gun as an adjuvant 
A large increase in the number of CD4+KJ1.26+ cells in draining lymph nodes, lasting at least 120 h, 
was seen following immunisation with p7.OVA. In contrast, a small, transient increase was seen when 
mice were treated with empty p7 vector only. Nevertheless, this increase occurred in the absence of 
any exogenous antigen. Further examination showed that the transient increase in lymph node T cells 
was not caused by proliferation. It is therefore likely to be caused by a change in the rate of 
immigration to and/or emigration from the lymph node.  
The increase in CD4+ T cells in the lymph node in the absence of antigen suggests that gene gun is 
immunostimulatory – its own adjuvant. Indeed, no external adjuvant is often required for PMDD 
immunisation, just the antigen-encoding plasmid. Two factors that may contribute to this phenomenon 
are the plasmid DNA itself and the cell damage caused by PMDD. 
Plasmid DNA (and bacterial DNA in general) has been known for some time to be immunostimulatory 
(reviewed in (Yamamoto et al., 2000)). The induced maturation of several cell types, including dendritic cells, 
has been attributed to unmethylated CpG sequences(Yamamoto et al., 1992a; Krieg et al., 1995; Segal et al., 1997; Sparwasser et 
al., 1997; Jakob et al., 1998)
 whose presence is suppressed in mammalian DNA(Schorderet and Gartler, 1992). More 
recently the receptor for these sequences was identified as toll-like receptor 9 (TLR-9)(Hemmi et al., 2000). 
CpG sequences, either as exogenous adjuvant with protein antigen(Chu et al., 1997; Lipford et al., 1997; Weiner et al., 
1997)
 or as an endogenous part of DNA vaccine(Sato et al., 1996; Klinman et al., 1997), have been shown to enhance 
immunogenicity and to modulate the response towards a TH1 bias. In addition, CpG sequences have 
been shown to induce the migration of Langerhans cells(Ban et al., 2000).  
Disruption of cell integrity caused by gene gun bombardment may also activate antigen presenting 
cells and induce their migration. Necrotic cells, in particular the heat shock proteins which they 
release, can activate dendritic cells via toll-like receptor- (TLR-) 2 and/or 4 and the NFκB 
pathway(Gallucci et al., 1999; Basu et al., 2000; Sauter et al., 2000; Vabulas et al., 2002). 
Thus both plasmid DNA and the cell damage caused by the gene gun may account for the transient 
increase in CD4+KJ1.26+ cells found in the draining lymph node following administration of empty p7 
vector. The mechamism by which these immune stimuli might affect the rate of T cell immigration 
and/or emigration remains unknown but could result from direct or indirect changes in T cell 
expression of CD69 and S1P1 which are known to regulate migration through lymph nodes(Matloubian et 
al., 2004; Shiow et al., 2006)
. In addition, an increased number of DC in the lymph nodes could increase the time 
which T cells spend sampling in the lymph node. 
4.3.5. Conclusion 
The DO11.10 adoptive transfer model has previously been used to examine the immune response to 
OVA antigen. This chapter demonstrates that it is suitable for the study of gene gun-administered 
immunisation strategies. This model will be used to establish whether the coadministration of the IL-
10-encoding plasmid p7.IL10 is effective at inhibiting the immune response to p7.OVA and/or 
inducing a tolerant state in recipient animals. 
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5. Effect of IL-10 on the response to antigen 
5.1. Introduction 
As mentioned earlier, one of the many advantages to genetic immunisation is the opportunity to choose 
from a range of immunomodulatory genes or gene products to administer alongside the antigen-
encoding gene. This was first shown using intramuscular injection of genes encoding both antigen and 
cytokine(Xiang and Ertl, 1995) and was later followed by injection of various recombinant cytokines into the 
site of gene-gun vaccination(Irvine et al., 1996). The next advance was gene-gun vaccination of a fusion of 
ovalbumin and il-12 genes(Maecker et al., 1997) which was later shown to be a more effective vaccine than 
the recombinant cytokine method of Irvine et al.(Kim et al., 1997c). 
Rodent models of immune disease lend themselves to the study of immunomodulation and have been 
an important part in the study of IL-10 in this capacity. Specifically relevant to this work is the 
utilisation of the IL-10 gene, il-10, to provide this cytokine. 
Early work showed that intramuscular injection of an IL-10-expressing plasmid was able to 
significantly reduce the incidence of diabetes in NOD mice when administered prophylactically(Nitta et 
al., 1998)
. One disadvantage to this technique is the requirement for repeated administration; another is 
the quantity of plasmid vector required. Viral vectors containing il-10 address both these limitations. 
Adenovirus vectors have been shown to prevent induced colitis(Cua et al., 1999; Barbara et al., 2000) but only in 
the case of colitis due to IL-10 deficiency have they also proven to be therapeutic(Lindsay et al., 2001; Lindsay et 
al., 2002; Lindsay et al., 2003)
. Similarly, protection of Nonobese Diabetic (NOD) mice from developing 
diabetes required treatment at an early age, before the onset of hyperglycemia. Adeno-associated-virus 
encoding vIL-10 protected NOD mice from becoming hyperglycemic if administered before 6 weeks 
of age(Yang et al., 2002).   
More success was seen in rodent models of arthritis (collagen-induced arthritis; CIA). Systemic 
administration of adenovirus vector encoding the Epstein-Barr Virus IL-10 homologue (vIL-10) at the 
onset of symptoms prevented the development of disease in murine collagen-induced arthritis(Apparailly et 
al., 1998)
. However, a later study suggested that this effect was only possible using viral doses high 
enough to cause hepatoxicity(Whalen et al., 1999). This study also showed that local administration of the 
vector into the periarticular area of mouse paws was effective in preventing development of CIA. 
Surprisingly, injection into one paw proved to be sufficient to prevent arthritis in the remaining paws. 
In addition, human IL-10-encoding adenoviral vector injected into the knee joint has been shown to 
suppress the onset of arthritis in the ipsilateral paw as well as in the knee itself. Interestingly, reduced 
liver inflammation compared to that caused by empty adenovirus suggests that hepatoxicity caused by 
the viral vector, as mentioned above, may be partially suppressed by the IL-10 it itself encodes(Quattrocchi 
et al., 2001)
. A study comparing IV and local administration of  such a vector agrees that the latter is more 
effective in preventing disease but that neither is able to reverse established arthritis(Ma et al., 1998). Similar 
results were obtained in a rabbit model of arthritis(Lechman et al., 1999; Keravala et al., 2006). In this case, the 
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inducing antigen was entirely foreign and it was possible to show that the therapeutic effect was 
antigen-specific(Lechman et al., 2003).
 
Retroviral vectors have also been used as IL-10 vectors but, in this case, indirectly via pre-transfection 
of DC. Whereas, in vitro, the immunostimulatory ability of these cells was diminished(Takayama et al., 1998; 
Takayama et al., 1999)
, attempts to utilise them in vivo resulted in limited success(Takayama et al., 2001b; Moore et al., 
2004)
. Injection of such vectors directly into cardiac allografts has been shown, however, to extend the 
period of graft acceptance (Qin et al., 1996; Qin et al., 2001). 
Safety concerns over the use of viral vectors and the established importance of the intestinal flora 
promote the concept of local treatment of colitis with IL-10-secreting bacteria. Lactococcus lactis, 
transformed with an IL-10-encoding plasmid, was shown to alleviate inflammation in two murine 
models of colitis(Steidler et al., 2000). Interestingly, the bacterium displays an affinity towards inflamed 
tissue(Waeytens et al., 2007). Refinement of the genetic modification(Steidler et al., 2003) and improvement of 
delivery(Huyghebaert et al., 2005b; Termont et al., 2006) have allowed this treatment to reach Phase I clinical trials(Braat 
et al., 2006)
. 
Local administration of IL-10 or its gene allow therapy to be targeted to specific tissues and 
occasionally, due to the confined nature of some immune disorders, this may be sufficient. However, 
cytokine secreted into the general environment has the potential to exert its effects on every antigen 
presentation event in the vicinity. The immunological synapse allows cytokines to be directed more 
specifically toward antigen-specific T cells that cluster around antigen-presenting DC(Creusot et al., 2002). 
This allows both the DC itself and previously activated and polarised T cells to bias the immune 
response to a presented antigen through the paracrine secretion of cytokines(Creusot et al., 2003a). 
Targeting the IL-10 gene to dendritic cells would exploit this existing mechanism for increasing 
antigen specificity. Gene gun technology allows the direct transduction of skin DC. The intention of 
this chapter is to examine whether gene gun administration of the IL-10 gene alongside that of antigen 
can inhibit the response to that antigen. 
5.2. Results 
5.2.1. Coadministration of p7.IL10 inhibits the response to antigen 
1x106 DO11.10 cells were adoptively transferred into naïve Balb/c recipients. 24 h later mice were 
immunised with cartridges containing both 0.5 µg p7.OVA and either 0.5 µg, 0.17 µg or 0.05 µg 
p7.IL10 (“Relative quantity” 1, 0.3 and 0.1, respectively). One control group received 0.5 µg p7.OVA 
only (“Relative quantity” 0) and a second received empty p7 vector only (“p7”). 72 h post-
immunisation draining lymph nodes were harvested and CD4+KJ1+ cells enumerated by flow 
cytometry (Figure  5-1). Consistent with earlier studies, whereas in mice immunised with empty vector 
DO11.10 cells never comprised more than 500 per million lymph node cells, in those that received 
p7.OVA this figure reached 4000 per million. Coadministration of p7.IL10 at a 1:10 ratio had no effect 
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on the number of DO11.10 cells in the lymph node. In contrast, coadministration at a 1:3 or 1:1 ratio 
reduced the number of DO11.10 cells by around 40%.  
Cytokine expression by the same lymph node cells was analysed by ELISpot (Figure  5-2). IL-2 was 
expressed by roughly 1500 cells per million in mice immunised with p7.OVA only. This proportion 
did not change upon coadministration of p7.IL10 at a 1:10 ratio. However when the ratio was increased 
to 1:3 the proportion of lymph node cells expressing IL-2 decreased to around 500 per million. Further 
increasing the dose of p7.IL10 had no further inhibitory effect on IL-2 expression. Fewer cells 
produced IL-4, IL-10 and IFN-γ in response to restimulation with OVA323-339: 1000, 300 and 150 per 
million lymph node cells, respectively. However the expression of these three cytokines was inhibited 
in a similar dose-dependent manner whereby p7.IL10 had no effect at a 1:10 ratio but at 1:3 and 1:1 
ratios, the number of cytokine-producing cells was reduced by 50-70%.  
CD62L (L-selectin) is expressed on naïve T cells, allowing entrance into secondary lymphoid tissue. 
Its expression is downregulated upon response to antigen, facilitating migration to the periphery. 
CD62L expression on CD4+ T cells was examined by flow cytometry following the aforementioned 
dose-response protocol (Figure  5-3). In OVA-naïve mice (p7), 80% of both antigen-specific DO11.10 
(CD4+KJ1.26+) and antigen-nonspecific (CD4+KJ1.26–) expressed CD62L. Whereas immunisation 
with p7.OVA had no effect on nonspecific T cells, it induced downregulation in a futher 30% of 
DO11.10 cells. This effect was slightly reduced by the coadministration of p7.IL10 at 1:3 and 1:1 
ratios. 
The lowest dose ratio of p7.IL10 to consistently, significantly inhibit the response to p7.OVA was 1:3 
i.e. 0.17 µg p7.IL10 to 0.5 µg p7.OVA. For this reason, this dose was used in all later experiments. 
5.2.2. Coadministration of p7.IL10 delays the proliferative response to antigen 
72 h post-immunisation was chosen as suitable to measure the effect of p7.IL10 because initial 
experiments had shown this timepoint to provide near-maximal cell proliferation and cytokine 
production whilst still providing a snapshot of the early stages of the response. Nevertheless it was 
important to examine the temporal effect(s) of p7.IL10 on this initial response.  
1x106 DO11.10 cells were adoptively transferred into naïve Balb/c recipients. 24 h later mice were 
immunised with cartridges containing either p7.OVA or a 1:3 ratio of the two plasmids as described in 
 5.2.1. Earlier experiments had shown the complete unresponsiveness of DO11.10 cells to empty p7 
plasmid. It was therefore decided that, in this experiment, this control was unnecessary. 24, 72 or 120 h 
post-immunisation draining lymph nodes were harvested and cytokine production by lymph node cells 
analysed by ELISpot (Figure  5-4). At 24 h there was no difference in expression in any of the 
cytokines measured between groups: Expression of IL-4, IFN-γ and IL-10 was undetected and only 
400 per million lymph node cells expressed IL-2. After 72 h the proportion which expressed IL-2 had  
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Figure  5-1 p7.IL10 inhibits the proliferative response to p7.OVA in a dose-dependent manner 
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Figure 5-1. p7.IL10 inhibits the proliferative response to p7.OVA in a
dose-dependent manner.
Following adoptive transfer, mice  (3 per group) were immunised with 0.5 µg
p7.OVA alone, or with 0.05 µg, 0.17 µg or 0.5 µg p7.IL10. Control mice
received empty p7 only. 72 h post-immunisation lymph nodes were
harvested and  DO11.10 cells counted by flow cytometry. Data are the
mean of two independent experiments.
* p<0.05 by one-way ANOVA as compared to p7.OVA ("Relative quantity
0.0") group
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Figure  5-2 p7.IL10 inhibits the cytokine response to p7.OVA in a dose-dependent manner 
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Figure 5-2. p7.IL10 inhibits the cytokine response to p7.OVA in a
dose-dependent manner.
Following adoptive transfer, mice (3 per group) were immunised with 0.5 µg
p7.OVA alone, or with 0.05 µg, 0.17 µg or 0.5 µg p7.IL10. Control mice
received empty p7 only. 72 h post-immunisation lymph nodes were
harvested and cytokine expression examined by  ELISpot. Data are the
mean of four independent experiments.
*** p<0.001 by one-way ANOVA as compared to p7.OVA ("Relative
quantity 0.0") group
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Figure  5-3 p7.IL10 inhibits the downregulation of CD62L in response to p7.OVA 
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Figure 5-3. p7.IL10 inhibits the downregulation of CD62L in
response to p7.OVA.
Following adoptive transfer, mice (3 per group) were immunised with 0.5 µg
p7.OVA alone, or with 0.05 µg, 0.17 µg or 0.5 µg p7.IL10. Control mice
received empty p7 only. 72 h post-immunisation lymph nodes were
harvested and CD62L expression on CD4+KJ1.26+ cells examined by flow
cytometry. Data are representative of two independent experiments.
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increased to over 1000 per million in mice that had received p7.OVA alone whereas in those that had 
received coadministered p7.IL10 it remained around 400 per million. During the next 48 h the 
proportion of IL-2-producers in the p7.OVA group remained at around 1000 per million whilst those in 
the group that received coadministered p7.IL10 increased to a similar proportion. Although the 
proportion of IL-4-producing cells from p7.OVA recipients continued to increase through all 
timepoints measured (to a maximum of 800 per million), a similar pattern was observed: In lymph 
nodes from mice that received coadministered p7.IL10 no increase in IL-4 expression was observed 
before 72 h but by 120 h the number of IL-4-producers had increased rapidly to a similar proportion as 
that seen in the p7.OVA group. A p7.IL10-induced delayed increase was also observed in the 
generation of IFN-γ- and IL-10-producing cells although both the absolute numbers and the differences 
between groups were much smaller for these cytokines. 
To examine this delayed response to antigen in more detail, DO11.10 cells were stained with 5µM 
CFSE prior to adoptive transfer. As above, recipient mice were immunised with p7.OVA alone or 
along with p7.IL10. Recipient Balb/c were culled and draining lymph nodes harvested at various 
timepoints post-immunisation. Division of DO11.10 cells was measured by flow cytometry (Figure 
 5-5). In both groups the number of CD4+KJ1+ cells present in the lymph node after 24 h was 
insufficient to examine CFSE staining. After 48 h there was a sufficient number but cell division had 
not occurred in either group. In mice which received p7.OVA only, proliferation of CD4+KJ1+ cells 
became evident after 60 h and accelerated until 84 h at which time over 1600 divisions had occurred. 
Over the next 12 h the rate of proliferation decreased, with a total of 2000 divisions by 96 h post-
immunisation. The proliferative response was delayed in mice which were coadministered p7.OVA 
and p7.IL10: From 60 h to 84 h the number of CD4+KJ1+ cell divisions remained roughly 40% of the 
number of divisions in mice which received p7.OVA only. However between hours 84 and 96, while 
the proliferation rate in mice which received p7.OVA only decreased, in mice which received both 
plasmids proliferation accelerated: By 96 h a total of 1700 CD4+KJ1+ divisions had occurred; only 
15% less than in mice that received p7.OVA alone. 
5.2.3.  The inhibitory effect of p7.IL10 on the response to p7.OVA is exaggerated 
by a repeat dose 
Several tolerising regimes involve repeated or continuous exposure to antigen under noninflammatory 
conditions(Larche et al., 2006). To examine the effect of a repeat dose in this model, Balb/c recipients which 
had received adoptive transfer and immunisation as described above were allowed to rest. 28 days later 
mice received a second dose of the same immunisation (either empty p7, p7.OVA or p7.OVA + 
p7.IL10). In order to identify longer-term differences between groups, rather than merely the delay 
described in  5.2.2, lymph nodes were harvested 5 days after this second immunisation.  
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Figure  5-4 p7.IL-10 delays the cytokine response to p7.OVA 
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Figure 5-4. p7.IL10 delays the cytokine response to p7.OVA.
Following adoptive transfer, mice (3 per group) were immunised with
0.5µg p7.OVA alone (red lines) or together with 0.17 µg p7.IL10 (blue
lines). 24, 72 and 120 h post-immunisation draining lymph nodes were
harvested and cytokine expression examined by ELISpot.  Data are the
mean of three independent experiments.
*** p<0.001;  ** p<0.01;  * p<0.05 by t-test between groups at each
timepoint
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Figure 5-5.  p7.IL10 delays the proliferative response to p7.OVA.
Prior to adoptive transfer, splenocytes were stained with 5 µM CFSE.
Following adoptive transfer, mice were immunised with 0.5 µg p7.OVA alone,
or together with 0.17 µg p7.IL10. Control mice received empty p7 only. 72
h post-immunisation lymph nodes were harvested and CFSE-fluorescence of
DO11.10 cells examined by flow cytometry (A). Total cell divisions were
calculated as described in Materials and Methods (B). Data are means of 3
mice per group. Graph is representative of two independent experiments.
** p<0.01; * p<0.05 by t-test between groups at each timepoint
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Figure  5-5 p7.IL10 delays the proliferative response to p7.OVA 
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Figure  5-6 The inhibitory effect of p7.IL10 on the proliferative response is exaggerated by a repeat 
dose 
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Figure 5-6. The inhibitory effect of p7.IL10 on the proliferative
response is exaggerated after a repeat dose.
Mice (3 per group) received two doses, separated by 4 weeks, of empty
p7 ("naive"), p7.OVA ("primed") or p7.OVA+p7.IL10 ("treated"). 5 days
after the second immunisation inguinal lymph nodes were harvested and
DO11.10 cells counted by flow cytometry. Data are the mean of four
independent experiments.
*** p<0.001 by one-way ANOVA
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Figure  5-7 The inhibitory effect of p7.IL10 on the cytokine response is exaggerated by a repeat dose 
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Figure 5-7. The inhibitory effect of p7.IL10 on the cytokine
response is exaggerated after a repeat dose.
Mice (3 per group) received two doses, separated by 4 weeks, of empty p7
("naive"), p7.OVA ("primed") or p7.OVA+p7.IL10 ("treated"). 5 days after
the second immunisation inguinal lymph nodes were harvested and the
cytokine response analysed by ELISpot. Data are the mean of two
independent experiments.
** p<0.01;  * p<0.05 by one-way ANOVA
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Following immunisation with two doses of p7.OVA, lymph nodes contained roughly 4000 DO11.10 
per million cells (Figure  5-6). Coadministration of p7.IL10 halved this number. Interestingly, double 
immunisation with empty p7 vector resulted in nearly 2000 DO11.10 per million lymph node cells, 
too. Therefore, under this protocol, coadministration of p7.IL10 reduced the number of DO11.10 cells 
in the lymph node to background levels. 
Similar to earlier experiments, in mice that received p7.OVA alone, IL-2, IL-4, IFN-γ and IL-10 were 
produced by roughly 1000, 600, 100 and 200 per million lymph node cells, respectively. In the 
previous experiments coadministration of p7.IL10 (at a 1:3 ratio) resulted in a 15-20% reduction of IL-
2 producers (Figure 5-2). However, upon receiving a repeat dose the inhibition was more exaggerated: 
60% fewer DO11.10 cells in the draining lymph nodes of recipient mice expressed IL-2 when p7.IL10 
was coadministered compared to immunisation of p7.OVA alone (Figure  5-7). The number of IL-4-
producing DO11.10 cells was reduced by 80% and the numbers of IFN-γ- and IL-10-producers also 
decreased by similar proportions. 
5.2.4.  The inhibitory effect of p7.IL10 on the response to p7.OVA is at least 
partially dependent on their expression by the same cell 
As previously mentioned, a major benefit of gene-gun immunisation is the increased ability to deliver 
vectors to individual cells. An important question is whether an immunomodulatory gene must be 
coexpressed by the antigen-expressing cell in order to affect the immune response. The answer to this 
question may differ depending on the nature of the gene product. Cell surface molecules, intracellular 
signalling molecules and secreted molecules that have autocrine effects might require coexpression. 
However, such dependence is less likely for those with paracrine or endocrine effects. 
In order to examine the importance of coexpression in this model, cartridge production was modified: 
Normal cartridge production involves first mixing plasmid vectors at their correct ratio and then 
coating this mixture onto gold particles. The result is that all gold particles are coated with the same 
ratio of vectors. In coadministration immunisations of p7.OVA and p7.IL10, both vectors would be 
found in the same ratio on all particles and would therefore be transfected into the same target cell. 
This immunisation will be referred to as ‘linked’. In contrast an ‘unlinked’ immunisation involves 
preparing p7.OVA- and p7.IL10-coated particles separately and mixing them only prior to cartridge 
preparation. A third treatment will be referred to as ‘adjacent’. In this case, entirely separate cartridges 
of p7.OVA and p7.IL10 are used. The total amount of DNA and the number of gold particles was 
constant between all groups. A detailed description of how this was achieved can be found in the 
Materials and Methods section ( 2.2.3). 
1x106 DO11.10 cells were adoptively transferred into naïve Balb/c recipients. 24 h later mice were 
immunised with p7.OVA alone (“Primed”) or with p7.OVA + p7.IL10 in linked, unlinked or adjacent 
formats. 5 days post-immunisation draining lymph nodes were harvested. DO11.10 proliferation and 
cytokine expression were examined, as previously. 
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In agreement with earlier experiments, flow cytometry showed that in mice that received p7.OVA 
alone, around 3000 per million lymph node cells were CD4+KJ1+ (Figure  5-8) and that linked p7.IL10 
could reduce this to 1000. Interestingly, when p7.IL10 was unlinked, this inhibitory effect was partially 
lost. A similar loss of effect was seen in mice which received the plasmids on separate cartridges. 
ELISpot analysis of the lymph node cells showed a similar pattern in cytokine expression (Figure  5-9). 
A significant 70% reduction of IL-2- and IL-4-producing cells was caused by coexpressed IL-10. A 
smaller, 30% reduction was observed when unlinked and adjacent formats were used. The number of 
IL-10- and IFN-γ-producing cells followed the same pattern across groups. 
ELISpot allows the enumeration of cytokine-producing cells at much lower percentages than is 
normally achieved by flow cytometry. However the exact identity of the cytokine-producers is not 
provided by this technique. In order to confirm that the OVA323-339-dependent ELISpots seen so far 
were, indeed, produced by adoptively transferred DO11.10 cells, in two experiments an aliquot of 
lymph node cells was reserved. These cells were stimulated with OVA323-339 in the presence of  
Brefeldin A, fixed, permeablised and intracellularly stained for IL-2. CD4+KJ1+IL-2+ cells were 
quantified by flow cytometry. 
Comparison of ELISpot and intracellular staining (ICS) techniques for the quantification of IL-2 
expression shows that they provide very similar information, at least qualitatively (Figure  5-10a). ICS 
also showed that coexpressed IL-10 reduces the number of IL-2-producing cells and that this effect 
was partially lost when unlinked and adjacent formats were used. However, the absolute number of IL-
2-producers identified by ICS was always roughly one-third of that identified by ELISpot. 
Gating on the CD4+KJ1+ population allowed the examination of IL-2 expression within the DO11.10 
population (Figure  5-10b). A very similar pattern was observed: OVA-dependent IL-2 expression by 
DO11.10 cells was inhibited more greatly by linked than by unlinked or adjacent p7.IL10.  
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Figure  5-8 The inhibitory effect of p7.IL10 on the proliferative response to p7.OVA is at least partially 
dependent on their coexpression by the same cell 
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Figure 5-8. The inhibitory effect of p7.IL10 on the proliferative
response to p7.OVA is at least partially dependent on their
coexpression by the same cell.
Following adoptive transfer, mice (3 per group) were immunised with
p7.OVA alone ("Primed") or together with p7.IL10 on the same beads
("Linked"), on separate beads ("Unlinked") or in a separate cartridge
("Adjacent").  See Materials and  Methods for details. 5 days
post-immunisation inguinal lymph nodes were harvested and DO11.10 cells
counted by flow cytometry. Data are the mean of four independent
experiments.
* p<0.05  by one-way ANOVA as compared to "Primed" group
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Figure  5-9 The inhibitory effect of p7.IL10 on the cytokine response to p7.OVA is at least partially 
dependent on their coexpression by the same cell  
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Figure 5-9. The inhibitory effect of p7.IL10 on the cytokine response
to p7.OVA is partially dependent on their coexpression by the same
cell.
Following adoptive transfer, mice (3 per group) were immunised with
p7.OVA alone ("Primed") or together with p7.IL10 on the same beads
("Linked"), on separate beads ("Unlinked") or in a separate cartridge
("Adjacent").  See Materials and  Methods for details. 5 days
post-immunisation inguinal lymph nodes were harvested and the cytokine
response analysed by ELISpot. Data are the mean of four independent
experiments.
*** p<0.001; * p<0.05 by one-way ANOVA
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Figure  5-10 Comparison of IL-2 expression analysis techniques 
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Figure 5-10. Comparison of IL-2 expression analysis techniques.
Following adoptive transfer, mice (3 per group) were immunised with
p7.OVA alone ("Primed") or together with p7.IL10 on the same beads
("Linked"), on separate beads ("Unlinked") or in a separate cartridge
("Adjacent").  See Materials and  Methods for details. 5 days
post-immunisation inguinal lymph nodes were harvested. An aliquot of
lymph node cells were stained for flow cytometric analysis, as previously,
but also fixed, permeablised and stained with anti-IL-2. A) Comparison of
ELISPot and intracellular staining for determining overall IL-2 expression. B)
Examination of IL-2 expression within the DO11.10 cell subset. Data are
the mean of two independent experiments.
* p<0.05 by one-way ANOVA compared to 'Primed' group
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5.3. Discussion 
5.3.1. p7.IL10 inhibits the response to antigen 
The inclusion of p7.IL10 in the immunisation of mice with p7.OVA clearly and consistently inhibited 
the response of DO11.10 cells to antigen. This effect was dependent on the quantity of p7.IL10 
administered, or at least relative to the quantity of antigen-encoding plasmid. This is fully in agreement 
with the many studies defining IL-10 as an immunosuppressive cytokine. 
The number of DO11.10 cells present in the draining lymph nodes was lower in groups that received 
coadministered p7.IL10 than in those that received p7.OVA alone. The difference between the two 
groups was exaggerated following a second immunisation. Further analysis, utilising CFSE-staining, 
showed this effect to correlate with fewer divisions of DO11.10 cells. This observation suggests that 
reduced proliferation, rather than migration, was the cause of the smaller DO11.10 population. 
The cytokine response was also inhibited by p7.IL10 in a dose-dependent manner. When restimulated 
with OVA323-339, fewer lymph node cells from mice that received coadministered p7.IL10 produced IL-
2, IL-4, IFN-γ and IL-10 than those from mice that received p7.OVA alone. Again, this inhibition was 
exaggerated following a second immunisation.  
Such a decrease in cytokine-producing cells might be caused purely by the reduced number of total 
DO11.10 cells found in the lymph node following coadministration of IL-10. However, intracellular 
staining clearly demonstrated that the ability of DO11.10 cells to produce IL-2 was also inhibited. It 
would be interesting to examine and compare IL-4 and IFN-γ expression in these cells using the same 
technique. 
Finally, in support of the notion that coadministration of p7.IL10 induces a change in DO11.10 cells, 
rather than only reducing their number, OVA-induced CD62L downregulation by these cells was 
inhibited in a p7.IL10-dependent manner. CD62L allows the migration of CD4+ T cells to the 
secondary lymph node tissues and its downregulation is associated with T cell activation and 
subsequent migration to the peripheral tissues. That coadministration of p7.IL10 resulted in both fewer 
DO11.10 cells and less CD62L downregulation suggests that decreased activation, rather than 
increased emigration, is the cause of the lower number of DO11.10 cells and ELISpots seen in 
p7.IL10-treated mice. 
5.3.2. p7.IL10 delays the response to antigen 
Examination of the temporal effect on cytokine production by p7.IL10 showed that, although there was 
significant inhibition at 72 h post-immunisation, after 120 h this difference was much reduced. A 
similar pattern was observed in the proliferative response to antigen. By staining donor cells with 
CFSE prior to adoptive transfer it was possible to study in more detail the division of DO11.10 cells. 
Again, the difference between mice that received p7.OVA alone and those that received 
coadministered p7.IL10 was greatest 72 h post-immunisation. By 96 h the number of  cell divisions in 
the latter group had begun to approach the number in the former.  
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Effectively, the response by DO11.10 cells to immunisation with p7.OVA was delayed by the 
coadministration of p7.IL10. One feasible cause of this effect is the relative persistence of the two gene 
products. Whereas ovalbumin is a structural and/or storage protein, IL-10, as a cytokine, is typically 
short-lived. In this system both genes are expressed via the same promoter but, after expression has 
ceased, it is possible that ovalbumin persists for longer than IL-10. Additionally, immunogenic OVA 
peptides may continue to be presented on MHC molecules after intact ovalbumin has been cleared. 
Continued antigen presentation in the absence of IL-10 might overcome any previous inhibition. 
Whilst taking into account this caveat, other evidence agrees that IL-10 may, in fact, delay the 
response to antigen(Bai et al., 1997; Zhao et al., 2005).  
As in  5.2.3, in order to examine less transient effects caused by coadministration of p7.OVA most 
future experiments examined lymph node cells 5, as opposed to 3, days post-immunisation. 
5.3.3. Dependence on linkage 
Examination of linkage in the above manner assumes that most, if not all, transfected cells receive only 
one bead. This is a complex issue involving both the initial coating of the beads and the distribution of 
beads in the transfected tissue. However, the evidence is certainly in favour of this occurrence:  
Firstly, previous work has shown that the procedure for combining separately coated beads in the same 
cartridge is, indeed, effective(Creusot, 2002). In addition, because only a small proportion of DC are 
transfected by PMDD it is likely that only one bead will enter an individual cell(Porgador et al., 1998). 
Secondly, on a macro scale, unlinked and adjacent immunisations result in a similar response. The 
latter is certainly ‘unlinked’ in that the individual p7.OVA and p7.IL10 shots are spacially separated. 
The literature and data presented here both, therefore, suggest that the unlinked immunisation does, 
indeed, transfer the two plasmids to separate cells.  
The response of T cells to antigen is known to be dependent on the microenvironment at the time of 
presentation by APC. This allows T cells of the same or different antigen specificity to enhance 
(cooperation(Kalams and Walker, 1998; Gerloni et al., 2000; Creusot et al., 2003b) or synergy(Wang et al., 2001; Mintern et al., 2002)), 
modify(Schuhbauer et al., 2000; Creusot et al., 2003a) or diminish (inhibition(Jonuleit and Schmitt, 2003) or competition(Laouar and 
Crispe, 2000; Smith et al., 2000)) the response of other T cells in the same DC cluster. 
The use of the adoptive transfer / gene gun model to dissect this mechanism has previously shown that 
in vitro-polarised T cells can influence naïve T cells of different antigen specificity if antigens are 
linked i.e. their genes are located on the same microprojectile during immunisation(Creusot et al., 2003a). 
Using this same model, this study has shown that the requirement for linkage is also true for the 
inhibitory effect of IL-10 on the response: The separation of p7.OVA and p7.IL10 onto different 
microprojectiles reduced the effect of the latter on the response to the former by half. 
Professional APC such as DC are able to uptake and present antigen from their surroundings (referred 
to here as antigen transfer). It is generally understood that antigen processed in this manner is 
presented on MHC class II molecules, whilst endogenously synthesised antigen is presented by most 
cells, including professional and non-professional APC, on MHC class I molecules. However, DC are 
115 
also able to pass exogenous antigen into the MHC class I pathway for presentation to CD8+ T cells; a 
mechanism known as cross-priming(Bevan, 2006; Shen and Rock, 2006; Basta and Alatery, 2007). Cross-priming has been 
demonstrated to be vital in the generation of not only the CD8+ but also the CD4+ T cell response in a 
model similar to ours(Lauterbach et al., 2006). In addition, peptides from endogenous, often membrane-bound, 
proteins have been isolated from MHC class II complexes(Rudensky et al., 1991; Chicz et al., 1993). The question of 
which antigens are processed by which MHC pathway is clearly complex and is the subject of 
extensive studies(Juncker et al., 2009). 
The markedly decreased effect of p7.IL10 in an unlinked format suggests that the separation of 
plasmids and/or gene products is maintained, at least to some degree, following immunisation. Directly 
transfected APC as the main source of presented antigen would cause presentation to occur away from 
unlinked p7.IL10. Conversely, if antigen transfer was central to the response, this would imply 
secretion and uptake of antigen; spatial separation of OVA and IL-10 would be greatly reduced and 
thus linkage would be less important. This agrees with the DC cluster model of Creusot et al. whereby 
DC present antigen in a distinct microenvironment created by both the DC and T cells under minimal 
influence of other clusters(Creusot et al., 2002). It would be reasonable to suggest, therefore, that at least a 
significant proportion of antigen presentation in this model is performed by directly transfected DC. 
A caveat that will not be fully addressed here is the skewed view of the immune response given by the 
use of the MHC class II-specific DO11.10 cell. Because the TCR of this CD4+ T cell only recognises 
the OVA323-339 epitope in the context of the MHC class II molecule, data is confined to this part of the 
response only. This is particularly important to note when studying an antigen that is assumed to be, to 
some degree at least, synthesised and presented by the same cell: Despite the complexity of the antigen 
processing pathways (described above) it might be expected that the primary presentation would still 
occur via the MHC class I pathway. Therefore results should be interpreted as being viewed through a 
particular window and not as a description of the response as a whole. Nevertheless, the dependence of 
IL-10 on linkage is clear. 
In conclusion, this chapter validates that IL-10 can be delivered via PMDD and that it will exert an 
immunosuppressive effect in a very localised manner. It seems reasonable to hypothesise that the 
microenvironment of this IL-10 effect is, in fact, the DC-T cell cluster. 
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6. Induction of Tolerance 
6.1. Introduction 
Although inclusion of the IL-10-encoding plasmid p7.IL10 has been shown to reduce the response to 
immunistion with p7.OVA it is important to understand whether the DO11.10 cells involved retain any 
memory of this treatment. A reduced response may be due to one or more of three possible reasons: 1) 
The presence of IL-10 inhibits antigen presentation and nonresponsive cells remain naïve(de Waal Malefyt et 
al., 1991b; Koppelman et al., 1997; Redpath et al., 1999; Faulkner et al., 2000)
. 2) The T cell is anergised during treatment and its 
response to subsequent antigen challenge is less vigorous than it otherwise would have been(Groux et al., 
1996; Steinbrink et al., 1997; Kubsch et al., 2003; Beinhauer et al., 2004)
. 3) The cell becomes a regulatory T (TR1) cell, 
modulating the response of neighbouring cells to subsequent antigen challenge(Takayama et al., 1999; Akbari et al., 
2001; Henry et al., 2008; Zhu et al., 2008a)
. There is evidence, however, that anergised T cells are, in fact, 
regulatory(Buer et al., 1998; Steinbrink et al., 2002). 
This chapter concentrates on elucidating which of these mechanisms is/are responsible for the 
previously observed inhibition by p7.IL10 and determining if the effect is long-lasting i.e. if tolerance 
is induced.  
6.2. Results 
The basic model used in both this and the next chapter is that of prime-boost-challenge. In this chapter 
the prime and boost immunisations were effectively the same as those of the double-dose studies in the 
last chapter. Two weeks after the latter of these immunisations mice received a third immunisation (the 
‘challenge’) with either p7.OVA alone or with the control p7 vector.  
6.2.1. Coadministration of p7.IL10 during two rounds of immunisation reduces 
the response to subsequent challenge with antigen 
Figure  6-1 shows that a prime-boost treatment followed by further challenge with p7.OVA 
significantly enhances the number of OVA-specific IL-2- and IL-4-producing cells in the lymph nodes 
compared to the control groups. Coadministration of p7.IL10 in the prime and boost immunisations 
reduced the number of cytokine-secreting cells in response to the challenge with p7.OVA. A similar 
pattern of stimulation and inhibition was seen at both 72 h and 120 h post-challenge but with roughly 
twice as many cytokine ELISpots in every group at the later timepoint. 
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Figure  6-1 Coadministration of p7.IL10 during prime-boost reduces the number of cytokine-producing 
cells in the lymph node in response to later challenge with p7.OVA  
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Fig 6-1 Coadministration with p7.IL10 during prime-boost reduces the
number of cytokine-producing cells in the lymph node in response to
later challenge with p7.OVA.
Balb/c mice (3 per group) were adoptively transferred with 1x106 DO11.10 T cells. 1
day later they were immunised ('prime') with either empty p7 ("control" and
"naïve"), p7.OVA  ("primed") or p7.OVA + p7.IL10 ("treated"). Two weeks
later mice were re-immunised with the same vector ('boost'). Two weeks
post-boost mice were immunised with p7.OVA ('challenge'); the control group
received empty p7 vector instead. 3 or 5 days post-challenge inguinal lymph
nodes were harvested. IL-2 and IL-4 ELISpots were performed as previously
described, using 1 µM OVA323-339 peptide. Data are the mean of three
independent experiments.
*** p<0.001;  ** p<0.01;  * p<0.05
IL-2
IL-4
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6.2.2. Inhibition by p7.IL10 of the cytokine response to p7.OVA is dependent on 
adoptive transfer of  DO11.10 cells 
Data in earlier chapters, that employed shorter immunisation protocols, was not replicable in Balb/c 
mice that had not received adoptively transferred DO11.10 cells because the small number of antigen-
specific T cells did not allow ELISpot or flow cytometric analysis; indeed, this is a key reason for the 
use of the adoptive transfer model in the first place. The three immunisations in the current protocol 
increase the number of endogenous antigen-specific T cells to a number detectable by ELISpot.  
Prime-boost with p7.OVA produced a detectable, and statistically significant, number of antigen-
specific, IL-2- and IL-4-producing T cells (Figure  6-2). In contrast to Figure  6-1, in the absence of 
DO11.10 cells the coadministration of p7.IL10 did not reduce the number of cytokine ELISpots 
produced in response to p7.OVA challenge.  
The endogenous response to OVA will likely involve epitopes other than 323-339. In order to 
understand the importance of the other epitopes in this system, cytokine ELISpots were performed 
using whole ovalbumin protein at the same molar concentration (Figure  6-3). The overall pattern was 
the same as that for peptide ELISpots: Prime-boost with p7.OVA increased the number of cytokine 
ELISpots and coadministration of p7.IL10 failed to significantly inhibit this stimulation (Figure 
 6-3a&b). As might be expected, the absolute number of ELISpots was higher in every case when whole 
protein was used.  
Interestingly, the ratio of 323-339:other epitope ELISpots was different for each cytokine. Only half of 
the IL-2 ELISpots were attributable to the 323-339 epitope whilst roughly 70% of IL-4 spots were 
(Figure  6-3 c&d). 
6.2.3. The pool of primed antigen-specific T cells is lower in mice that are primed 
with p7.OVA+p7.IL10 than in mice that receive p7.OVA alone  
One of the reasons for the experiments in section  6.2.1 was to dissect the direct effect of the 
immunisation on naïve T cells from any indirect downstream effects that might be caused by these 
changes. To understand the immune situation at the time of the final antigenic challenge, rather than 
administer the challenge immunisation, spleens were examined two weeks post-boost. 
The number of DO11.10 cells in the spleen was roughly doubled in mice that received a prime-boost of 
p7.OVA alone compared to controls (Figure  6-4). This increase was completely abrogated by the 
inclusion of p7.IL10 in the immunisation. Interestingly, the large increase in DO11.10 number 
corresponded to only a small increase in the number of IL-2-producing cells (Figure  6-5). In contrast, 
the inhibition caused by coadministration of p7.IL10 was, indeed, reflected by a highly significant 
reduction in the number of IL-2-producers. No significant effect was seen on the number of IL-4-
producers, either by p7.OVA or by p7.OVA+p7.IL10.  
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Figure  6-2 In the absence of adoptively transferred DO11.10 cells coadministration with p7.IL10 
during prime-boost has no effect on the number of OVA323-339-specific cytokine-producing cells in the 
lymph node in response to later challenge with p7.OVA 
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Figure 6-2. In the absence of adoptively transferred DO11.10 cells
coadministration with p7.IL10 during prime-boost has no effect on
the number of OVA323-339-specific   cytokine-producing cells in the
lymph node in response to later challenge with p7.OVA.
Balb/c mice (3 per group) were immunised ('prime') with either empty p7
("control" and "naïve"), p7.OVA  ("primed") or p7.OVA + p7.IL10 ("treated").
Two weeks later mice were re-immunised with the same vector ('boost'). Two
weeks post-boost mice were immunised with p7.OVA ('challenge'); the
control group received empty p7 vector instead. 3 days post-challenge
inguinal lymph nodes were harvested. IL-2 and IL-4 ELISpots (A and B,
respectively) were performed as previously described, using 1µM OVA323-339
peptide.
*** p<0.001;  ** p<0.01;  * p<0.05 by one-way ANOVA
A B
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Figure  6-3 In the absence of adoptively transferred DO11.10 cells coadministration of p7.IL10 during 
prime-boost has no effect on the number of ovalbumin-specific cytokine-producing cells in the lymph 
node in response to later challenge with p7.OVA. Other epitopes are more TH2-biased than is the 323-
339 epitope. 
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Figure 6-3. In the absence of adoptively transferred DO11.10 cells
coadministration with p7.IL10 during prime-boost has no effect on
the number of ovalbumin-specific   cytokine-producing cells in the
lymph node in response to later challenge with p7.OVA.  Other
epitopes are more TH2-biased than is the 323-339 epitope.
Balb/c mice (3 per group) were immunised ('prime') with either empty p7
("control" and "naïve"), p7.OVA  ("primed") or p7.OVA + p7.IL10 ("treated").
Two weeks later mice were re-immunised with the same vector ('boost'). Two
weeks post-boost mice were immunised with p7.OVA ('challenge'); control
groups received empty p7 vector instead. 3 days post-challenge inguinal
lymph nodes were harvested. IL-2 and IL-4 ELISpots (A and B, respectively)
were performed as previously described, but using 1µM ovalbumin protein as
the stimulating antigen.
Data were compared to the corresponding ELISpots that utilised OVA323-339
peptide and are displayed as the percentage of cytokine ELISpots produced in
response to the 323-339 epitope vs those produced in response to other
epitopes (C and D).
*** p<0.001 by one-way ANOVA
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Figure  6-4 Coadministration of p7.IL10 during prime-boost reduces the size of the pool of DO11.10 
cells in the spleen 
 
 
 
Figure 6-4. Coadministration with p7.IL10 during prime-boost
reduces the size of the pool of DO11.10 cells in the spleen.
Balb/c mice (3 per group) were adoptively transferred with 1x106 DO11.10
T cells. 1 day later they were immunised (=prime) with either empty p7
("naïve"), p7.OVA  ("primed") or p7.OVA + p7.IL10 ("treated"). Two weeks
later mice were re-immunised with the same vector (=boost). Two weeks
post-boost spleens were harvested.  Spleen cells were examined by flow
cytometry as previously described to quantify the number of DO11.10 cells
present. Data are the mean of two independent experiments.
* p<0.01 by one-way ANOVA
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Figure  6-5 Coadministration with p7.IL10 during prime-boost reduces the size of the pool of cytokine-
producing cells in the spleen 
 
 
 
 
 
 
 
Figure 6-5. Coadministration with p7.IL10 during prime-boost
reduces the size of the pool of cytokine-producing cells in the spleen.
Balb/c mice (3 per group) were adoptively transferred with 1x106 DO11.10
T cells. 1 day later they were immunised (=prime) with either empty p7
("naïve"), p7.OVA  ("primed") or p7.OVA + p7.IL10 ("treated"). Two weeks
later mice were re-immunised with the same vector (=boost). Two weeks
post-boost spleens were harvested.  Cytokine production by spleen cells
were examined by IL-2 and IL-4  ELISpot (A and B, respectively). Data are
the mean of two independent experiments.
*** p<0.001;  * p<0.01 by one-way ANOVA
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6.2.4. Host antigen experience, and not the coadministration of p7.IL10, 
determines the proliferative capacity of freshly-transferred DO11.10 cells 
To further examine the possibility that DO11.10 cells were tolerised their ability to affect the activation 
of naïve T cells was examined. An in vivo approach was devised whereby a second adoptive transfer of 
DO11.10 cells was administered following prime-boost treatment. These fresh DO11.10 cells were 
labeled with CFSE prior to transfer, firstly to distinguish them from cells from the initial transfer and 
secondly to examine their proliferative response to the final challenge with p7.OVA (Figure  6-6). 
Two control groups received a final challenge with empty p7 vector. One of these had previously 
received prime-boost immunisations of p7 and the other had received p7.OVA. Importantly, 
irrespective of earlier immunisations, CFSE-stained T cells in both groups exhibited no proliferation 
(Figure  6-7). This shows that previously activated T cells cannot induce proliferation in naïve T cells 
in the absence of antigen and that there is no residual antigen presentation two weeks after gene gun 
immunisation. 
72 h post-challenge proliferation was seen in all groups whose challenge immunisation contained 
p7.OVA. Interestingly, the degree of proliferation was the same in all groups. Over the next 12 hours, 
however, the total number of divisions in those groups that had previously experienced antigen 
increased by 150-200% whilst the number in previously naïve mice increased by 300-450%. A key 
observation is that the presence of p7.IL10 in prime and boost immunisations had no effect on the 
proliferation of CFSE-stained DO11.10 cells.  
The number of CFSE— DO11.10 cells was also counted at 72 h and 84 h post-challenge (Figure  6-7). 
In this case control groups which received no second adoptive transfer, and therefore could not be 
examined as above, were included. In most groups, CFSE— DO11.10 comprised roughly 5000 per 
million lymphocytes at 72 h post-challenge and 10,000 per million after 84 h. The largest anomaly 
from this pattern was observed in mice that received prime-boost immunisations of empty p7 vector: 
Elimination of the second adoptive transfer resulted in double the number of CFSE— DO11.10 
compared to mice that did receive the CFSE-stained DO11.10 cells. 
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Figure  6-6 The CFSE challenge model 
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Figure  6-7 Host antigen experience, and not the coadministration of p7.IL10, determines the 
proliferative capacity of freshly-transferred DO11.10 cells 
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Figure 6-7. Host antigen experience, and not the coadministration of
p7.IL10, determines the proliferative capacity of freshly-transferred
DO11.10 cells.
Balb/c mice (3 per group) were adoptively transferred with 1x106 DO11.10 T
cells. 1 day later mice were immunised ("prime”) with empty p7, p7.OVA or
p7.OVA+p7.IL10. Two weeks later mice received a second immunisation
(”boost”) with the same vector(s). Two weeks post-boost mice received a
second adoptive transfer of 1x106 naive DO11.10 cells which, this time, had
been stained with 5µm CFSE. Control mice received no adoptive transfer. 24
hours later mice received a challenge immunisation of p7.OVA. Control mice
received empty p7 vector instead.  See Figure 6.6 for full details. 72 h and 84
h post-challenge mice were sacrificed and inguinal lymph nodes harvested.
Lymph node cells were stained and examined by flow cytometry:
CD4+KJ1.26+ (DO11.10) cells were gated and CFSE fluorescence was
examined.
(A) Calculated total cell divisions based on CFSE fluorescence peaks (see
Materials  & Methods for details); graphs show data from two independent
experiments. (B) Frequency of CFSE— cells in the same draining lymph
nodes; data are representative of two independent experiments.
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6.3. Discussion 
6.3.1. The inhibitory effect of p7.IL10 has long-term ramifications for later 
antigen challenge 
The inclusion of p7.IL10 in prime and boost immunisations clearly resulted in fewer cytokine-
producing cells in the draining lymph nodes (Figure  6-1). This could be interpreted as inhibition of 
DO11.10 cells to future stimulation; either anergy or tolerance. However, earlier experiments showed 
that a double immunisation with p7.OVA+p7.IL10 results in a smaller number of cytokine-producing 
DO11.10 cells in the draining lymph nodes (Figures Figure  5-6 and Figure  5-7) and examination of the 
spleen at the time of the challenge immunisation confirms that this reduction is mirrored in the general 
T cell pool (Figure  6-4 and Figure  6-5). Therefore the reduced number of cytokine-producing cells in 
the “treated” group may reflect the smaller number of DO11.10 at the time of challenge. At no time 
was a lower number of cytokine-producing cells detected in the IL-10-treated group than in the “naïve” 
group. Therefore classical tolerance was not observed. 
6.3.2. The inhibitory effect of p7.IL10 is dependent on adoptively transferred 
DO11.10 cells. 
Interestingly, the coadministration of p7.IL10 in prime and boost immunisation had no significant 
effect on the response to challenge with p7.OVA if mice did not initially receive adoptively transferred 
DO11.10 cells (Figure  6-2 and Figure  6-3). Earlier experiments with shorter experimental protocols 
could not be performed without adoptive transfer because the number of responder cells was too low; 
indeed, this is a reason for introducing adoptive transfer in the first place. Several possible 
explanations for this observation exist: 
Are epitope 323-339-specific T cells easier than others to inhibit or tolerise? There is no evidence in 
the literature to suggest that certain epitopes might be more or less inherently tolerogenic than others. 
In addition, comparison of Figure  6-2 and Figure  6-3 shows that whole ovalbumin-stimulated ELISpot 
exhibited a similar degree of inhibition as did OVA323-339 peptide-stimulated ELISpot. It is also 
unlikely that the physical transfer of DO11.10 cells makes them more susceptible to inhibition or 
tolerisation. A more feasible explanation may be that an increased absolute number of naïve antigen-
specific T cells allows a sufficient number to be exposed to antigen and IL-10 and therefore tolerised 
and/or merely allows the effects of IL-10 to be more clearly observed due to the higher number of total 
ELISpots. 
Another explanation might be connected to the importance of ‘linkage’ of OVA- and IL-10-encoding 
vectors and, therefore, of directly-transfected DC (see  5.2.4). If the frequency of directly-transfected 
DC is low compared to the number which present captured OVA rare, endogenous OVA-specific T 
cells are less likely to encounter these key immunosuppressive cells than are populous, adoptively 
transferred DO11.10 cells.  
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6.3.3. The OVA323-339 epitope may have intrinsic TH2 properties 
Information on the relative quantities of epitope-specific T cells could only be supplied by experiments 
that did not involve adoptive transfer. Specifically, it was possible to compare the number of ELISpots 
produced in response to restimulation with OVA323-339 peptide by those to whole ovalbumin protein. It 
was only possible to examine data from those groups that exhibited significant numbers of ELISpots 
i.e. those that received prime and boost with p7.OVA either alone or with p7.IL10 (“Primed” and 
“Treated”, respectively). Interestingly, the data from both groups suggest that the 323-339 epitope 
itself has a TH2 predisposition: It is responsible for roughly half of IL-2 ELISpots but almost 70% of 
IL-4 ELISpots. This observation was made late in the project and was not investigated further.  
6.3.4. p7.IL10 does not induce ‘infectious tolerance’ such as regulatory T cells 
The double-adoptive transfer experiments using CFSE-stained cells were intended to identify any 
regulatory effect, induced by coadministration of p7.IL10, that might inhibit a response by naïve 
DO11.10 T cells to a challenge with p7.OVA. That there was no observable difference between mice 
that received prime-boost of p7.OVA and those that received p7.OVA+p7.IL10 demonstrates that no 
prolonged inhibitory effect is confered.  
In contrast it appears that any prior exposure to antigen, with or without IL-10, reduced the 
proliferative capacity of freshly transferred DO11.10 cells. Mice that received prime-boost with empty 
p7 vector exhibited twice as much CFSE-stained DO11.10 cell division than those immunised with 
p7.OVA or p7.OVA+p7.IL10. This suggests an inhibitory effect by all antigen-experienced T cells. 
This latter explanation is supported by the data in Figure  6-7b where the inverse effect is seen: The 
expansion of the initially transferred, unstained, DO11.10 is greater when there is no secondary 
adoptive transfer, implying that there are, indeed, limited resources, such as antigen or cytokine, for 
which the two populations compete.  
6.3.5. Competition and inhibition? 
The responses of DO11.10 cells freshly transferred into “treated” (p7.OVA+p7.IL10) mice showed 
similar inhibition to subsequent antigenic challenge as those transferred into “primed” (p7.OVA) mice. 
However, it has already been shown that “treated” mice contain far fewer DO11.10 cells than do those 
in the “primed” group. There is therefore a hint that cells in “treated” mice are more efficient at 
inhibiting naïve cells than are those in “primed” mice. This might suggest that the “treated” group 
contains regulatory T cells. However the data as they stand support the notion that, in this model, 
competition, not active suppression, is the major mechanism whereby antigen experience diminishes 
activation of naïve T cells. 
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7. The effect of IL-10 on antigen-induced asthma 
7.1. Introduction 
Asthma can be defined as an inflammation of the airways associated with airway hyperresponsiveness 
and mucous hypersecretion(Busse and Lemanske, 2001). However it is a complex condition and its aetiology and 
pathology is not always congruous between individuals or between humans and and animal 
models(Anderson, 2008). It is therefore difficult to extrapolate conclusions from a particular animal model to 
a prediction of outcome in  clinical disease. Nevertheless, in itself, the ovalbumin-dependent asthma 
model in this chapter can serve as a useful tool in examining the initiation of allergy and allergen-
induced asthma.  
7.1.1. Asthma - a TH2 disorder? 
Allergen-induced asthma appears to be associated with, if not mediated by, an increased number of 
TH2 cells and elevated levels of TH2 cytokines in the lung tissue(Robinson et al., 1992). Indeed, IL-4-deficient 
mice exhibit a much milder inflammation in terms of both lung histology and eosinophil 
infiltration(Brusselle et al., 1994). TH2 cytokines play such an important role that merely administering IL-4 or 
IL-13 is sufficient to cause asthma(Grunig et al., 1998; Wills-Karp et al., 1998; Kuperman et al., 2002). 
Clinical data in agreement with this include two studies which show in vitro stimulation of cells can 
distinguish atopic/allergic individuals from healthy; the former producing TH2 cytokines whilst the 
latter produce a mixture of TH1, TH2 and IL-10(Akdis et al., 2004; Tiemessen et al., 2004). 
The reciprocal relationship between TH1 and TH2 cells and cytokines has been known for some 
time(Mosmann and Coffman, 1989; Street and Mosmann, 1991; Abbas et al., 1996). Antigen-specific CD4+ T cells isolated from 
from atopic individuals have been shown to produce IL-4 in response to Ag whilst those from normal 
individuals produce IFN-γ(Wierenga et al., 1990). Particularly relevant to this model of atopic asthma, IFN-γ 
and IL-4 have been shown to inhibit and promote, respectively, production of IgE by plasma 
cells(Snapper and Paul, 1987; Pene et al., 1988).  
A series of studies by Cohn et al. elegantly demonstrated the relationship between TH1 and TH2 cells in 
asthma: Adoptive transfer of TH2-primed DO11.10 cells before administration of aerosolised 
ovalbumin dramatically increased airway inflammation, mucous production and eosinophilia compared 
to that induced by naïve DO11.10 cells(Cohn et al., 1997). TH1 cells allowed inflammation but did not induce 
increased mucous production or eosinophilia. Cotransfer of these cells reduced, in an IFN-γ-dependent 
manner, the level of mucous production and eosinophilia caused by transfer of TH2 cells alone(Cohn et al., 
1999)
.  
Many studies have attempted to use this relationship to treat asthma. Early work showed that 
administration of TH1 cytokines, either systemically or directly to the target tissue, could abrogate 
disease(Iwamoto et al., 1993; Gavett et al., 1995; Lack et al., 1996). Infection with BCG, a known TH1-inducing 
microorganism, was also able to reduce inflammation and eosinophilia in the lung(Erb et al., 1998). 
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However, this TH1/TH2 paradigm may be an oversimplification, at least in human disease; many 
allergic individuals produce a mixture of TH1 and TH2 cytokines to allergens(Li et al., 1998; Randolph et al., 1999a; 
Randolph et al., 1999b; Magnan et al., 2000)
. 
Despite the studies described above, it has become understood that human asthma is far more complex 
than a symptom of atopy and certainly more complex than the original models of allergic airway 
inflammation(Wenzel and Holgate, 2006). The paradigm of asthma as a TH2 disorder is challenged by the 
discovery of elevated levels of TH1 cytokines such as IFN-γ and IL-12 in some cases of human 
asthma(Kenyon et al., 2000; Brown et al., 2003). In contrast to the mouse studies described above, clinical trials 
targeting TH2 cytokines were disappointing(Borish et al., 1999; Leckie et al., 2000). 
Not only has the TH2 nature of asthma been challenged, so has the notion that it is mediated purely by 
the adaptive immune system(Akbari et al., 2003; Kim et al., 2008; Hammad et al., 2009). It has become apparent that 
asthma is far more complex, perhaps a syndrome  (i.e. a defined collection of symptoms) rather than a 
disease with a specific cause such as atopy or allergy(Pearce et al., 1999; Borish and Culp, 2008).  
In human asthma, the smooth muscle cells of  the airways undergo hyperplasia and/or hypertrophy, 
often described as ‘remodelling’(James and Carroll, 2000). This phenomenon is central to true human asthma 
and is the cause of airway hyperresponsiveness(Zuyderduyn et al., 2008).  
Mouse models of asthma have been developed or advanced to take into account airway 
hyperresponsiveness(Henderson et al., 2002). However, even in more developed models, the cause of 
hyperresponsiveness may be allergy/thickening of mucosa, not the constriction of smooth muscle(Wagers 
et al., 2004)
. Even those models which do involve remodelling of the airway tissues are limited: 
Remodelling involves deposition of extracellular matrix material, fibrosis and inflammation of the 
pulmonary vasculature; phenomena that do not occur in human asthma(Tormanen et al., 2005; Xisto et al., 2005). 
Interestingly, however, there is evidence that some earlier mouse models of allergic asthma do induce 
the smooth muscle changes associated with hyperresponsiveness(Koya et al., 2006; Southam et al., 2007). 
Nevertheless, even in more representative models, the actual measurement of hyperresponsiveness in 
mice is problematic and controversial(Adler et al., 2004; Bates et al., 2004). 
Human asthma is likely the result of chronic exposure to allergen and/or other triggers whereas animal 
models generally involve acute doses. Attempts to bring the induction of allergic asthma model more 
in line with that of true human asthma actually led to tolerisation(Yiamouyiannis et al., 1999). In order to make 
models of allergic asthma more relevant to the human disease, known allergens such as extracts of dust 
mite and ragweed were coadministered. These exacerbate disease and are able to replace the 
traditional, and very artificial, alum adjuvant(Fattouh et al., 2005; Goplen et al., 2009). In addition, these studies 
were able to avoid the tolerisation described above. 
Finally, non-allergic induction of airway hyperresponsiveness using cationic proteins directly targeting 
smooth muscle, either alone or in combination with allergic challenge, may provide models more 
relevant to human asthma(Homma et al., 2005; Bates et al., 2008; Allen et al., 2009).  
Asthma is a complex condition affecting humans only. It is therefore likely that all models will be 
significantly limited.  
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7.1.2. Mast cells and IgE in asthma 
Mast cells reside in the peripheral tissues and express the high-affinity IgE receptor FcεRI. This 
receptor is also found on basophils and, in humans, on many other cell types including eosinphils and 
APCs(Kinet, 1999). Mainly due to this receptor the majority of IgE, unlike other immunoglobulin 
molecules, is cell-bound rather than free in the plasma. Crosslinking of IgE molecules by antigen 
triggers degranulation of mast cells and basophils, causing the classical signs of the early phase of the 
allergic reaction(Wedemeyer et al., 2000). In addition, mast cells secrete IL-4 – this is the initial TH2 stimulant, 
recruiting T cell help(Sherman et al., 1999; Wang et al., 1999b). In this way IgE confers on the mast cell antigen-
specificity, allowing it to effectively act as a coordinator between the innate and acquired immune 
responses.  
The IgE-mast cell system has the potential for at least two positive feedback loops: Firstly, increased 
levels of IgE increases the number of FcεRI molecules on the surface of mast cells, increasing their 
sensitivity to antigen-induced crosslinking(Yamaguchi et al., 1997; Smurthwaite et al., 2001; Macglashan, 2005). Secondly, 
activated mast cells can induce localised B cells to undergo class-switching to IgE via expression of 
cytokines (IL-4 and IL-13) and costimulatory molecules (CD40L)(Gauchat et al., 1993; Coker et al., 2003; Takhar et al., 
2005)
. This positive-feedback system, and the opportunity to break it, has made IgE a key target for 
treatment of atopic conditions(Chang, 2000) and may also explain why IgE expression has evolved to 
become tightly regulated(Oettgen and Geha, 1999; Hellman, 2007). 
Differentiation of smooth muscle cell bundles into a more contractile phenotype is a key feature of 
asthma, being the primary cause of airway restriction. Mast cell progenitors are recruited to inflamed 
airways by CXCR2-regulated VCAM-1(Hallgren et al., 2007). Infiltration of mast cells into airway smooth 
muscle defines the difference between human airway hyperresponsiveness associated with asthma and 
eosinophilic bronchitis, a disease closer to mouse models of allergic airway inflammation(Brightling et al., 
2002)
. Several studies suggest that mast cell infiltration of airway smooth muscle is key in inducing this 
differentiation(Amin et al., 2005; Woodman et al., 2008), although recent work questions this hypothesis(Kaur et al., 2010). 
New mechanisms by which mast cells may be involved in the pathogenesis of asthma are still being 
described(Skokos et al., 2003; Kambayashi et al., 2008; Margulis et al., 2009). The role of mast cells in asthma is clearly 
complex and will not be exhaustively discussed in this work. 
7.1.3. T cells in asthma 
Mast cell activation also readies the local environment for the late-phase response. Increased vascular 
permeability and expression of TNF-α causes infiltration of leukocytes to the site of antigen. Mast cell-
synthesised IL-4 and IL-13 can induce DCs to bias infiltrating cells towards a TH2-skewed 
response(Webb et al., 2007). T-cell produced IL-4 is vital for their own migration; T cells transferred from 
IL-4-/- mice are not recruited to the lung(Cohn et al., 1997). Perhaps more important though is mast cell-
derived TNF-α. Indeed, recruitment of T cells, even from IL-4-/- mice can be artificially induced by 
local administration of TNF-α(Wershil et al., 1991; Cohn et al., 1997). T cell help enhances the TH2 bias by 
expression of IL-4, IL-13 and CD40L as well as inducing eosinphilia by production of IL-5 (see  7.1.4).  
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7.1.4. Eosinophils in asthma 
Whilst mast cells may be regarded as the cells involved in the initiation of an episode of asthma, 
eosinophil infiltration can be considered its defining histologic feature(Wardlaw et al., 1995). Clinical studies 
show a correlation between eosinophil numbers and severity of disease(Bousquet et al., 1990; Rao et al., 1996; Duncan 
et al., 2003)
. The potential of eosinphils to secrete effector molecules that could directly cause the 
characteristic symptoms of asthma is consistent with the notion that eosinophils are the final-stage 
effectors of asthma(Thomas and Warner, 1996). 
The primary chemoattractant for eosinophils is eotaxin, produced by fibroblasts, endothelial cells and 
epithelial cells during inflammation(Garcia-Zepeda et al., 1996). TNF-α, IL-4 and IL-13, produced by 
infiltrating TH2 cells as well as mast cells, enhance eotaxin expression(Lilly et al., 1997; Li et al., 1999a). The TH2 
nature of eosinphilia is demonstrated by the inbibition of eotaxin expression by the TH1 cytokines IFN-
γ and IL-12(Miyamasu et al., 1999; Zhao et al., 2000). 
The cytokine with the most obvious relationship with eosinophilia is IL-5. IL-5 may increase 
eosinophil numbers by enhancing emigration from the bone marrow(Palframan et al., 1998) or by increasing 
eosinophil longevity(Simon et al., 1997). Whatever the precise mechanism, in the absence of IL-5, either 
through genetic knockout(Foster et al., 1996) or by administration of passive antibody(Coffman et al., 1989; Van 
Oosterhout et al., 1993; Kurup et al., 1997; Stein et al., 2008)
, eosinophil infiltration and activation are dramatically 
reduced. Therefore, whilst eosinophilia is the key effector of disease symptoms, CD4+ T cells, as IL-5-
producers, are responsible for recruiting eosinophils and are viable targets for therapy. 
Finally, it is becoming understood that eosinophils have significant antigen-presenting and 
lymphocyte-recruitment capability during airway inflammation(Wang et al., 2007; Jacobsen et al., 2008; Spencer et al., 
2009)
. This eosinphil:lymphocyte feedback loop, along with the mast cell:IgE:B cell feedback loop 
described above, are key factors in the induction and perpetuation of asthma and are likely to 
contribute significantly to the difficulty in treating the disease. 
7.1.5. Basophils in asthma 
Basophils are mature granulocytes and are recruited from the circulation to peripheral tissues by 
allergic inflammation or helminth infection. 
Recently, they have been associated with the development of TH2 responses(Sokol et al., 2008). Genetically 
modified mice with a TH2 polarisation have a highly expanded basophil population and splenocytes 
from these mice, producing IL-4, can induce naïve T cells to express IL-4 in response to antigen in 
vitro(Hida et al., 2005). Similarly, artificially increasing basophil numbers in vivo by administration of IL-3 
enhances, in an IL-4-dependent manner, the TH2 response to antigen(Oh et al., 2007). There is also evidence 
that basophils can act independently as antigen presenting cells(Sokol et al., 2009). 
Increased airway basophil frequency and activation level has been described in asthmatics, in 
particular during incidents of asthma(Macfarlane et al., 2000; Kepley et al., 2001; Schroeder et al., 2001; Yoshimura et al., 2002). 
Conversely, successful treatment of asthma with anti-IgE is associated with reduced basophil FcεRI 
expression and, more importantly, degranulation(MacGlashan et al., 1997; Lin et al., 2004a). 
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7.1.6. Existing treatments 
The major treatment for asthma is currently steroid drugs, either alone or in combination with beta 2 
agonists. This treatment has been effective in general but a significant proportion of patients do not 
respond to treatment. Those that do are normally subject to long-term, often lifelong, treatment which 
is unpopular and can have side-effects. Recently, the involvement in regulatory T cells in the 
therapeutic effect of steroid therapy has been identified. Deficiency in number and/or activity of 
regulatory T cells in asthmatic lungs have been restored by corticosteroid treatment(John et al., 1998; 
Karagiannidis et al., 2004; Hartl et al., 2007; Ali et al., 2008)
. Coadministration of 1,25-Dihydroxyvitamin D3 has been 
shown to enhance this effect on regulatory T cells(Barrat et al., 2002; Topilski et al., 2004; Bartels et al., 2007). 
Interestingly, therefore, the mechanism of action of traditionally broad-acting, antigen nonspecific 
steroids is at least partly carried out by regulatory T cells. 
Aside from steroid-based therapies, immunosuppressants, specifically calcineurin inhibitors, 
previously restricted to anti-rejection therapy, have shown considerable promise in treatment of atopic 
disease when administered either locally(Hultsch et al., 2005) or systemically(Madan and Griffiths, 2007). These drugs 
inhibit T cell activity, therefore breaking the positive-feedback cycle described above. Although they 
may avoid many of the long-term side effects of steroid treatment, they remain just as antigen-
nonspecific. This therefore allows an, at least theoretical, possibility of increased risk of unchecked 
infection and neoplasia. 
Specific immunotherapy (SIT), discussed in sections  1.4 and  1.5, has shown some success in allergy-
induced asthma (Penagos et al., 2008)(reviewed in(Mohapatra et al.)). Refinement of treatment is ongoing but 
exposure of allergic individuals to allergen carries with it obvious risks. Similarly to steroid therapy, 
this therapy requires long-term treatment. 
As mentioned in  0, IgE has become a target for asthma therapy. The humanised monoclonal IgG1, 
omalizumab, has been successfully introduced as a treatment for asthma(Chang and Shiung, 2006). In 
developed countries, modern hygeine has dramatically reduced our exposure to the classical targets of 
IgE, helminths. Therefore, despite its antigen-nonspecificity, the theoretical risks of a systemic 
reduction of IgE are perhaps lower than those of nonspecific T-cell inhibitors. 
As noted in  7.1.4, T cells are viable targets for anti-allergy therapy. In contrast to the above treatments, 
the targeting of specific T cells potentially allows for antigen-specific, curative, treatment of disease. 
The existing antigen-specific treatment for allergic disease is known as specific immunotherapy 
(SIT)(Larche et al., 2006) (discussed in detail in the introduction to this thesis). A wide range of protocols 
exist but, in general, they involve extended and/or noninflammatory exposure to antigen. IL-10 appears 
to be intrinsically involved in the effect of SIT although the mechanism is still unclear(Akdis et al., 1998; 
Hawrylowicz et al., 2002; Xystrakis et al., 2006)
. In addition, it may be possible that, because of its reliance on the 
natural response to antigen, SIT may be ineffective in cases where a residual pathological response to a 
previous exposure still endures(Hurst et al., 2001). Tolerisation via DNA immunisation should allow the 
introduction of relevant immunomodulatory molecules in order to produce similar results to successful 
SIT but more consistently and via a more convenient procedure.   
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7.1.7. IL-10 vs asthma 
Impaired IL-10 production has been suggested as a potential cause of asthma(John et al., 1998; Matsumoto et al., 
2004)
. Studies in knockout mice agree(Tournoy et al., 2000). In vitro, corticosteroids have been shown to 
promote IL-10 synthesis(Hodge et al., 1999; Richards et al., 2000). In agreement, effective corticosteroid treatment is 
associated with increased IL-10 production whilst nonresponsiveness to steroids correlates to a poor 
IL-10 response(John et al., 1998; Hawrylowicz et al., 2002; Karagiannidis et al., 2004; Xystrakis et al., 2006). As discussed in the 
introduction chapter, IL-10 is able to induce regulatory T cells via several mechanisms. It is therefore a 
valid candidate molecule for the treatment of allergic asthma. Perhaps just as relevant to asthma, IL-10 
is also able to downregulate IgE receptor expression on mast cells(Kennedy Norton et al., 2008) and dendritic 
cells(Faith et al., 2009). Previous work has shown that intranasal administration of IL-10(Zuany-Amorim et al., 1995) 
or IL-10-encoding viral vector(Stampfli et al., 1999), intravenous administration of IL-10-encoding 
plasmid(Nakagome et al., 2005) and intratracheal administration of IL-10-expressing DC(Henry et al., 2008) are able 
to inhibit disease in ova-induced asthma models.  
As mentioned earlier, IL-10 has been described both as a TH2 and as a TR1 cytokine. It may well be 
that in a TH1-based immunological disease, the distinction is less important; a TH2 influence might 
sufficiently balance the response and alleviate symptoms. However, in a TH2 disease such as the 
allergic asthma model in this study, coadministration of antigen and IL-10 genes must promote a 
regulatory response in order to abrogate disease. Indeed, if IL-10 were ineffective in doing so, it may 
be more effective to rely on the intrinsic TH1-inducing nature of DNA vaccines and to immunise with 
antigen gene alone(Hsu et al., 1996; Raz et al., 1996; Zindler et al., 2008). However, it remains likely that the induction of 
TR1 tolerance is a more rational approach than is TH1 shifting(Tournoy et al., 2002). 
7.1.8. Aim of experiments 
This chapter examines the effect of prophylactic DNA immunisation on the induction of disease. 
Specifically, it asks if IL-10 is sufficient, when present at the site of antigen presentation, to inhibit a 
future asthma-inducing antigenic challenge. 
7.2. Results 
The original antigen-induced asthma model used in this chapter was developed at GlaxoSmithKline. 
Briefly, 1x106 DO11.10 cells are adoptively transferred into naïve Balb/c mice. The recipient mice are 
sensitised by intraperitoneal (i.p.) administration of ovalbumin in alum. One week later asthma is 
induced by intranasal (i.n.) administration of ovalbumin solution. The asthma is characterised by 
increased airway eosinophilia, a TH2 shift of serum antibody and production of TH2-associated 
cytokines such as IL-4. This chapter examines the effect of PMDD immunisation on the outcome of 
asthma induction by introducing a prime-boost immunisation before the initial sensitisation step. This 
model is illustrated in more detail in Figure  7-1. It should be noted that the names of test groups are  
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Figure  7-1 The model of antigen-induced asthma 
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imperfect descriptions. For example the “naïve” group is naïve only with regards to the PMDD 
immunisations, before the OVA-alum sensitisation step.  
Mice underwent a prime-boost procedure with either empty p7, p7.OVA or p7.OVA + p7.IL10. As 
previously, the first immunisation (prime) took place one day following adoptive transfer and the 
second (boost) four weeks after that. Two weeks post-boost the asthma model was resumed: Mice were 
sensitised and asthma induced (henceforth refered to as sensitisation/induction) as described above. 
7.2.1. Effect of DNA immunisation on IgE responses 
IgE levels in blood plasma were measured by ELISA (Figure  7-2). A significant increase in OVA-
specific IgE was observed in both groups that received p7.OVA; the coadministration of p7.IL10 had 
no observable effect on the concentration of OVA-specific IgE in the plasma (Figure  7-2a). In contrast, 
the level of total (nonspecific) IgE was further increased by coadministration of p7.IL10 (Figure  7-2b).  
7.2.2. Effect of DNA immunisation on IgG responses 
The TH1/TH2 balance of an immune response, or of the state of the immune system in general, is often, 
at least in part, observed via the relative prevalence of IgG subtypes. In particular, elevated levels of 
IgG2 indicate a shift towards a cellular, TH1, response(Kuperman et al., 1998; Randolph et al., 1999b).  
OVA-specific IgG subtypes were quantified by ELISA (Figure  7-3). A significant increase in IgG1 was 
observed after sensitisation/induction (‘naïve’ group) but no further increase was induced by pre-
immunisation with p7.OVA. Coadministration of p.IL10 also had no observable effect on IgG1. 
Similarly to IgG1, IgG2a expression was increased by sensitisation/induction. This was increased 
significantly by pre-immunisation with p7.OVA. Mice that received coadministered p7.IL10 exhibited 
significantly lower plasma concentrations of IgG2a compared to those that received p7.OVA alone. 
However the concentration remained significantly higher than mice that received empty p7 alone. 
A similar pattern was observed in IgG2b concentrations but with key differences: Firstly, 
sensitisation/induction alone was not sufficient to elevate levels above those in control mice. Secondly, 
although immunisation with p7.OVA significantly increased IgG2b plasma concentration, 
coadministration of p7.IL10 was effective in completely eliminating this. Taken together, these data 
suggest that the quantitative activation threshold for class-switching to IgG2b is higher than that for 
IgG2a. 
IgG3 plasma levels exhibited a similar pattern to those of IgG1: Unprimed sensitisation/induction 
caused a significant increase in IgG3 compared to control mice but neither p7.OVA alone nor 
p7.OVA+p7.IL10 had any further effect. This is not necessarily unexpected; class switching to IgG3 
appears to require activation of TLR4(Quintana et al., 2008). Although this might conceivably be achieved 
through the release of heat-shock proteins by cell damage caused by the particle bombardment, the 
more classical TLR4 ligand, bacterial-derived LPS, is not present. 
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Figure  7-2 Prophylactic p7.IL10 does not inhibit a p7.OVA-induced increase in serum IgE following 
the induction of asthma 
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Figure 7-2. Prophylactic p7.IL10 does not inhibit a p7.OVA-induced
increase in serum IgE following induction of asthma.
Balb/c mice (3 per group) were adoptively transferred with 1x106 DO11.10 T
cells. 1 day later they were immunised ('prime') with either empty p7 (naive),
p7.OVA (primed) or p7.OVA + p7.IL10 (treated). Four weeks later mice were
re-immunised with the same vector ('boost'). Two weeks post-boost mice
were sensitised to ovalbumin by intraperitoneal administration in an alum
adjuvant.  One week after sensitisation asthma was induced by intranasal
administration of ovalbumin solution. A control group received prime and
boost immunisations of empty p7, sensitisation with IP ova-alum and
índuction with intranasal PBS. 84 h post-induction all mice were sacrificed
and blood was obtained by severing the aorta.
OVA-specific (a) and total (b) IgE were measured by ELISA. Because no
standard OVA-specific IgE was available, quantification was not possible,
therefore OVA-specific IgE data are displayed in arbitrary units (optical
density).
Data are the means of three independent experiments.
***p<0.001; **p<0.01 by one-way ANOVA
a b
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Figure  7-3 Prophylactic p7.IL10 inhibits a p7.OVA-induced increase in serum TH1 IgG subtypes 
following the induction of asthma 
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Figure 7-3. Prophylactic p7.IL10 inhibits a p7.OVA-induced increase
in serum TH1 IgG subtypes following induction of asthma.
Balb/c mice (3 per group) were adoptively transferred with 1x106 DO11.10
T cells. 1 day later they were immunised ('prime') with either empty p7
(naive), p7.OVA (primed) or p7.OVA + p7.IL10 (treated). Four weeks later
mice were re-immunised with the same vector ('boost'). Two weeks
post-boost mice were sensitised to ovalbumin by intraperitoneal
administration in an alum adjuvant.  One week after sensitisation asthma
was induced by intranasal administration of ovalbumin solution. A control
group received prime and boost immunisations of empty p7, sensitisation
with IP ova-alum and índuction with intranasal PBS. 84 h post-induction all
mice were sacrificed and blood was obtained by severing the aorta.
OVA-specific IgG subtypes were measured by ELISA. Because no standard
OVA-specific IgG was available, quantification was not possible, therefore
data are displayed in arbitrary units (optical density).
Data are the means of three independent experiments. Repeated-measures
ANOVA was performed on data across serial dilutions.
**p<0.01; ***p<0.001
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7.2.3. LN ELISpot 
To examine the cytokine response to sensitisation/induction mediastinal lymph nodes were harvested 
84 h following intranasal challenge. OVA-dependent cytokine expression by lymph node (LN) cells 
was examined by ELISpot (Figure  7-4).  
Compared to control mice, those that were naïve until sensitisation/induction exhibited significantly 
increased numbers of IL-2-expressing cells (Figure  7-4a). Earlier prime-boost with p7.OVA did not 
increase this number further. However, coadministration of p7.IL10 was able to reduce the prevalence 
of IL-2-producing cells by a small but significant number. 
Unprimed sensitisation/induction was also able to increase the number of IL-4-expressing LN cells 
compared to the number in control mice (Figure  7-4b). Unlike IL-2, however, the number of cells 
producing IL-4 in response to OVA was increased futher by prime-boost with p7.OVA. Interestingly, 
coadministration of p7.IL10 caused a statistically insignificant, but noticeable, increase in the 
prevalence of IL-4-producing cells. This indicated that immunisation with p7.OVA alone was able to 
prime for the IL-4 response induced by OVA-alum and that this effect was not diminished by 
coadministration of p7.IL10. 
7.2.4. BAL ELISpot 
To better understand the immune response at the site of inflammation, bronchoalveolar lavage (BAL) 
was performed on mice at the time of sacrifice. Attempts to measure cytokine levels in the BAL fluid 
failed but examination of cells in the fluid was successful.  
ELISpot was performed on BAL cells (Figure  7-5). Control mice had fewer than 100 IL-2-producing 
cells per million BAL cells (Figure  7-5a). Sensitisation/induction increased this number significantly. 
Similar to what was observed in LN cells, prime-boost with p7.OVA did not further increase the 
number of IL-2-producing cells. Interestingly, prior immunisation with p7.OVA+p7.IL10 did increase 
the number of IL-2-producing cells – by an order of magnitude compared to both naïve and p7.OVA-
treated mice. This was in contrast to the lack of effect of p7.I10 in the lymph node IL-2 ELISpot. 
When examining IL-4 expression in BAL cells it was observed that background expression, in the 
absence of exogenous OVA323-339, was far higher than normal (Figure  7-5b). Ordinarily, background 
wells have fewer than 10% of the number of spots as do test wells and the background figure is 
subtracted from the test figure. In this test, the numbers were almost equal in both groups that received 
p7.OVA (either with or without coadministered p7.IL10). This suggests that cells in the BAL fluid 
spontaneously produce IL-4 without the need for further in vitro stimulation. To present this data 
clearly, rather than subtracting them, background values are displayed alongside test values. 
Again, sensitisation/induction produced a significant increase in cytokine-expressing cells compared to 
the control group. Unlike IL-2-producers, however, IL-4-producers were three times more prevalent 
following p7.OVA priming. A further significant increase was provided by coadministration of 
p7.IL10. 
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Figure  7-4 Prophylactic p7.IL10 reduces the number of IL-2-, but not IL-4-, producing OVA-specific 
lymphocytes in the draining lymph nodes following the induction of asthma 
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Figure 7-4. Prophylactic p7.IL10 reduces the number of IL-2-, but not
IL-4-, producing OVA-specific lymphocytes in the draining lymph
nodes following induction of asthma.
Balb/c mice (3 per group) were adoptively transferred with 1x106 DO11.10 T
cells. 1 day later they were immunised ('prime') with either empty p7 (naive),
p7.OVA (primed) or p7.OVA + p7.IL10 (treated). Four weeks later mice were
re-immunised with the same vector ('boost'). Two weeks post-boost mice
were sensitised to ovalbumin by intraperitoneal administration in an alum
adjuvant.  One week after sensitisation asthma was induced by intranasal
administration of ovalbumin solution. A control group received prime and
boost immunisations of empty p7, sensitisation with IP ova-alum and
índuction with intranasal PBS. 84 h post-induction all mice were sacrificed and
cell populations from mediastinal lymph nodes were examined for
OVA-dependent IL-2 and IL-4 expression by ELISpot.
Data are representative of three repeated experiments.
*** p<0.001;  ** p<0.01;  * p<0.05 by one-way ANOVA
a b
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Figure  7-5 Prophylactic p7.IL10 increases the number of IL-2- and IL-4-producing OVA-specific 
lymphocytes in the BAL fluid following the induction of asthma 
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Figure 7-5. Prophylactic p7.IL10 increases the number of IL-2- and
IL-4-producing OVA-specific lymphocytes in the BAL fluid following
induction of asthma.
Balb/c mice (3 per group) were adoptively transferred with 1x106 DO11.10 T
cells. 1 day later they were immunised ('prime') with either empty p7 (naive),
p7.OVA (primed) or p7.OVA + p7.IL10 (treated). Four weeks later mice were
re-immunised with the same vector ('boost'). Two weeks post-boost mice
were sensitised to ovalbumin by intraperitoneal administration in an alum
adjuvant.  One week after sensitisation asthma was induced by intranasal
administration of ovalbumin solution. A control group received prime and
boost immunisations of empty p7, sensitisation with IP ova-alum and
índuction with intranasal PBS. 84 h post-induction all mice were sacrificed and
cell populations from bronchoalveolar lavage (BAL) fluid were examined for
OVA-dependent IL-2 and IL-4 expression by ELISpot.
Unlike all other ELISpot data where background spots (from wells without
exogenous OVA323-339) are subtracted from test values (from wells with
exogenous OVA323-339) to provide a net, antigen-induced, figure, these
graphs display both test (solid bars) and background (striped bars) figures.
Data are representative of three repeated experiments.
*** p<0.001;  ** p<0.01 by one-way ANOVA
a b
Test well (with OVA peptide)
Control well (without OVA peptide)
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Figure  7-6 The inclusion of p7.IL10 in prophylactic immunisation has no effect on the p7.OVA-
induced increase in cellular infiltration to the lung following induction of asthma 
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Figure 7-6.  The inclusion of p7.IL10 in prophylactic immunisation has
no effect on the p7.OVA-induced increase in cellular infiltration to the
lung following induction of asthma.
Balb/c mice (3 per group) were adoptively transferred with 1x106 DO11.10 T
cells. 1 day later they were immunised ('prime') with either empty p7 (naive),
p7.OVA (primed) or p7.OVA + p7.IL10 (treated). Four weeks later mice were
re-immunised with the same vector ('boost'). Two weeks post-boost mice
were sensitised to ovalbumin by intraperitoneal administration in an alum
adjuvant.  One week after sensitisation asthma was induced by intranasal
administration of ovalbumin solution. A control group received prime and
boost immunisations of empty p7, sensitisation with IP ova-alum and
índuction with intranasal PBS. 84 h post-induction all mice were sacrificed and
immune cell populations in the bronchoalveolar lavage (BAL) fluid were
counted using forward- and side-scatter (FSC and SSC) flow cytometry.
(a) FSC-SSC  plot with gates for four key cell populations. (b) Count of
eosinophils per ml of BAL fluid. (c) Count of lymphocytes per ml of BAL fluid.
Figures are the mean of three identical experiments.
*** p<0.001 by one-way ANOVA
Lymphocytes
Eosinophils
Neutrophils
Macrophages
a b
c
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7.2.5. Effect of DNA immunisation on BAL cell subsets 
As noted above, a key factor in the pathology of asthma is the infiltration into the airway of 
inflammatory cells and their activation. These cell populations were examined by performing flow 
cytometry on the BAL fluid of mice at the time of sacrifice (Figure  7-6). 
Cell populations were gated according size (forward-scatter; fs) and granularity (side-scatter; ss) 
(Figure  7-6a). Gates were previously defined by reverse-plotting of cell markers onto the fs/ss plot 
(data kindly provided by Maria Daly, GSK). BAL fluid from control mice contained fewer than 1x105 
eosinophils per ml and that from sensitised/induced mice contained up to 5x105. Previous 
immunisation with p7.OVA significantly increased the number of eosinophils in BAL fluid; by 
approximately an order of magnitude. Coadministration of p7.IL10 had no effect on this infiltration. 
An almost identical pattern was seen in the lymphocyte population of the BAL fluid but on a smaller 
scale (Figure  7-6b). 
7.3. Discussion 
The data generated by the experiments in this chapter are summarised inTable  7-1. As evidenced by 
levels of IL-4 production and eosinophil infiltration prior immunisations with p7.OVA increases 
disease severity in this model. These data also show that coadministration of p7.IL10 does not impede 
this exacerbatory effect; much less protect against disease induction. This agrees with data in earlier 
chapters which show that p7.IL10 can inhibit an immediate response to p7.OVA but does not induce 
tolerance or protect against a later challenge. 
7.3.1. Immunisation with p7.OVA selectively enhances serum antibody isotype 
levels whilst inclusion of p7.IL10 promotes a TH2 antibody isotype bias. 
Allergic disorders such as asthma and allergic rhinitis are often associated with elevated plasma levels 
of IgE. This despite the fact that, unlike the majority of antibodies, most IgE is cell-associated before 
binding antigen(Metzger, 1992; Bonnefoy et al., 1993). In agreement with this, the serum concentration of both 
OVA-specific and nonspecific IgE was increased by prior immunisation with p7.OVA. In contrast, 
serum IgG2a and IgG2b concentrations were also increased; this normally implies a TH1-biased 
response, especially when compared with the absence of such an increase in IgG1.  
Whilst coexistence of TH1 and TH2 responses to allergen have been described(Li et al., 1998; Hansen et al., 1999; 
Randolph et al., 1999a; Randolph et al., 1999b)
 it may also be possible that the asthma-inducing sensitisation-induction 
protocol increases serum IgG1 to maximal levels and that further stimulation is unable to increase the 
concentration further. This would artificially distort the data, implying a TH1-shift when, in fact, IgG 
subtype ratios might remain the same. 
Nevertheless, the data in  7.2.1 clearly demonstrate increased serum concentrations of both OVA-
specific and total IgE in mice in which asthma was induced.  0. This agrees with the literature on both 
experimental and clinical asthma (see 1.1.2).  
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Table  7-1 Summary of data from asthma experiments 
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The effect of inclusion of p7.IL10 in the immunisation is to further increase serum total IgE whilst 
causing a small but significant decrease in OVA-specific IgG2a and IgG2b. Unfortunately the data do 
not provide an explanation for the unexpected observation that this treatment increases total, but not 
OVA-specific, IgE. However there is evidence elsewhere that the ratio of specific:nonspecific IgE is 
potentially much higher locally(Smurthwaite et al., 2001). In addition, there is a possibility that the continuous 
presence of antigen allows epitope-spreading via CD23-mediated Facilitated Antigen Presentation 
(FAP) by OVA-nonspecific B cells(Mudde et al., 1990; Karagiannis et al., 2001; Carlsson et al., 2007): Via CD23, B cells are 
able to internalise, process and present antigen which their BCR does not recognise if the antigen is 
bound by IgE. If the B cell is in an activated state and/or part of an antigen-presenting cluster this may 
provide sufficient stimuli to activate T cells which are specific to irrelevant antigen.   
A caveat when examining IgE plasma data is that it has the potential to be unrepresentative of local 
IgE concentrations: A high local concentration of antigen and Fcε receptors has the potential to mop up 
locally-secreted IgE and, in addition, there is evidence that once local FcεRI receptors are saturated 
excess locally-produced IgE is preferentially secreted into mucous rather than blood(Negrao-Correa et al., 1996; 
Wilson et al., 2002)
. Therefore the relationship between local and plasma IgE concentrations is unlikely to be 
linear. Nevertheless it is likely that an increase in plasma IgE would reflect increased local production. 
IL-10 has been shown to block signalling through the ICOS costimulatory receptor(Taylor et al., 2007) which, 
in turn is key in antibody class-switching to IgE(McAdam et al., 2001). It is therefore surprising that, in this 
study, the inclusion of IL-10 in the immunisation was unable to diminish the IgE response. One 
explanation for this could be the kinetics and location of the response: IL-10 blockade of ICOS through 
SHP-1-mediated dephosphorylation of the ICOS cytoplasmic tail is brief(Taylor et al., 2007). IL-10 provided 
by the immunisation would be localised to the abdominal skin and, if dendritic cells were directly 
transfected, the skin-draining lymph nodes. In contrast, class-switching to IgE tends to occur locally in 
the target organ(Coker et al., 2003; Takhar et al., 2005). Transfected cells are unlikely to reach the lung or lung-
draining lymph nodes. Rather, they would be required to exert their effect on naïve T cells which 
would subsequently encounter antigen elsewhere. If naïve T cells were insufficiently tolerised, either 
in quality or quantity, the generation of IgE-secreting plasma cells would remain possible. 
7.3.2. Immunisation with p7.OVA alone enhances IL-4, but not IL-2, production 
It is perhaps surprising, given the previously established ability of p7.OVA to stimulate T cell 
proliferation and IL-2 production, that pre-immunisation with the vector did not increase the number of 
OVA-specific IL-2-producing T cells beyond the number induced by the asthma-induction protocol. In 
contrast, the number of IL-4-producers in both lymph node and BAL was significantly increased by 
gene gun immunisation. Whilst accompanying flow cytometry data would have provided confirmation, 
examination of the lymph node ELISpot data suggests that prior immunisation with p7.OVA results in 
all OVA-responsive T cells being dual-producers of IL-2 and IL-4; in effect, TH2 cells.  
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7.3.3. Inclusion of p7.IL10 in the immunisation increases the number of cytokine-
producing cells at the site of inflammation. 
It was shown earlier ( 6.2.1) that a prime-boost immunisation with p7.OVA+p7.IL10 is able to reduce 
the number of l/n IL-2 ELISpots in response to subsequent challenge compared to mice that received 
p7.OVA alone. However, that treatment was unable to reduce the number of IL-2-producing cells in 
the lymph nodes to below that of naive mice. In contrast, the data in this chapter show that treatment 
was able to reduce, by a small but significant number, the number of IL-2-producing cells in the 
draining lymph nodes. A caveat to this comparison is that the ‘naïve’ group in the former experiment 
were truly experiencing antigen for the first time whereas, in the latter, the ‘naïve’ group experienced 
antigen during the i.p. priming. In addition, the sample time in the former was 72 h post-immunisation 
and, in the latter, 84 h. Figure  5-5 shows that this 12-hour window provides the opportunity for much 
cell division, especially in naïve cells. Nevertheless, in both cases the inclusion of p7.IL10 in the 
immunisation reduces the number of IL-2-producing cells in the draining lymph nodes by roughly one 
third. 
In contrast to the lymph nodes, the number of IL-2-producing cells in the BAL is doubled by inclusion 
of p7.IL10 in the immunisation. A similar effect is seen on IL-4-producing cells although the number 
of IL-4-producing cells in the BAL is an order of magnitude higher than the number of IL-2 producers. 
Examining the lymph node data alongside the BAL data suggests that the inclusion of p7.IL10 in the 
immunisation either induces activated T cells to migrate to the lung or causes additional activation or 
proliferation in the lung. As described earlier ( 1.3.2), IL-10 can induce DC to migrate preferentially to 
the periphery, as opposed to lymph tissue(Dieu-Nosjean et al., 2001; Takayama et al., 2001a; Demangel et al., 2002). The 
inclusion of p7.IL10 in the immunisation may, therefore, potentially increase the quantity of antigen 
presentation at the site of inflammation. This supports, to some degree, the possibility that the 
additional cytokine production is due to increased proliferation and/or activation in the lung. In partial 
opposition to this is data that suggests T cells that have migrated to lung are unable to divide(Harris et al., 
2002)
. This would therefore limit the mechanism to either increased T cell migration or an increased 
state of activation. 
A phenomenon that is not seen elsewhere in this study is the large number of IL-4 ELISpots seen in 
‘background’ control wells containing no exogenous antigen. Three possibilities exist: 1) Residual 
antigen. Antigen was last administered 84 h prior to sacrifice and there is no equivalent IL-2 
background. This makes it unlikely that residual antigen is responsible, although it has been shown 
elsewhere that intranasal antigen can persist for several days(Byersdorfer and Chaplin, 2001). 2) IL-4 is produced 
by another cell type. Mast cells and eosinophils both constitutively express IL-4 mRNA and are 
therefore primed for fast production of the cytokine(Gessner et al., 2005). Mast cell production of IL-4 is 
linked to local IgE which, although not directly measured, is likely to be elevated. The cycle described 
in  0 provides a niche for long-term IgE production and, therefore, mast cell sensitisation(Smurthwaite et al., 
2001; Hiepe and Radbruch, 2006; Radbruch et al., 2006)
. It would have been enlightening to have performed IgE ELISA 
on BAL fluid to confirm local concentrations. Although mast cells were not enumerated by 
146 
morphologic flow cytometry, it is possible to calculate that, in the “primed” and “treated” groups, 50-
60% of cells in a BAL ELISpot well would be eosinophils whilst only 20% are lymphocytes. This 
certainly allows for eosinophilic production of IL-4 to contribute significantly to the total number of 
IL-4 ELISpots. 3) The kinetics of T cell IL-4 production are different to those of IL-2 production. 
There is certainly evidence that IL-4 can be produced for an extended period of time post-
stimulation(Laaksonen et al., 2003). Previous work by Prof. B.M. Chain has shown similarly high background 
IL-4 spots in the spleen following repeated immunisation of mice with sheep red blood cells 
(unpublished data).  
Flow cytometry of intracellularly cytokine-stained cells would likely provide a clearer picture of the 
cell type(s) producing IL-4. Due to time constraints, however, this experiment could not be repeated 
further and, as yet, the cause remains unexplained.  
7.3.4. The cellular infiltration caused by immunisation with p7.OVA is not reduced 
by coadministration of p7.IL10 
Repeated immunisation with p7.OVA prior to asthma induction increased the number of lung-
infiltrating lymphocytes by four times and the number of eosinophils by an order of magnitude. The 
coadministration of p7.IL10 had no effect on infiltration. Because immunisation was at a distal site 
priming of the airway specifically is unlikely and, therefore, the mechanism involved in this disease 
exacerbation must be systemic. The pattern of a p7.OVA-induced increase which is unaffected by 
p7.IL10 is similar to that of total plasma IgE. Increased OVA-specific IgE caused by immunisation 
would prime mast-cells systemically, allowing a swift and powerful response to antigenic challenge, 
wherever it may be. Intranasal challenge would activate local mast cells, which, in turn, would allow 
infiltration of lymphocytes and(, later,) eosinophils.  
One might expect IL-4 production in the lung to follow a similar pattern to that of lymphocyte 
infiltration and OVA-specific IgE production. However the BAL ELISpot data show a further increase 
in mice that received coadministered p7.IL10. This could be due to the background IL-4 production as 
discussed in  7.3.3 or to the fact that all in vivo immunisations and challenges are performed with OVA 
protein whereas this ELISpot (and most of the others in this study) is performed with OVA323-339 
peptide. Section 1.2.2 previously demonstrated that a significant number of T cells are primed to non 
323-339 epitopes of the OVA protein. It is also possible that differences in ELISpot data between 
lymph node and BAL are due to the kinetics of cell migration to and from these tissues. 
As discussed in  7.1.4 T cells are key mediators of eosinophil infiltration, both directly through 
expression of IL-5 and indirectly through TNF-α-, IL-4- and IL-13-dependent stimulation of eotaxin 
secretion by tissue cells. It is therefore unsurprising that eosinophil infiltration is closely associated 
with lymphocyte infiltration. Further establishment of this association may have been possible by 
examining BAL IL-5 concentration by ELISA and/or the ability of BAL cells to express IL-5 by 
ELISpot. 
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7.3.5. Conclusion 
Whilst the cytokine data in this chapter might provide useful mechanistic information, the degree of 
eosinophilia provides the answer to the question: “Does p7.IL-10 protect from disease 
induction?”(Humbles et al., 2004). Previous studies have successfully demonstrated protection from allergic 
asthma and associated eosinophilia(Stampfli et al., 1999). However, it is apparent that, in this study, 
coadministration of IL-10 with antigen does not protect from disease. The most likely explanation for 
this difference is that the former technique was able to generate a sufficient number of TR1 cells, whilst 
the protocol used in this study was not. 
The work in this chapter was originally intended to be relevant to the question of of allergic asthma. As 
described in the chapter introduction this, and other, models of asthma are of limited relevance to the 
human disease. In fact, this model may be more comparable to eosinophilic bronchitis than to 
asthma(Brightling et al., 2003). Another key caveat to such animal models is the use of a simple antigenic 
stimulant such as antigen-alum complexes. These may successfully trigger allergic inflammation but 
the complexity of real-world triggers of asthma and the importance of their innate immunostimulatory 
properties is becoming increasingly appreciated(Akbari et al., 2003; Kim et al., 2008; Hammad et al., 2009).  
The complexity of this disease is compounded by differences between various animal models, and 
between them and clinical asthma. Nevertheless, the work is relevant, as-is, to aspects of allergic 
airway inflammation. 
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8. General Discussion 
8.1. The induction of regulatory T cells by IL-10 
8.1.1. Inhibition of T cell activation by IL-10 
The data in chapter 4 shows that proliferation and production of IL-2 and IL-4 in response to PMDD 
immunistion were dose-dependent and that the maximal response was obtained at a dose of 0.1 µg 
p7.OVA per mouse. This agrees with even the earliest studies, despite the use of different propulsion 
technology and bead size(Eisenbraun et al., 1993). It is important to note that, in these cases, an increased 
‘dose’ corresponds to a higher copy number of plasmid on each gold particle. Therefore, rather than 
increasing the number of transfected cells, increased dose increases the copy number in each 
transfected cells. Maximal responses are likely the result of maximal expression which, itself, is likely 
the result of the saturation of the transcription/translation and/or antigen processing/presentation 
machinery of the cell. 
The data in chapters 5 and 6 show that the coadministration of p7.IL10 reduces the immunogenicity of 
the OVA-encoding plasmid. As detailed in the introduction to this thesis, several mechanisms for this 
inhibition have been described: 1) Direct inhibition of T cells both by inhibition of CD28 signalling 
and by recruitment of the immunoinhibitory STAT3 transcription factor. 2) reduction of the number of 
antigen-presenting dendritic cells (DC) in the draining lymph nodes by inhibiting migration and 
inducing apoptosis. 3) Inhibition of antigen presentation by downregulation of MHC class II 
molecules, costimulatory molecules and cytokines via recruitment of STAT3. Which of these 
mechanisms is important under natural conditions, and which in this model, are important questions, 
the answers to which are likely to be at least partially dependent on the source of IL-10 in each 
context; dendritic cells, regulatory T cells or local tissue cells. In the case of PMDD immunisation both 
skin DC and local tissue cells such as keratinocytes may be transfected. Transfection of DC would, in 
theory, allow IL-10 to exert its effect on DC during and after maturation and migration as well as on T 
cells in the DC-T cell cluster. Transfection of keratinocytes may expose skin-resident DC to IL-10 
until they migrate away from the site whilst lymph node T cells would not encounter the cytokine.  
Figure  5-8 and Figure  5-9 show that the effect of coadministration of p7.IL10 is at least partially 
dependent on its expression in the same cell as p7.OVA. This somewhat agrees with earlier 
literature(Morita et al., 2001; Ross et al., 2003) that directly-transfected DC are key in PMDD immunisation (see 
 1.7.3). Autocrine, DC-derived IL-10 is known to maintain the cells in a hypoimmunogenic state(Corinti et 
al., 2001; Demangel et al., 2002; Lang et al., 2002b; Monteleone et al., 2008)
 and both naturally-occurring and artificially-
transfected IL-10-secreting DC can also tolerise T cells to which they present antigen(Takayama et al., 1998; 
Takayama et al., 1999; Akbari et al., 2001; Chirdo et al., 2005)
. In contrast, IL-10 produced by transfected keratinocytes 
would have only a very short time in which to affect skin DC as the danger signal provided by PMDD 
induces migration of both transfected and non-transfected DC away from the skin before maximal gene 
expression(Porgador et al., 1998; Bot et al., 2000; Creusot, 2002). Therefore IL-10 expressed by directly-transfected DC 
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is likely the critical element in this model, allowing the cytokine to exert its inhibitory effects in all 
three ways described above.  
8.1.2. Tolerance is not induced by IL-10 
TR1 cells were originally defined as IL-10-secreting regulatory cells which could be induced by their 
activation in the presence of IL-10(Groux et al., 1997). Indeed, the potential to induce TR1 was central to the 
hypothesis that coadministration of IL-10-encoding vector could induce tolerance to antigen. The data 
in chapter 5 clearly show that IL-10 inhibited T cell activation by PMDD immunisation. Chapter 6 
addressed the issue of tolerance induction. Initial experiments indicated that some degree of 
tolerisation did occur: The number of OVA-specific, cytokine-secreting T cells in the lymph node in 
response to a challenge with p7.OVA was lower in the group that were primed with p7.OVA and 
p7.IL10 than in the group that received p7.OVA alone. However, examination of the spleen showed 
that, at the time of challenge, the p7.OVA+p7.IL10 group had far fewer available OVA-specific 
DO11.10 T cells; as few as in control mice that received no antigen at all. Therefore it is possible, even 
likely, that the reduction in cytokine-secreting lymph node cells in response to p7.OVA challenge was 
simply due to a smaller pool of DO11.10 cells at the time of immunisation. 
To examine this further fresh, CFSE-labeled DO11.10 cells were adoptively transferred prior to the 
p7.OVA challenge. Caution is required when comparing the results of this experiment to those 
involving only one cell transfer. Nevertheless the data clearly show no difference in the proliferation of 
freshly transferred cells between mice that were primed with p7.OVA alone and those that received 
coadministered p7.IL10. This important observation confirms that OVA-specific regulatory T cells 
were not induced by coadministered p7.IL10.  
It could be suggested that the induction of TR1 cells by IL-10 is an in vitro-only phenomenon(Groux et al., 
1996; Fu et al., 2008)
. Evidence for tolerance induced by injected recombinant IL-10 existed even before TR1 
cells were defined(Rott et al., 1994) (Enk et al., 1994). However, it is unclear whether the mechanism behind these 
observations is the induction of regulatory T cells as opposed to the induction of anergy in antigen-
specific T cells or skewing towards a less pathogenic TH2 response. In fact, the majority of studies 
point to inhibitory effects of IL-10 on antigen presentation and antigen-presenting cells (see sections 
 1.3.2 –  1.3.4). Less and/or inferior antigen presentation to T cells would result in inexperience and/or 
anergy, not specifically to the induction of regulatory T cells.  
It may seem contradictory that IL-10 may not be a key inducer of regulatory T cells when it is clear 
that TR1 cells exist and that their regulatory properties are dependent on IL-10 (see  1.4.2). However it 
has not been demonstrated that TR1 cells induce naïve T cells to become TR1 cells. More likely, 
antigen-specific TR1 cells inhibit antigen presentation and T cell activation at the DC: T cell cluster via 
the IL-10-dependent mechanisms described in the introduction to this thesis. Nevertheless, IL-10-
secreting DC have been shown to protect against pathogenic immunity in several models (see  1.6.4), 
and there is evidence that these cells can induce the generation of TR1 cells in vivo(Akbari et al., 2001; Wakkach 
et al., 2003)
.  
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The anatomy of the immune system might explain at least some of these discrepancies. Much of the 
work done on TR1 cells was based on mucosal tissues and inflammation initiated by homeostatic 
expansion of adoptively transferred CD4+ T cells. A theory put forward by Maynard and Weaver(Maynard 
and Weaver, 2008)
 and described in section  1.4.3 suggests that IL-10-secreting Treg play a specific role in 
regulating effector cells at the mucosal interface whilst Foxp3+ Treg inhibit the activation of naïve T 
cells in the secondary lymphoid tissues.  
It may also be the case that the induction of TR1 cells is also anatomically restricted(Duchmann et al., 1995; 
Meiler et al., 2008)
. There are several examples of protocols utilising IL-10-expressing DC which are 
tolerogenic using one administrative route but ineffective via another route(Cua et al., 2001; Oberholzer et al., 2001; 
Zhang et al., 2004; Xiao et al., 2006; Pedersen et al., 2007)
. Additionally, naturally-occurring tolerogenic DC have been 
described in mucosal tissues(Akbari et al., 2001; Chirdo et al., 2005; Monteleone et al., 2008; Ginhoux et al., 2009). Tissue-specific 
non-immune cells such as skin keratinocytes(Cao et al., 2003; Dominguez-Castillo et al., 2008) and intestinal epithelial 
cells(Iliev et al., 2009) appear to play a significant role in maintaining a tolerogenic environment at those 
sites. As stated in  1.5.3 it is possible that so-called ‘specialised’, tolerogenic DC are the result of their 
anatomical location.  
The anatomical restriction of induction and function of IL-10-secreting TR1 cells has implications for 
the model used in this thesis. Firstly, it brings into question the appropriateness of gene gun 
immunisation for IL-10-based induction of  TR1 cells: Whilst there is evidence that IL-10-transfected 
DC can induce TR1 cells, this function appears to be largely restricted to mucosal tissues. Nevertheless, 
tolerisation via the skin has been shown in the literature and it is possible that IL-10-expressing skin 
DC may induce the generation of TR1 cells. Secondly, examination of T cell activation in the lymph 
node may not be relevant to the examination of TR1 induction by IL-10: It is not clear that the 
induction of TR1 cells occurs in the lymph nodes and both effector and regulatory T cells share similar 
proliferative characteristics during their response to antigen(Adler et al., 2000).  
8.1.3. Asthma 
As discussed above, examination of T cell activation in the lymph node may not be the ideal readout 
for the tolerisation of DO11.10 cells in this model. Whether the induction of OVA-dependent 
experimental asthma can be inhibited is perhaps more appropriate. Noninflammatory administration of 
antigen has shown some limited tolerogenic success in similar models(Barbey et al., 2004; Vissers et al., 2004; Van 
Hove et al., 2007)
. The adminstration of IL-10-treated and IL-10-expressing dendritic cells (introduced in 
 1.6.3 and  1.6.4, respectively) have been demonstrated to inhibit inflammation in models of OVA-
dependent airway inflammation(Koya et al., 2007; Henry et al., 2008). Nevertheless, the data in chapter 7 shows 
that PMDD coadministration of OVA and IL-10 does not protect against disease.  
It is understood that allergic asthma is primarily a TH2 disorder and that TH1-biasing genetic vaccines 
have been demonstrated to be protective(Lee et al., 1997; Maecker et al., 1997; Maecker et al., 2001; Ludwig-Portugall et al., 2004). 
The aim of this study, however, is to examine T cell tolerisation; a different solution to this disease. 
Because gene gun immunisation is more TH2-inducing than plasmid injection it can exacerbate airway 
inflammation(Bartholdy et al., 2004; Scheiblhofer et al., 2007). Therefore any suppressive effects of a gene gun-based 
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vaccine would almost certainly be due to the gene(s) being transferred and not to the 
immunomodulatory effects of the protocol itself.  
Lymphocytes, as opposed to mast cells, are key in the induction of asthma(Brusselle et al., 1994). Therefore 
the induction of regulatory T cells that control antigen-specific responses is certainly an appropriate 
approach to abrogating disease. Indeed, inadequate regulatory T cell function likely plays an important 
role in the development of asthma (Akdis et al., 2004; Jaffar et al., 2004) whilst both CD4+CD25+ regulatory T cells 
and IL-10-secreting TR1 cells (Akbari et al., 2002; Akdis et al., 2004; Kearley et al., 2005; Lewkowich et al., 2005; Kearley et al., 2008) 
have been shown to inhibit disease. Therefore, in agreement with earlier chapters, the failure of the 
treatment used in this project to protect against asthma suggests that it does not induce the generation 
of regulatory T cells. 
8.2. Implications for PMDD-based immunotherapy 
8.2.1. Limitations of this study 
A significant gap in this study is the range of cytokines examined in harvested cells. In particular, it 
would have been interesting to examine the effect of coadministration of p7.IL10 on IL-5 and IL-13 
expression by DO11.10 cells, especially in the longer-term experiments. In general, advances in 
immunoassays such as multiplex sandwich ELISA and microbead-based assays now allow wider 
screening of cytokine expression. Utilisation of such an assay may have provided a clearer 
understanding of the response. 
Although phenotyping of regulatory T cells is still far from perfect, flow cytometric analysis of Foxp3 
expression has proven very useful and is now routine. Such analysis would have been an insightful 
addition to the flow cytometry performed in this study.  
Finally, repetition of some experiments using IL-10R-/- DO11.10 donor mice, and perhaps also in IL-
10R-/- balb/c recipients, might increase confidence that the suppressive effects observed were directly 
attributable to coexpressed IL-10. 
8.2.2. Future studies with IL-10 
Firstly, there is evidence that substitution of mammalian IL-10 with viral IL-10 might improve the 
immunosuppressive effect of the coadministered p7.IL-10 plasmid(Takayama et al., 2001b; Moore et al., 2004).  
The question of direct transfection of, vs cross-presentation by, DC has been discussed above and in 
earlier chapters. Section  1.7.3 describes the three mechanisms likely to be involved in naked DNA 
immunisation. Clearer answers might be provided by the restriction of antigen expression to dendritic 
cells by placement of the ova gene under the control of a DC-specific promoter such as that of fascin 
or dectin-2. Similar information might be obtained by the use of OVAcyt, a mutant ovalbumin protein 
whose secretion signal has been removed and which remains largely confined to the cytoplasm, rather 
than being secreted into the extracellular milleu. 
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Whether the effect of IL-10 is directly on T cells or via an effect on DC might be examined further by 
the use of IL-10-/- DO11.10 T cells. Similarly, the repetition of the original in vitro work by H. Groux 
et al., but substituting a non-APC stimulator such as anti-CD3 antibodies, would illustrate the 
importance (or lack thereof) of the effect of IL-10 on APC in the IL-10-dependent generation of TR1 
cells(Groux et al., 1997).  
One of the explanations proposed earlier for p7.IL10 not inducing tolerance is the kinetics of 
expression of each plasmid relative to the other. Placement of il10 under the control of a promoter with 
a more extended expression profile may enable the cytokine to persist until presentation of OVA has 
ceased. This can also be extended to the antigen gene, ova. Other studies have shown that placing the 
antigen gene under control of an APC-specific promoter greatly reduces the efficiency of both injected 
plasmid and gene gun immunisations(Corr et al., 1999; Cho et al., 2001; Hon et al., 2005). When developing a 
tolerisation protocol, however, this may be desirable. Section  1.7.3 describes the three mechanisms 
likely to be involved in naked DNA immunisation. Restriction of antigen expression to dendritic cells 
would ensure that only directly-transfected DC would present antigen and, in the case of linked 
p7.IL10 coadministration, that all OVA-presenting cells coexpress IL-10. This effect could be further 
guaranteed by the use of OVAcyt, a mutant ovalbumin protein whose secretion signal has been removed 
and which remains largely confined to the cytoplasm, rather than being secreted into the extracellular 
milleu. 
8.2.3. Other molecules / techniques 
Since IL-10 exerts many effects via its action on DC, the pathway downstream of IL-10 is an 
appropriate target for immunosuppressive treatments. Gene gun immunisation is mediated mainly by 
directly-transfected DC and is therefore a good tool for exploration of intracellular immunomodulatory 
molecules. Therefore coadministration of the gene encoding STAT3, a transcription factor activated by 
IL-10, may bypass the need for cytokine expression and detection and directly activate the DC 
antiinflammatory response described in  1.3.4. Even further downstream, transfection with SOCS3 
might induce tolerogenic effects on DC(Li et al., 2006). 
The maturation status of DC has been suggested to play a role in activation vs tolerisation of T cells 
(see  1.5.1). Coadministration of molecules that interfere with the maturation of DC, such as iκB and 
CTLA-4 may result in tolerogenic presentation of antigen(Tan et al., 2005). 
As described in the introduction to this thesis the gene gun, and genetic immunisation in general, 
provides a platform through which encoded proteins can be administered with relative ease. Therefore 
more recently discovered immunomodulatory molecules such as IL-35 and galnectin-1, about which 
relatively little is known, could be examined as candidates for inclusion in a tolerogenic vaccine(Collison 
et al., 2007; Collison et al., 2009; Ilarregui et al., 2009)
. 
Despite the plethora of available molecules, one further hurdle remains. This study has examined 
prophylaxis; vaccination to prevent future immune responses. In the context of pathological immunity, 
the ability to interfere with an ongoing response is more desirable. Unfortunately, experienced T cells 
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are more resistant to tolerisation than are naïve T cells and ongoing responses can make tolerising 
protocols ineffective or even detrimental(London et al., 2000; Hurst et al., 2001).  
 
Although an effective inhibitor of immune responses, it is unlikely that coadministration of IL-10 in a 
gene gun vaccine is an appropriate method for the induction of tolerance and/or regulatory T cells, 
especially in remote tissues such as the lung. The gene gun remains a very flexible immunisation tool, 
allowing the continued study of immunomodulatory molecules in the search for an effective 
immunosuppressive vaccine. 
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